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Abstract 
 
Drugs with poor aqueous solubility generally possess unfavorable pharmacokinetic 
properties. Upon oral administration, such drugs can form supersaturated solutions within the 
gastrointestinal tract, causing the formation of insoluble aggregates which may be prone to 
precipitate out in the body. Clofazimine, an oral leprostatic drug in clinical use since the 1960s, 
is known to massively bioaccumulate in the form of insoluble, crystal-like drug inclusions 
(CLDIs). These CLDIs are primarily found within tissue macrophages of the liver, spleen, and 
lungs. Here, we hypothesized that CLDIs are stabilized by an active, macrophage-dependent 
concentrative proton and chloride transport process.  To test this, we developed a multi-
parameter imaging and analysis system which combines polarization and fluorescence 
microscopy to track the accumulation and stabilization of CLDIs in different macrophage 
populations throughout treatment, revealing tissue-specific differences in the ability to stabilize 
intracellular drug aggregates, and an active remodeling of the internal arrangement of the 
macrophage’s membranes to maximize drug loading. Additionally, following chemical depletion 
of macrophages in the liver and spleen, CLDI accumulation was significantly inhibited, resulting 
in a reduction in the total drug accumulation within the organs. Most importantly, depletion of 
hepatic macrophages alongside drug treatment caused liver damage and systemic toxicity, 
leading us to postulate that drug sequestration and subsequent granuloma formation by 
macrophages functions as a protective mechanism. When macrophage-depleted mice were 
injected with isolated CLDIs, there was a significant increase in the rate of decay of the crystals, 
indicating that phagocytosis by the macrophage stabilizes the crystal and prevents dissolution. 
Finally, we determined that CLDI-containing macrophages showed significantly higher levels 
TFEB activation, lysosomal content and autophagic flux, pointing to an active adaptation of the 
macrophages’ endolysosomal system to accommodate and stabilize CLDIs. To conclude, 
macrophages are actively involved in sequestering drug and help to limit drug toxicity.
1 
 
Chapter 1 
Introduction 
1.1 Background 
1.1.1 Clofazimine 
Leprosy is a devastating illness caused by the bacterium Mycobacterium leprae, and is a 
major problem throughout much of the developing world, with more than 180,000 new cases 
being diagnosed in 2013 [1]. The development of new therapies and the widespread availabilities 
of treatment options have led to a significant reduction in the number of new cases of leprosy, 
dropping from more than 550,000 in 1996 [2]. Nevertheless, this disease remains a significant 
public health dilemma throughout the world. One of the most effective treatment options for 
leprosy is the FDA approved drug clofazimine (CFZ), a red-pigmented phenazine compound 
developed in the 1950s. This drug shows powerful antimicrobial and anti-inflammatory activity, 
especially in the treatment of multiple drug resistant leprosy [3].  
 The physical and chemical properties of CFZ are very unique, and greatly influence the 
pharmacokinetics of the drug. Clofazimine is a highly lipophilic, weakly basic compound that 
contains two ionizable amine functionalities. Due to the high lipophilicity (cLogP=7) of CFZ, the 
drug accumulates within lipid-rich tissues during the initial stages of treatment [4]. The high 
degree of accumulation within lipid-rich tissues results in an extremely long half-life (about 70 
days) and large apparent volume of distribution.  
Following three weeks of continuous treatment, CFZ begins to accumulate within 
macrophages of the liver, spleen, and lung, among other locations. The accumulation of CFZ 
within these cells eventually leads to the formation of intracellular, highly ordered, crystal-like 
drug inclusions [5]. These crystals have not been found outside of the cell or in the vascular 
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system, indicating that their formation may be dependent on a cellular process or the result of an 
ion-trapping mechanism [6]; due to the presence of an ionizable amine group, the majority of the 
drug in solution will exist in the protonated form in the highly acidic environment of the 
lysosome [7], preventing it from freely diffusing across the membrane back into the cytosol. As 
the drug concentrates, it precipitates out of solution, forming the highly ordered crystal-like 
structures that are found throughout the body of CFZ-treated patients. 
CLDIs are a different polymorphic form of CFZ than the form used in treatment. The 
formulations of CFZ that are used therapeutically are either the monoclinic or triclinic (TC) 
polymorphic form of the drug [8]. CLDIs can be isolated from the tissues of treated animals, and 
further experiments can be performed using these crystals. CLDIs can be separated from the 
surrounding tissue and cellular debris through the use of a sucrose density gradient. By using this 
gradient, one can separate CLDIs from the TC form of the drug due to the differences in their 
densities: TC CFZ has a density of 1.3 g/mL, while CLDIs have a slightly higher density of 1.36 
g/mL [9].  
Powder X-ray diffraction patterns obtained from the TC form of CFZ and isolated spleen 
CLDIs also indicate a polymorphic change occurs during CLDI formation: the TC form of CFZ 
contains a peak at 2θ=9.3° that is not seen in the isolated CLDIs, and isolated CLDIs contain a 
peak at 2θ=7.2° not present in the TC form [9]. Proton NMR spectroscopy was also performed 
on isolated CLDIs to shed further light on the biotransformation of CFZ within the body. This 
revealed that the CFZ present in CLDIs exists in a monoprotonated form [9]. Bulk elemental 
analysis was performed to determine the elemental composition of the CLDI, and this led to the 
discovery that CLDIs exist as a hydrochloride salt of CFZ. The X-ray powder diffraction pattern 
of synthetic CFZ hydrochloride crystals and CLDIs contained the same major peaks, and single 
crystal analysis was used to determine that the underlying crystal structure was orthorhombic [9]. 
Raman microscopy performed on CFZ powder and CLDIs isolated from the spleen of CFZ 
treated animals has also been used to demonstrate the polymorphic change that occurs during 
CLDI formation. The vibrational spectra of the crystalline CLDIs differs significantly from that 
of the dry CFZ powder, or other amorphously recrystallized forms: CLDIs possess two 
vibrational peaks at 1396 cm
-1
 and 1301 cm
-1
 that are very strong, but these peaks are absent in 
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the TC or other amorphously recrystallized forms of the drug [9, 10]. Thus, the formation of 
CLDIs can be tracked through a multitude of chemical and physical analysis methods. 
Aside from their physical and chemical differences, the presence of one polymorph 
versus another can be detected by their differing optical properties. The TC form of CFZ shows a 
strong fluorescence in the FITC (495 nm excitation/ 519 nm emission) channel, which can be 
used to track cells that have taken up the drug [10]. Transformation from the TC form of CFZ to 
the orthorhombic form results in a loss of the FITC signal and development of signal in the Cy5 
(650 nm excitation/ 670 nm emission) channel [11]. Isolated CLDIs polarize light as a single 
domain, and are homogenously birefringent. Pure TC CFZ crystals, on the other hand, give a 
mixed yellow-orange birefringent signal [5]. Thus, due to these optical property differences, the 
accumulation of CFZ and formation of CLDIs can be studied at a cellular and subcellular level 
through polarization and fluorescence microscopy. 
Clofazimine also displays potent anti-inflammatory properties. Treatment with CFZ leads 
to an increase in the levels of the anti-inflammatory protein IL1-RA, with significant down 
regulation of the pro-inflammatory signaling molecules Macrophage Inflammatory Protein 1-β 
(MIP-1β) and TNF-α [6]. The formation of CLDIs may also be a protective mechanism put in 
place by the body to prevent toxic effects of CFZ accumulation. CLDIs are much more tolerated 
by isolated macrophages, displaying 80% viability when cultured with 10 μM CLDIs versus 20% 
when cultured with 10 μM soluble CFZ [12]. The presence of CLDIs within macrophages may 
be the reason behind the increase in anti-inflammatory signaling in treated animals: cultured 
macrophages which phagocytose CLDIs display increased IL1-RA production, along with 
decreased activity of Toll-like receptors 2 and 4, resulting in lowered NF-κB translocation and 
TNF-α production [12]. Treatment with CFZ also alters the expression levels of various 
lysosomal enzymes, which may also play a role in the anti-inflammatory activity seen in 
treatment. Following treatment with CFZ for 21 days in mice, a significant increase in the levels 
of N-acetyl-β-D-glucosaminidase was seen in isolated macrophages [13]. There is also some 
evidence that CFZ treatment may lead to an increase in the synthesis of lysosomal enzymes [14] 
in macrophage cultures in vitro.  
1.1.2 Drug Accumulation 
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The ability of a medication to effectively treat a disease is dependent on the drug 
reaching the therapeutic concentration at the appropriate site of action. For an oral drug to reach 
therapeutic levels, it must have favorable pharmacokinetic parameters. The bioavailability of a 
drug is one of the most important factors in determining the effectiveness of a therapeutic 
regiment. Bioavailability is defined as the fraction of a dose that enters the systemic circulation. 
For an intravenous treatment, bioavailability is 100%. Bioavailability will decrease with other 
dosage forms due to incomplete absorption of the drug in the small intestine, or metabolism of 
the drug by the liver and elimination in urine or feces. Hurdles such as this limit the ability of the 
drug to accumulate and reach therapeutic concentrations. The most frequent cause of poor oral 
bioavailability is poor solubility of the parent compound [15]. As drugs with poor solubility are 
often candidates for development, there are a variety of strategies used to improve solubility.  
One common approach to improving poor solubility is the introduction of an ionizable 
functionality, such as a weakly acidic or basic functional group. The majority of drugs on the 
market today contain a weak acid or base moiety [16], demonstrating the power of ionization 
when it comes to improving solubility. The addition of a weakly basic functionality to a 
molecule, such as an amine group, greatly improves the solubility and dissolution profile of a 
compound [17]. However, this improvement in solubility can often result in unwanted drug 
accumulation. The pKa value of amine groups are usually between 8 and 10, which would result 
in the drug being mostly unionized after freely diffusing into the cytosol. Once in the cytosol, the 
unionized drug freely diffuses throughout the cell into various compartments. After entering the 
highly acidic (pH=4.5-6.0) endo-lysosomal system, the drug becomes ionized, and is unable to 
freely diffuse across the membrane back into the cytosol, causing the drug become trapped 
within the lysosome[18]. Chemicals with a propensity to accumulate in the endo-lysosomal 
system are commonly referred to as lysosomotropic agents. 
The trapping and accumulation of a drug within the lysosome has a variety of 
implications. Studies by Krise et. al have demonstrated that drug accumulation by 
lysosomotropic agents results in an expanded volume of the lysosome [19], and they have also 
illustrated that the expansion of the volume of the lysosome is a potential drug interaction 
pathway that can form within the cell [20]. They hypothesize that these drug interactions result 
from changes in lysosomal sequestration, which alter the ability of the drug to interact with non-
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lysosomal targets. Further work by this group has demonstrated that lysosomal drug 
accumulation results in nuclear localization of the transcription factor EB, which regulates 
lysosomal biosynthesis, and leads to an increase in the number of small, lipid-filled lysosomes 
[21]. The trapping and accumulation of a drug within the lysosome has significant biological 
outcomes, and can greatly impact the pharmacokinetics and pharmacodynamics of amine-
containing drugs. 
Aside from impacting the pharmacokinetics of the drug, accumulation can lead to 
toxicity. Transporters in the bile ducts of the liver are used to remove exogenous substrates from 
the body, and their inhibition can result in damage to hepatocytes. Drugs such as cyclosporine A 
have been shown to inhibit the canalicular transport protein Multidrug resistance-associated 
protein 2 (MRP2) when accumulating in the liver. The inhibition resulting from the accumulation 
leads to significant cytotoxicity towards the hepatocytes [22], which can severely damage the 
liver. 
Accumulation of the soluble form of a drug can cause complications due to saturation of 
transport proteins, inhibition of enzymes, or due to changes of key pharmacokinetic parameters. 
The formation and accumulation of insoluble drug aggregates, however, poses entirely new 
problems. Drug precipitation in vivo often results from a change in the pH of the environment the 
drug is dissolved in, which is often seen when exiting the highly acidic environment of the 
stomach and entering the much more alkaline small intestine [23]. Crystallization is also 
commonly seen in the distal tubular lumen of the kidney due to poor solubility in urine, and can 
lead to crystal nephropathy [24]. The formation of drug crystals in the kidney can block urine 
flow, eventually causing renal failure. Antibiotics such as amoxicillin [25] and protease 
inhibitors such as indinavir [26] have the potential to form insoluble aggregates within the 
kidney and in urine, demonstrating that drug precipitation in vivo is a common hurdle which 
must be overcome when developing a new drug product.  
1.1.3 Macrophages 
One of the key functions of the immune system is the isolation and removal of “non-self” 
antigens from the body, and the mononuclear phagocytic system (MPS) is a major component in 
this. The MPS is comprised of “professional phagocytes”, which includes monocytes, 
6 
 
macrophages, and dendritic cells. Monocytes are one of the parent-cells of the MPS, and 
differentiate from hematopoietic stem cells in the bone marrow [27], which can then differentiate 
into various macrophage populations. The main function of the monocyte is to replenish resident 
tissue macrophage populations, respond to inflammatory signals, and to illicit immune responses. 
There are two main subsets of monocytes in the mouse, and they are classified based on their 
expression of the surface marker lymphocyte antigen 6C (LY6C) [28]. One subset expresses high 
levels of LY6C, while the second subset expresses lower levels of this marker. After maturation, 
LY6C
high
 monocytes exit the bone marrow and enter the systemic circulation via C-C chemokine 
receptor type 2 binding by C-C chemokine ligand [29]. LY6C
high 
macrophages can then 
differentiate into LY6C
low
 monocytes in circulation. LY6C
high 
monocytes are preferentially 
recruited to sites of inflammation due to CCL2 binding to the CCR2. Monocytes low in LY6C 
function to patrol the endothelium, and are more likely to differentiate into the anti-inflammatory 
macrophage subtype [28, 30].  
There are distinct subsets of macrophage populations that play different roles in the 
immune system. When stimulated, macrophages will polarize to a phenotype dependent on the 
environment the macrophage is in, as well as the stimuli, which will promote or inhibit 
inflammation. During an inflammatory event, the first macrophages to enter the site of 
inflammation will be the pro-inflammatory macrophage population subset. These macrophages, 
called M1 macrophages, are activated by cytokines such as TNF-γ, and elicit a pro-inflammatory 
response in the tissue. M1 macrophages exhibit potent antimicrobial activity, and play a major 
role in fighting bacterial, viral, and fungal infections [27]. The other macrophage population, 
called M2 macrophages, exhibit more of an anti-inflammatory phenotype, participate in tissue 
repair, and secrete cytokines such as IL-10 [28]. Tissue macrophages are generally polarized 
more towards the M2, anti-inflammatory phenotype. 
When monocytes extravasate across the endothelium, they differentiate into tissue 
macrophages. These tissue macrophages, which are found in the liver, lung, spleen, peritoneum, 
and brain, among other organs, are constantly surveying for inflammatory damage or foreign 
invaders [30]. Tissue macrophages mainly fulfill the role of fighting inflammation, immune 
surveillance and maintaining homeostasis in organs through the removal of apoptotic cells and 
communication with cells specialized for tissue repair, such as fibroblasts [31]. Macrophages are 
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constantly surveying their environment for signs of distress, foreign invaders, or xenobiotics 
through the use of phagocytosis, and this process will be explained further in later sections.  
1.1.4 Macrophage Depletion 
It has been reported by our laboratory that CFZ accumulates within tissue macrophages 
of the spleen, liver, and lung [5, 6, 12]. Because of the propensity of CFZ to accumulate within 
macrophages, depleting the population of macrophages within different tissues during the course 
of treatment is a potentially interesting avenue to explore. One well-studied model of 
macrophage depletion is the use of liposomal formulations of bisphosphonates, such as 
clodronate or alendronate [32, 33]. Clodronate is a bisphosphonate used to treat bone diseases 
due to its activity towards specialized bone degrading cells known as osteoclasts. The drug 
accumulates within the hydroxyapatite of the bone, and is absorbed by the osteoclast as it resorbs 
bone. Encapsulating these small, strongly hydrophilic molecules inside liposomes allows for 
them to be preferentially phagocytosed by macrophages. Once inside the cell, lysosomal 
enzymes break down the liposome, releasing the chemical intracellularly [32-35]. The clodronate 
is metabolized to a toxic analog of ATP that inhibits ATP/ADP translocase, interfering with 
mitochondrial membrane potential and cellular metabolism, eventually leading to apoptosis. 
Macrophage depletion by this method is specific towards macrophages and will not impact other 
cells, such as normal dendritic cells [33]. Non-phagocytic cells do not take in unformulated 
clodronate, nor is it toxic. Free, unformulated clodronate has a half-life of about fifteen minutes, 
and is rapidly eliminated via the renal system [34]. 
 Depletion of specific tissue macrophage populations using liposomal formulations of 
bisphosphonates is possible, and can be controlled by the route of administration [32-36]. To this 
end, the depletion of various populations of macrophages and the effect that this has on CFZ 
accumulation can be studied. Injection of liposomal clodronate intravenously causes the 
depletion bone marrow macrophages and Kupffer cells in the liver within one day [33], and 
causes all macrophages within the red pulp and marginal zone of the spleen to die within two 
days [32]. Two injections two days apart were required to get complete depletion within the bone 
marrow. Subcutaneous injection in the foot pad eliminated macrophages within the draining 
lymph nodes [33], while intratracheal administration depletes alveolar macrophages [36]. 
Intraperitoneal injection has been shown to be the most effective at impacting the largest 
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population of macrophages, depleting macrophages of the parathymic lymph nodes, spleen, liver, 
and peritoneal cavity. This is due to the larger volume which can be administered via the IP route 
[33]. Performing these macrophage depletion experiments in both animals during a long-term 
CFZ treatment regimen and animals that have already formed CLDIs can test the idea that 
macrophages specifically stabilize CLDIs, if CLDIs can potentially form in other cell types, and 
the fate of CLDIs released from dead cells. 
1.1.5 Endolysosomal Pathway 
Macrophages, or “big-eaters”, utilize the cellular process of phagocytosis to take in 
foreign particles and pathogens to prevent them from damaging the body. As high concentrations 
of CFZ have been shown to be detrimental to the health of cells [37], it is believed that the 
massive accumulation of the drug in macrophages is a protective mechanism put in place to 
curtail the cytotoxic effects of the drug [5]. Clofazimine may accumulate in the highly acidic 
lysosomal compartment of the cell, potentially as a result of ion trapping. Ion trapping, as 
previously discussed, is a phenomenon which occurs due to the ionization of a molecule after 
crossing a biological membrane, which severely limits the ability of the molecule to freely 
diffuse.  
Endocytosis is one of the major cellular pathways for the uptake of nutrients, destruction 
of pathogens, and degradation and recycling of cellular components [38]. Clofazimine 
accumulation most likely occurs within the endolysosomal system, and CLDIs are most likely 
formed in the highly acidic lysosomal environment of the macrophage [6]. Internalization occurs 
through a variety of mechanisms, such as formation of clathrin-coated pits or through other types 
of receptor-mediated endocytosis [39]. However, one thing that is common to the internalization 
of extracellular components is the fusion of the plasma membrane with the early endosome, 
where the intracellular location of the cargo is determined [40]. Proteins on the surface of the 
early endosome are often used to track the trafficking of internalized materials. The early 
endosome can be detected by the presence of a group of endocytic regulators referred to as Ras-
associated binding proteins (Rab proteins) [40], with RAB5A and RAB4 unique to the EE 
compartment [38]. The early endosome is for all intents and purposes, a sorting compartment 
that is used to determine the fate of internalized goods.  
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If the contents of the early endosome are targeted for degradation by the cell, the early 
endosome transforms into a late endosome. During this process, the membrane of the early 
endosome begins to invaginate, and multivesicular bodies form within the compartment [40]. 
The late endosome is characterized by the presence of the surface protein markers RAB7 and 
RAB9, as well as two mannose receptors [41], which help differentiate it from both the early 
endosome and the lysosome.  
Lysosomes contain the enzymes necessary to degrade the various proteins, lipids, and 
other waste products that pass through the endolysosomal system [38], and many of these 
enzymes require a highly acidic environment to function properly. The acidification of the 
lysosome most likely plays a very significant role in the formation of intracellular CLDIs, as 
previous work has shown that CFZ hydrochloride requires an acidic, chloride-rich environment 
to form [9]. Thus, it is believed that biomolecular proton and chloride transporters play a 
significant role in maintaining the CLDI within the cell. 
1.1.6 Biomolecular Proton and Chloride Transport Mechanisms 
During the various stages of the endolysosomal pathway, the pH of each compartment 
(early endosome, late endosome, endolysosome) becomes more acidic as the degradation process 
occurs. When first formed, the early endosome has a luminal pH between 6.1 and 6.8, which 
becomes more acidic as it transitions into a late endosome (pH=5.5) [41]. Fusion with the 
lysosome results in further acidification, with the luminal pH of lysosomes reaching as low as 
4.5 [38]. The low pH and oxidizing environment present in the endolysosome is necessary for 
the function of many of the enzymes present, and this environment may also be the reason 
behind the stability of CLDIs in cells. Mammalian lysosomes range in size from 0.1 to 1.0 μm 
[42], and have an average volume of around a femtoliter, assuming a spherical shape. Given the 
typical pH of a lysosome of 4.5, this corresponds to 19,000 protons in the typical acidified 
lysosome. The average chloride concentration in the lysosome has been measured to be on the 
order of 30 mM [43], which means that the typical lysosome contains more than 18,000,000 
chloride ions. Maintaining homeostasis of these ions is a complex process, and interference with 
these ions can significantly hamper the ability of the lysosome to properly function.  
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The acidification of the lysosome is the result of an interplay of many ion channels, 
transporters, and pores, each playing different roles. The primary membrane channel involved in 
the acidification of the endolysosomal system is vacuolar-type H
+
-ATPase (V-ATPase); this 
protein hydrolyzes ATP, providing the free energy needed for protons to be pumped against their 
concentration gradient into the lumen of the lysosome [42]. V-ATPase is present in nearly every 
eukaryotic cell type [44], and is found along many intracellular membranes, such as those in 
synaptic vesicles, Golgi vesicles, and endosomes [45]. Trafficking within the endolysosomal 
system is on many levels dependent on acidification of the various compartments by V-ATPase 
[38, 40, 41] due to the role pH changes play in binding and release of various surface markers. 
Inhibition of V-ATPase in the endolysosomal system has led to markedly slower cycling of 
receptors, showing that acidification is necessary for endolysosomal pathways [44, 46]. With 
respect to drug therapy, impairment in acidification of the lysosome is implicated in increased 
toxicity with certain chemotherapeutics. When lysosomal acidification is hindered through the 
use of the weak base chloroquine, co-administration of lysosomotropic anti-cancer agents 
resulted in hepatotoxicity, which was not observed following treatment with non-lysosomotropic 
agents [47]. 
V-ATPase is a unidirectional proton transporter, allowing two protons to cross into the 
lumen of the acidifying compartment for every molecule of ATP that is hydrolyzed [42]. As 
there is no concurrent ion transport coinciding with the addition of the two protons, the actions of 
V-ATPase are electrogenic, and will result in an increase in the membrane potential of the 
lysosomal compartment [48]. The resting membrane potential of the lysosome is between -20 
mV and -40 mV [49], and addition of protons results in a shift towards a more neutral membrane 
potential. To effectively acidify the lysosome or other cellular compartment, this positive 
membrane potential needs to be dissipated. The membrane potential can be dissipated through 
the actions of counter-ion exchange channels. These channels could shuttle a cation from the 
lumen of the lysosome into the cytoplasm, or a channel could add an anion to the lysosome to 
counteract the electrogenicity of the V-ATPase [42].  
Because CFZ accumulates as a hydrochloride salt [9], CLDI formation is most likely 
dependent on the activity of intracellular and extracellular chloride transporters. The chloride 
exchanger ClC-7 plays a key role in the acidification of endosomes and lysosomes, and may be 
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vital in the stabilization of CLDIs. CLC-7 is expressed ubiquitously throughout the body, and is 
found in the endosome and lysosome. In fact, CLC-7 colocalizes quite well with lysosomal-
associated membrane protein-1 (LAMP-1) [50]. This exchanger works to dissipate the positive 
membrane potential by adding two chloride ions to the lumen of the endosome or lysosome, and 
concurrently removing one proton from the compartment [51]. This exchange system accounts 
for much of the chloride permeability into the lysosome [52, 53].  
ClC-7 has a variety of roles throughout the body, and most functions are related to the 
acidification of lysosomes and endosomes. Genetic mutations associated with loss-of-function of 
ClC-7 lead to the development of neurodegenerative illnesses due to the accumulation of lipids 
within the lysosome, and animals with defective ClC-7 exchangers also display a phenotype of 
osteopetrosis due to the inability of osteoclasts to properly recycle bone as a result of incomplete 
lysosomal acidification [50]. Because a hydrochloride salt accumulates during CFZ treatment, it 
may play a major role in this accumulation. 
There are many different transporters that are involved in maintaining chloride 
homeostasis. Another chloride transporter of interest that is found on both the plasma membrane 
and various intracellular membranes is the cystic fibrosis transmembrane conductance regulator 
(CFTR). CFTR is an anion-exchange channel that is permeable to chloride, and dysfunction of 
this channel leads to a clinical manifestation of cystic fibrosis [54, 55]. This transporter is 
expressed in a variety of epithelial cells, from the intestines to the lung [55]. CFTR is not only 
expressed in cells of the epithelium; in alveolar macrophages, CFTR plays a significant role in 
lysosomal acidification, and this may help kill pathogens which enter the body through the lung 
[56]. CFTR colocalizes with LAMP-1, and when phagocytosis was induced in macrophages, 
CFTR staining was observed surrounding the ingested latex beads [56]. When macrophages were 
treated with the CFTR inhibitor CFTRinh-172, the cells failed to fully acidify the lysosome, being 
approximately one pH unit more alkaline than control cells. This indicates that CFTR, in 
conjunction with V-ATPase, may play a significant role in acidification of the lysosome in 
macrophages. 
A cation-exchange channel may also be partially responsible for the stability of 
intracellular CLDIs. A family of channels known as the transient receptor potential (TRP) 
channels has been associated with the endolysosomal system, and one channel is of particular 
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interest. TRP Mucolipin 1 (TRPML1) is an ion channel permeable to calcium, sodium, 
manganese, and iron, and is comprised of six transmembrane-spanning domains [57]. TRPML-1 
is expressed in almost every tissue in the body, with the highest amounts found in the brain, 
kidney, heart, liver, and spleen [58]. TRPML-1 is localized mostly to the late endosome and 
lysosome in humans, and plays a significant role in intracellular calcium release [59]. In humans, 
genetic mutations can lead to a loss-of-function of the TRPML-1 channel, resulting in a 
pathological state known as Mucolipidosis Type IV. This disease is characterized by 
psychomotor retardation, corneal clouding, and accumulation of lipids in endolysosomal-like 
compartments [60]. Cells isolated from TRPML -/- patients displayed enlarged vacuolar 
compartments where undigested lipids and biomaterials accumulate, indicating that TRPML-1 
plays a role in the trafficking of endocytosed materials and the formation of lysosomes [60, 61].  
Calcium is necessary for the formation and stabilization of the membranes of the late 
endosome/lysosome hybrid organelle [61]. The formation of lysosomes in TRPML -/- 
macrophages was studied, revealing that TRPML-1-mediated calcium release is required for the 
budding of lysosomes from the LEL; macrophages treated with calcium chealators displayed a 
similar phenotype as the TRPML-1 knockout macrophages, further illustrating the role calcium 
plays in lysosomal formation [58]. The TRPML-1 channel may play a role to maintain the pH 
environment of the endolysosome as well, but there are conflicting reports about the effects that 
loss of this channel plays in the acidification of the lysosome [58-60].  
At a larger scale, the regulation of the lysosome and subsequent acidification mechanisms 
is controlled through a nuclear transcription factor known as transcription factor EB (TFEB) 
[62]. In normal cellular conditions (i.e., appropriate nutrient conditions or low lysosomal stress), 
TFEB is found in its phosphorylated form within the cytosol, where it is inactive. However, 
when cells are stimulated via nutrient or some other stressor, TFEB becomes dephosphorylated 
and translocates to the nucleus, becoming an active cellular transcription factor [49, 62]. The 
genes that TFEB controls regulate lysosome biogenesis, membrane formation, and autophagic 
functions within the cell [63, 64]. Additionally, it has been shown that TFEB and the expression 
of biomolecular ion transporters, in particular, V-ATPase, are closely linked [65, 66], and are 
regulated by the kinase mammalian target of rapamycin complex 1 (mTORC1). TFEB activation 
can also occur due to stresses to the lysosome brought about by ion-trapping. Lysosomotropic 
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compounds incubated with cultured cells have been shown to activate TFEB, resulting in 
increased lysosomal volume and intracellular vesicles [18-20, 67, 68]. TFEB activation and 
subsequent lysosomal biogenesis is also implicated as a potential mechanism behind 
chemoresistance to weakly basic anti-cancer agents [69] due to increased lysosomal exocytosis, 
indicating that this may be a cytoprotective mechanism. 
1.1.7 Proton and Chloride Transporter Inhibition 
In order to assess the role that these biomolecular proton and chloride transporters play in 
maintaining CLDI stability, pharmacological inhibitors of specific channels can be utilized. By 
interfering with the actions of these channels, the CLDI may become destabilized, leading to 
release of drug from the cell and into the surrounding environment.   
 The role of chloride transporters in maintaining the CLDI can be tested using the 
inhibitors 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB), 4,4'-Diisothiocyano-2,2'-
stilbenedisulfonic acid (DIDS), and 2-[3-(trifluoromethyl)anilino]nicotinic acid (Niflumic 
acid/NFA). DIDS is the most effective in inhibiting ClC-7, with a reported IC50 of 40 μM [70], 
with other sources reporting an irreversible inhibition at concentrations above 30 μM [71] . This 
inhibits over 90% of the activity of the channel within isolated cells [70]. NPPB is also a very 
effective inhibitor of ClC-7, with a reported IC50 of 150 μM [70], with other sources reporting 
values between 100 and 200 μM, depending on the tissue [71, 72]. NPPB has been shown to 
inhibit around 90% of the activity of ClC-7 when incubated with cells [70]. Niflumic acid is less 
specific in its activity toward ClC-7. NFA shows some inhibitory effects on ClC-7, inhibiting 
roughly 30% of the activity of ClC-7 channels when tested between 1 and 1000 μM [70]. NFA is 
a general inhibitor of chloride channel activity, and it is a very potent inhibitor of calcium-
activated chloride channels [73].  
 Inhibitors for CFTR are more specific in their activity. The anti-diabetic drug 
glibenclamide is a powerful, widely used inhibitor of CFTR activity [74, 75]. Glibenclamide has 
a reported IC50 of 20 μM, which will irreversibly inhibit more than 90% of CFTR activity [76]. 
Other sulfonylureas, such as tolbutamide inhibit CFTR; however, glibenclamide is the most 
potent in its activity [76]. A second CFTR inhibitor, 3-[(3-trifluoromethyl)phenyl]-5-[(4-
carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone (CFTRinh-172), can also be tested. 
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CFTRinh-172 inhibits greater than 90% of CFTR activity at concentrations above 10 μM [77] and 
does not display cytotoxicity at concentrations below 50 μM [78].  
 The calcium channel TRPML is permeable to divalent cations, such as Ca
2+
 and Fe
2+
, and 
is inhibited by trivalent cations, such as Gd
3+
, Fe
3+
 and La
3+
 [59-61]. Incubation of cells with 1 
mM solutions of Gd
3+
 or La
3+
 resulted in a loss of more than 70% of the current from the 
TRPML channel [79].  Solutions of GdCl3, LaCl3, and FeCl3 will be tested for their ability to 
inhibit TRPML-1. These trivalent ions work to inhibit channel function by blocking the pore, 
preventing the normal, divalent ions from passing. Treatment with Gd
3+ 
has been shown to 
inhibit Kupfer cell function [80].  
In order to probe the role of V-ATPase in maintaining the CLDI, two V-ATPase 
inhibitors can be tested. Bafilomycin A1, a macrolide antibiotic produced by Streptomyces [81, 
82], is an extremely potent inhibitor of V-ATPase, with an IC50 on the order of 5 nM [83, 84]. 
Concanamycin A, a macrolide antibiotic in the same family as bafilomycin A1, is another very 
potent inhibitor of V-ATPase. Con A inhibits V-ATPase with an IC50 of 10 nM in yeast [85, 86], 
which is similar to what is seen with bafilomycin. These two inhibitors are very specific for V-
ATPase at these concentrations, and should not impact other cellular transporters. However, 
there is some evidence that treatment with these antibiotics can lead to increased cell death via 
apoptosis [87].  
1.1.8 Polarized Light and the Detection of Ordered Aggregates 
Polarized light microscopy is a highly sensitive analytical tool which can be used to study 
changes in the optical properties of a material as a result of minute changes to its underlying 
molecular order or chemical composition [88]. This allows for polarized light to be used to study 
changes to the molecular structure of a biological material without the need for chemical labeling 
[89]. A material can interact with light in one of two ways: in an isotropic manner or in an 
anisotropic manner. An optically isotropic material is one whose optical properties do not change 
regardless of its orientation with respect to the incident light. An optically anisotropic material, 
on the other hand, interacts with light in a non-uniform manner, depending on the orientation of 
the material or incident light [90]. An example of an anisotropic optical property is the 
attenuation of light passing through a cell membrane; the membrane, composed of a complex 
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arrangement of phospholipids, carbohydrates, and proteins, differentially allows for light to pass 
through depending on its orientation with respect to the plane of the membrane.  Optical 
anisotropy reflects the orientation of membrane-associated molecules in relation to the plane of 
the membrane, leading to variations in the absorption and scattering of polarized light 
transmitted through the samples in different directions with respect to the plane of the membrane 
[89-91].  
By taking advantage of this, one can use linear diattenuation to study the molecular order 
of anisotropic materials. Linear diattenuation is a property of a material where the intensity of 
linearly polarized light transmitted through a sample is dependent on the polarization state of the 
light used to probe the sample [89, 92, 93]. When linearly polarized light passes through a 
material, any molecular alignment within the material creates two principal axes: a high 
transmittance and low transmittance axis, corresponding to the axis of molecular alignment [89]. 
Light that is not polarized parallel to the high or low axis of transmittance is split into two 
components when it enters a diattenuating material [89, 93]. One beam of light is polarized to the 
high transmittance axis, and the other beam is polarized orthogonally to the axis. When the two 
beams leave the material, they recombine and the intensity of the recombined light can be 
represented as a function of the angle of the incident polarized light. The intensity of this 
transmitted light displays a sinusoidal relationship with the angle of polarization of the incident 
light [89]. 
Using linear diattenuation, assessment of the optical anisotropy of histological and live cell 
samples can be used to identify and study the formation of insoluble ordered molecular 
aggregates within cells and tissues. To accomplish this, a specialized microscopic imaging 
platform has been developed for our laboratory: the LC-PolScope [94] is a microscope imaging 
system that utilizes a computer controlled liquid crystal (LC) compensator capable of generating 
linearly polarized light of any orientation [95]. This microscope set-up allows linear 
diattenuation, fluorescence, and brightfield images to be captured from the same field of view, 
allowing these optical properties to be correlated with one another during various stages of 
treatment and washout of the drug. 
1.2 Rationale 
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Prolonged treatment with clofazimine (CFZ) leads to the formation of ordered, insoluble 
aggregates. This formation results from the accumulation of solubilized drug, which then 
undergoes a chemical transformation to form highly ordered, crystal-like drug inclusions 
(CLDIs). The inclusions that form are solid, bright red, birefringent objects with strong 
fluorescence in the Cy5 channel (650 nm excitation/ 670 nm emission). CLDIs are chemically 
different from the triclinic (TC), free base form of CFZ, which is the form present in commercial 
formulations of CFZ. The TC form is orange-red in color, slightly birefringent, and shows a 
strong fluorescence in the FITC channel (495 nm excitation/ 519 nm emission). The TC form of 
the drug does not show any signal in the Cy5 fluorescence channel. This, along with changes in 
the X-ray powder diffraction pattern of isolated CLDIs, indicates that a polymorphic change 
occurs during accumulation of the drug by the body. Crystal formation within cells is not 
harmful, and CLDI formation promotes an anti-inflammatory phenotype in macrophages by 
stimulating the production of various anti-inflammatory signaling molecules. These studies can 
also demonstrate other benefits of treatment with CFZ, such as the immunomodulatory effects of 
treatment. Once inside the cell, these crystals display great stability, and remain in the body long 
after treatment has ended. By characterizing the cell types which form CLDIs, as well as the time 
scale in which the crystals form and leave the body, we can provide valuable insight to not only 
the accumulation of CFZ, but also other drugs with the propensity to accumulate within cells and 
tissues, or drugs which form ordered, insoluble aggregates as a result of treatment.  
1.3 Central Hypothesis 
Clofazimine has been demonstrated to accumulate within F4/80 positive cells in the liver, 
spleen, lung, and almost every other organ in the body. These cells accumulate and sequester the 
drug in a manner to most likely protect the body from toxicity related to high levels of CFZ. 
There is no evidence of extracellular CLDI formation, and CLDIs have not been observed in 
non-macrophage like cells in histological sections. For example, in the liver, CLDIs are 
exclusively seen in Kupffer cells, with no insoluble aggregates seen in hepatocytes. Clofazimine 
also displays immunomodulatory properties, and this may result from accumulation within 
immune cells. CLDIs are incredibly stable once inside the macrophage, and do not readily 
degrade once CFZ treatment ends. The stability within the macrophage may be due to the action 
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of biomolecular proton and chloride transporters. CLDIs are formed and stabilized by an active, 
macrophage-dependent mechanism. 
1.4 Specific Aims 
1.4.1 Specific Aim 1 
Clofazimine that is administered to patients is in the TC form, and possesses a strong signal 
in the FITC range and weak diattenuation anisotropy signal. Following prolonged treatment, 
insoluble aggregates of the drug form, and have optical properties that allow for it to be 
distinguished from the TC form. These properties include a loss of signal in the FITC range, 
appearance of signal in the Cy5 range, and the development of a strong diattenuation signal. 
The first aim of this project is to develop a microscopic imaging and analysis method to 
study the formation of CLDIs at a cellular and subcellular level. 
1.4.2 Specific Aim 2 
The accumulation of clofazimine and transformation into an insoluble salt form is 
hypothesized to be an active process dependent on the action of macrophages. In order to test 
this, the cell types that accumulate clofazimine will be determined to see if non-macrophages 
form CLDIs. The chemical depletion of macrophages with liposomal formulations of 
clodronate will be used to probe both the impact of macrophage depletion on CFZ 
accumulation and CLDI formation, as well as macrophage depletion on CLDI stability. This 
will allow us to confirm the role of macrophages in the formation and stabilization of CLDIs 
by specifically killing the cell type that preferentially accumulates the drug. 
1.4.3 Specific Aim 3 
Clofazimine, due to the fact that it contains a weakly basic, ionizable amine, most likely 
accumulates within the endolysosomal system. The insoluble form of CFZ precipitates as a 
hydrochloride salt, which indicates that the formation and stability of the crystals may rely on 
the action of a chloride transport system. One of the major lysosomal acidification channels 
is V-ATPase, but other channels and exchangers are necessary to dissipate the positive 
membrane potential gained. CLDIs are extremely stable in tissues and cells, and even 
following cessation of treatment, will remain in tissues for extended periods of time. The role 
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that these transporters play will allow us to identify specific mechanisms that mediate the 
stability of the CLDI within macrophages. 
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Chapter 2 
A Role for Low Density Lipoprotein Receptor-Related Protein 1 in 
the Cellular Uptake of Tissue Plasminogen Activator in the Lungs 
2.1 Relevance to Thesis 
Microscopy and the development of reproducible, broadly applicable quantitative image analysis 
algorithms form the basis of one of the three aims of the research of this dissertation. Prior to 
designing and implementing image analysis algorithms to study the accumulation of clofazimine 
and stabilization of biocrystals in tissue and live cell samples, work was performed to compare 
and quantify the expression of the plasma membrane receptor low-density lipoprotein receptor-
related protein 1 (LRP1) within lung and liver tissues following immunohistochemical staining 
with 3-3’-diaminobenzideine (DAB). Because of the organization of the two organs, with the 
liver being a much more dense, cellular organ and the lung having large, empty pockets of air, an 
analysis strategy was required that would account for this difference in tissue organization, while 
at the same time allowing for an accurate comparison of the levels of protein expression. 
Because of the pigmentation of the DAB within the tissue sections, as well as the unique 
absorbance spectrum of the molecule itself, my own contribution to the work presented in this 
chapter involved isolating the specific signal contribution of the DAB within each tissue section 
and relating that to the expression of LRP1 within the organ. Through the use of various optical 
filters ranging from the far red range to the blue range, tissue background signal was eliminated, 
allowing us to accurately isolate the DAB staining from the unstained tissue components, which 
in turn, let us quantify the total percentage of tissue area that was stained for the protein of 
interest through thresholding and use of other quantitative image analysis methodologies. The 
strategies implemented in this image analysis methodology helped guide the image analysis of 
cells isolated from clofazimine treated animals discussed in chapters 6, 7, and 8, in particular, by 
showing that the pigmentation and absorbance of the chemical can be an appropriate parameter 
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to use in quantitative image analysis methodology. Additionally, the image analysis 
methodologies used to quantify tissue staining of a cellular target of interest developed here were 
further applied to design and implement quantification of cellular and tissue markers of both 
chemically tagged markers through DAB and fluorescently tagged cellular markers in both live 
cells and tissue cryosections. 
2.2 Abstract 
Using an in vivo mouse model and ex vivo murine whole organ cell suspensions, we examined 
the capability of the lungs to utilize LRP1 receptor-mediated endocytosis (RME) for the uptake 
of exogenous tPA with and without an LRP1 inhibitor, receptor associated protein (RAP), and 
quantitatively compared it to the liver. We also used a novel imaging technique to assess the 
amount LRP1 in sections of mouse liver and lung. Following intratracheal administration, tPA 
concentrations in the BALF declined over time following two-compartment pharmacokinetics 
suggestive of RME clearance mechanism. Ex vivo studies showed that lung and liver cells are 
similarly capable of tPA uptake via LRP1 RME which was reduced by ~50% by RAP. The 
comparable lung and liver uptake of tPA is likely due to equivalent amounts of LRP1 of which 
there was an abundance of LRP1 in alveolar epithelium. Our findings indicate that LRP1 RME is 
a candidate clearance mechanism for inhaled tPA which has implications for the development of 
safe and effective dosing regimens of inhaled tPA for the treatment of plastic bronchitis and 
other fibrin-inflammatory airway diseases in which inhaled tPA may have utility. 
2.3 Introduction 
Plastic bronchitis is a rare, primarily pediatric disease that is characterized by the 
formation of obstructive, exudative, inflammatory fibrin casts in the tracheobronchial tree [1–4]. 
Inhaled nebulized tPA (alteplase, Genentech, South San Francisco, CA, USA) is often clinically 
used off-label to treat acute exacerbations of PB [5–9]. tPA is a serine protease that degrades 
fibrin via the activation of plasminogen which yields plasmin and is used therapeutically to 
dissolve thrombus associated with MI, pulmonary embolism, and AIS [10–12]. For PB 
treatment, inhalation of tPA permits targeted delivery to the site of drug action which requires 
repeated administration into the airways [5]. 
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The dosing regimen of inhaled tPA for PB treatment was derived from the weight-based 
adult intravenous regimen used in the treatment of MI or AIS. Systemic administration and 
clearance of tPA in adults has been well characterized [10–12]. The drug has a reported initial 
(α) half-life of 5 minutes that is followed by a more prolonged terminal (β) phase which is 
characteristic of a two-compartment model [13, 14] and follows non-linear pharmacokinetics 
[15, 16]. Its clearance from the systemic circulation occurs by hepatic RME via LRP1 and 
mannose receptors [12, 16–19] and RME likely contributes to the nonlinearity of tPA clearance 
[15, 16]. LRP1 is ubiquitous and is expressed on hepatocytes and many other cell types [20], 
including lung fibroblasts and macrophages [21, 22] and it has been detected in pneumocytes and 
bronchial epithelium [23]. To date, most of the pulmonary LRP1 related research has focused on 
the receptor's role in inflammatory lung disease [24], pulmonary function [25] and lung cancer 
[26]. 
To study the fate of tPA in the lungs, animal studies have been performed following IT 
administration of tPA. Following IT dosing, tPA is detectable in BALF of healthy mice up to 
several hours after dosing and fatal pulmonary hemorrhage occurred in a group of mice that 
received high, repeated doses of tPA (> 1mg/kg/d), suggesting that tPA may accumulate in the 
airways [27, 28]. Since LRP1 plays an essential role in the elimination of tPA from the systemic 
circulation, we hypothesized that pulmonary LRP1 will bind and transport inhaled tPA from the 
airway lumen into the epithelial cell lining, and potentially into the circulation. We previously 
reported that lower levels of LRP1 in the airways compared with the liver, may explain slower 
elimination of inhaled tPA in the lungs [29]. Here, we have expanded on the details of these 
findings and now show that lung LRP1 is abundant in type II alveolar epithelium through a 
combined approach of ex vivo studies and state-of-thescience imaging techniques. In addition, 
whole organ cell studies show that the lung has a similar capability as the liver for LRP1-
mediated uptake of tPA. This knowledge has significant implications for improving 
understanding of the fate of therapeutic macromolecules in the airways as well as for the 
development of safe and effective dosing regimens of inhaled tPA for the treatment of PB and 
other fibrin-inflammatory airway diseases [30–32] in which inhaled tPA may have utility. 
2.4 Materials and Methods 
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Animals. Male mice (C57BL/6; 8 weeks old) were purchased from the Jackson Laboratory (Bar 
Harbor, ME, USA) and housed for at least one week prior to experimentation. The animal 
protocols were reviewed and approved by the Institutional Animal Care and Use Committee of 
the University of Michigan in accordance with the principles of the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
Isolation of Mouse Alveolar Epithelial Cells. Murine type II alveolar epithelial cells were 
isolated using the method developed by Corti et al. [33] and as previously described [34]. 
Briefly, following CO2 euthanasia, the pulmonary vasculature was perfused, and the lungs were 
first filled with dispase (1mL; Worthington, Lakewood, NJ) and then low melting point agarose 
(1mL) and placed in ice-cold PBS to harden. The lungs were then submerged in dispase for 45 
min before being minced and incubated in DMEM with 0.01% DNase for 10 min. A single-cell 
suspension was obtained by passing the lung mince over a series of nylon filters. Myeloid cells 
were removed by first incubating cells with biotinylated antibodies against CD32 and CD45 (BD 
Pharmingen, San Diego, CA) and then streptavidin-coated microbeads (Promega, Madison, WI), 
followed by negative selection using a magnetic tube separator. Mesenchymal cells were 
removed by overnight adherence in a Petri dish. Non-adherent AEC were plated on fibronectin-
coated plates and cultured for 72 h in complete DMEM. At the time of harvest, media was 
removed, lysis buffer was added to the plate and samples were frozen (−80°C). The method is 
known to result in a sample that consists of approximately 93% and 95% type II cells by 
Papanicolaou staining, which detects the lamellar bodies of type II cells [35], and ultrastructural 
analysis, respectively. 
Administration of Tissue Plasminogen Activator (tPA). Human recombinant tissue 
plasminogen activator (htPA; alteplase, Activase®, Genentech, South San Francisco, CA, USA) 
was formulated and nebulized for pulmonary delivery as previously described [36]. The 
collected aerosol was assayed by UV spectroscopy to determine protein concentration and the 
extent of protein aggregation [28, 36]. Using the protein concentration derived from this method, 
mice received a single IT dose (via the oral route) of 0.3mg/kg. For this, mice were anesthetized 
under isoflurane (Fluriso; Vet One, Boise, ID), placed on a rodent intubation table (Hallowell 
EMC, Pittsfield, MA, USA), and the vocal cords were visualized using an otoscope (Welch-
Allyn Medical Products, Skaneateles Falls, NY, USA) [27, 28]. The tip of a gavage needle (22G, 
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Hallowell EMC) attached to a syringe containing a dose of either pf-mtPA or an equivalent 
volume of sterile saline was gently moved past the vocal cords and into the trachea; the dose was 
delivered by depression of the syringe's plunger. Following drug or saline administration, the 
mouse was held upright for approximately 5 s, after which it was returned to a cage and allowed 
to recover from anesthesia. 
Collection of BALF and Blood Samples and Measurement of htPA. At each respective time 
point, mice were anesthetized with ketamine (50mg/kg) and xylazine (5 mg/kg) administered by 
intraperitoneal injection. A blood sample was collected via cardiac puncture into a heparinized 
tube which was centrifuged (1000 × g, 4°C for 5 min) to generate plasma. These samples were 
stored (−80°C) until the time of assay. After the collection of the blood sample, a tracheotomy 
was performed. The BALF was collected by flushing 2× 400μL of PBS into the lung via the 
tracheal cannula. The BALF was centrifuged (1000 × g, 4°C for 5 min) and the supernatant was 
collected and frozen (−80°C) until the time of assay. At the time of assay, samples were thawed 
on ice and the concentration of htPA was measured using an enzyme-linked immunosorbent 
assay (ELISA). For this, the wells of a 96-well microtiter plate were coated with 100 μL/well of 
capture antibody (1 μg/mL; rabbit anti-human tPA, Molecular Innovations, Novi, MI) and 
incubated for 1 h (37° C). The plate was washed with wash buffer (0.05% Tween-20 in 1X PBS, 
pH 7.2) using a 96-well plate washer (BioTek ELx405, Winooski, VT) three times after which 
blocking reagent (5% milk in 1X PBS 0.05% Tween-20 buffer) was added to each well. The 
plate was covered and incubated (1 h) at room temperature (RT) and the wash step was repeated. 
Upon completion of the second wash, standards (htPA, 0–1000 ng/mL) and diluted samples (100 
μL/well) in duplicate were added to respective wells and the plate was covered and incubated (1 
h, RT). The plate was washed again and 100 μL of detection antibody (1μg/mL; mouse anti-
human tPA, Calbiochem, Gibbstown, NJ) was added to each well and the plate was covered and 
incubated (1 h, RT). Following this incubation, the plate was washed and 100 μL of a 
horseradish perioxidase (HRP) conjugated antibody (1μg/mL; goat anti-mouse IgG HRP, 
Millipore, Billerca, MA) was added to each well followed by incubation (20 min, RT) and the 
addition of TMB substrate solution (100 μL/well). The reaction was stopped by the addition of 
sulfuric acid (100μL of 2N). The assay was previously validated to show no cross reactivity with 
rat or mouse tPA and the lower limit of detection was determined to be 10 ng/mL. The 
absorbance data were acquired using a ThermoMax microplate reader (Molecular Devices, 
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Sunnyvale, CA). The total tPA concentration of each sample was derived from the linear phase 
of the standard curve as analyzed by reader's software (Softmax PRO 4.1, Molecular Devices). 
The resulting mean BALF htPA concentration data were plotted as ln concentration versus time 
which revealed a pharmacokinetic profile with a biphasic elimination pattern indicative of a two-
compartment model [14]. Best line fitting of the first five, initial (α) phase, ln concentration 
measurements and the last three, terminal (β) phase, ln concentration measurements were used to 
calculate the elimination rate constants (Kd) of each phase. The elimination half-life (t1/2) of 
each phase was calculated by dividing 0.693 by the respective Kd. 
Generation of Primary Cell Suspensions. Whole lung and liver organs were harvested from 
mice for generation of primary lung and liver cell suspensions. Mice were euthanized under CO2 
in a contained chamber and following thoracotomy and appendectomy, the organs were perfused 
blood free with PBS (Life Technologies, Carlsbad, CA, USA). Blood-cleared lungs and livers 
were excised en bloc, placed into DMEM high glucose media (Life Technologies) and were 
manually dispersed and passed through cell strainers to remove connective tissues. The resulting 
whole organ cell suspensions were then centrifuged (800 × g, 4°C, for 5 min) to acquire primary 
cells. The pelleted cells were resuspended in PBS and residual red blood cells (RBC) were lysed 
with the addition of RBC lysis buffer (Sigma-Aldrich, St. Louis, MO, USA). The cell suspension 
was washed with PBS and centrifuged an additional three times after which the final cell 
suspensions were maintained in DMEM on ice. Primary lung and liver cells were stained with 
trypan blue and counted using an automated cell counter (Countess, C10227, Life Technologies). 
For the experiments, 20,000 cells were plated per well into 24-well plates in DMEM media and 
maintained at 37°C (5% CO2). 
Mouse Tissue Plasminogen Activator (mtPA) Treatment. In advance of tPA treatment, 400 
nM of receptor associated protein (RAP, P30533, Molecular Innovations), an inhibitor of LRP1, 
or an equivalent volume of PBS was added to some cells and they were incubated (30 min, 5% 
CO2, 37°C). Recombinant mtPA protein (P11214, Molecular Innovations, Novi, MI, USA) in 
doses of 25, 50, or 100 ng or an equivalent volume of PBS was added to whole lung and liver 
primary cells and the plates were incubated (5% CO2, 37°C) for 30 min. Following incubation, 
the contents of each well were transferred to a microcentrifuge tube and centrifuged (800 × g, 
4°C, for 5 min). The supernatant was removed and stored (−80°C). Cell pellets were washed 
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with PBS and centrifuged again, after which wash buffer supernatant was removed and stored 
(−80°C). The final cell pellet was resuspended in radioimmunoprecipitation assay (RIPA) buffer 
(Sigma-Aldrich) and frozen (−80°C). Time course studies (0–30 min) of mtPA uptake by whole 
lung and liver cell suspensions in the presence and absence of RAP (400 nM) were done as 
described above following the addition of mtPA (50 ng). 
Western Blotting. Frozen samples containing 10,000 whole cell lysates were eluted with 
Laemmle 2X sample buffer (Sigma-Aldrich) with 5% β-mercaptoethanol and separated by 10% 
SDS-PAGE (BioRad, Hercules, CA). Proteins were transferred to polyvinylidene fluoride 
(PVDF) membranes and blocked (5% milk in PBS with Tween-20 (Sigma-Aldrich)). Membranes 
were immunoblotted overnight (4°C) with a nti-mouse tPA (ASMTPA-GF, Molecular 
Innovations) and LRP1 (ab92544, Abcam, Cambridge, MA, USA) in 1:5000 and 1:15,000 
dilutions (5% milk in PBS with Tween 20), respectively. Post immunoblotting, membranes were 
washed with PBST (PBS with Tween 20, three times for 5 min each). Then membranes were 
incubated with a horseradish peroxidaseconjugated secondary antibody (goat antirabbit, 
AQ132P, Millipore, Billerica, MA, USA) in 1:10,000 dilution (2 hours at RT). Signal detection 
was achieved using enhanced chemiluminescence (Pierce ECL Western Blotting Substrate, 
Thermo Scientific, 32106, Rockford, IL) and exposure to radiographic film (BioMax Light Film, 
Z370371, Kodak, Rochester, NY). The image was acquired using a Medical Film Processor 
Model SRX-101A (Konica Minolta) and Image J (ImageJ 1.44b, NIH, Bethesda, MD, USA) was 
used to quantify protein band density. 
Measurement of mtPA Uptake by Lung and Liver Cell Suspensions. The concentration of 
mtPA in lung and liver cell lysates (intracellular fraction) and supernatants (extracellular 
fraction) was detected using mtPA total antigen assay ELISA kit (MTPAKT-TOT, Molecular 
Innovations). The mtPA concentrations of the samples were derived from the standard curve. 
Immunohistochemistry. Existing C57BL/6 mouse and 13N159 macaque monkey lung and liver 
formalin fixed, paraffin embedded (FFPE) samples were sectioned at the University of Michigan 
Unit for Laboratory Animal Medicine and analyzed by immunohistochemical staining for LRP1. 
Heat-induced antigen retrieval of the sample sections was performed using Rodent Decloaker 
(RD913, Biocare Medical LLC, Concord, CA) and EDTA Decloaker (CB917, Biocare Medical). 
Tissue sections were then blocked with Peroxidazed 1 (PX968M, Biocare Medical) and Rodent 
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Block M (RBM961, Biocare Medical). Immunohistochemical staining was assessed using a titer 
titration of the primary antibody (1:500, 1:1000, and 1:5000) and the pathologist determined that 
the 1:1000 dilution was optimal. Samples were incubated in monoclonal LRP1 antibody diluted 
1:1000 (rabbit α-mouse ab92544, Abcam). Secondary and tertiary incubations were carried out 
with Rabbit-on-Rodent HRP-polymer (RMR622, Biocare Medical) and intelliPATH Universal 
HRP Tertiary Reagent (IPT5002, Biocare Medical), respectively. LRP1 was detected and 
visualized using 3'3'-diaminozenzidine (DAB) (intelliPATH FLX™ DAB Chromogen Kit, 
IPK5010, Biocare Medical) followed by DAB post-enhancing solution (DAB sparkle, DS830G, 
Biocare Medical). All sections were counterstained with hematoxylin (CAT Hematoxylin, 
CATHE-M, Biocare Medical). Negative control slides were also generated by omitting the DAB 
staining step. 
Image Acquisition and Analysis. Digital images of stained and unstained lung and liver 
sections at 40× magnification were acquired on a Ti Eclipse inverted microscope (Nikon 
Instruments, Inc., Melville, NY, USA) using bright field optics under Kohler illumination. To 
acquire and quantify DAB stained images, a red filter (655 ± 30 nm), which corresponds to the 
absorbance peak of the background staining, and a blue filter (480 ± 30 nm), which corresponds 
to the absorbance peak of DAB, were used. The density of DAB staining is indicative of LRP1 
receptor density. To analyze quantify DAB staining density all images were analyzed with 
ImageJ. 
Statistical Analysis. Statistical analyses were performed using PRISM 6 software (GraphPad, 
La Jolla, CA, USA) and differences between groups and treatments were estimated by unpaired 
Student's t-test or ANOVA with post-hoc analyses, as appropriate. Dose-response was assessed 
by linear regression. A p-value of ≤ 0.05 was considered statistically significant. 
2.5 Results 
2.5.1 BALF Levels of Lung Delivered htPA Declined Over Time. Instillation of htPA into 
the mouse lung resulted in detectable levels of htPA that declined over time (Figure 1). At no 
time point was htPA detected in the blood. Pharmacokinetic fitting of the htPA log 
concentration-time data revealed that the change in htPA concentration was most consistent with 
a two-compartment model. 
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2.5.2 Antagonism of the LRP1 Receptor Reduced mtPA Uptake in Whole Lung Cell 
Suspensions. To determine the role of LRP1 on lung clearance of tPA, we proceeded to establish 
that the uptake of mtPA into primary murine lung and liver whole cell suspensions was affected 
by the presence of a known LRP1 inhibitor, receptor associated protein (RAP). Quantitation and 
representative Western blots of both lung and liver cell uptake of mtPA in the presence and 
absence of RAP are shown in Figure 2. The amount of mtPA uptake into lung, but not liver cells, 
was dose dependent (r
2
=0.823, p=0.155, respectively). In both lung and liver, mtPA uptake was 
reduced by 20–67% in the presence of RAP. 
2.5.3 Timecourse of mtPA Uptake in the Presence and Absence of RAP is Similar in the 
Lung and Liver. To further substantiate the role of LRP1 in the uptake of mtPA, we assessed 
the time course of mtPA uptake in lung and liver whole cell suspensions. Pre-treatment with 
RAP reduced LRP1-mediated uptake of mtPA in both lung and liver cells as measured by 
Western blot (Figure 3A and Figure 3B). This finding was corroborated by a corresponding 
increase in intracellular fraction mtPA levels as measured by ELISA (Figure 3C and 3D). 
Although initial (time 0) intracellular fraction concentrations were lower in liver than in lung 
cells (Student's t-test p=0.036), RAP inhibited mtPA uptake in both liver and lung cells (Figure 
2-3E and 2-3F). Using the extracellular fraction mtPA concentrations that are less prone to 
degradation than intracellular fraction mtPA, the average percent RAP-mediated reduction in 
LRP1 uptake of mtPA over the entire 30 min time course was similar for the lung and liver cell 
suspensions, 58% and 52%, respectively. 
2.5.4 Lung and Liver Cell Suspensions Have Similar Amounts of LRP1 Protein. The 
relative amounts of LRP1 in murine lungs and murine liver samples were quantified and 
displayed similar amounts of the receptor. Based on a linear relationship between the measured 
LRP1 protein density (Figure 4A and 4B) and cell number, densitometry data show that the 
LRP1 protein density per cell is similar (mean±S.D.: 1.2±1.1 vs. 1.0±0.78, p = 0.81) in liver and 
lung cells, respectively. LRP1 was also detected in isolated type II alveolar epithelial cells 
(Figure 4C). 
2.5.5 The Lung and Liver Have Similar Ratios of LRP1 Staining. As an independent 
measurement of the relative amounts of LRP1 protein in liver and lung cells, FFPE liver and 
lung tissue sections were immunohistochemically stained for LRP1. Brightfield images were 
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acquired using a transmitted light microscopy set up (Appendix A, Image Acquisition and 
Analysis Workflow) with two different wavelengths of light (655nm and 480nm) corresponding 
to the peak absorbance signal of the LRP1-specific probe (brown DAB staining), and the peak 
absorbance of the nonspecific, background tissue signal (Figure SI. 1). In the liver (Figure 5A), 
brown DAB staining corresponding to the distribution of LRP1 was ubiquitous across the section 
(also see Figure SI. 3A and SI. 3B). In the lung (Figure 5B), brown DAB staining corresponding 
to the distribution of LRP1 was localized along the epithelial lining of the alveoli and in 
macrophages (Figure SI. 3C and SI. 3D). Based on quantitative image analysis, the density of 
LRP1 staining over the cellular regions of liver and lung sections was not different between the 
two organs (Figure 5C). Image analysis of LRP1 stained 13N159 macaque lung and liver 
sections produced similar staining results (Figure SI. 4). 
2.6 Discussion 
Inhalation of nebulized tPA has therapeutic potential as a treatment for the rare, pediatric 
illness, PB [5–9]. However, very little is known about the transport of tPA following delivery 
into the airways. Here, we show that the concentration of IT administered tPA declined over time 
in the BALF and that the time-dependent tPA concentration change followed two-compartment 
pharmacokinetics with an estimated α-phase elimination halflife of 0.7h and an estimated β-
phase elimination half-life of 5.8h. We cannot confirm nonlinear kinetics because we only tested 
one dose of tPA. However, similar to what has previously been reported [15], the BALF tPA 
concentration versus time curve showed an upward trend suggesting a zero-order component. 
This is consistent with RME [16, 17] and suggests that tPA is either degraded or removed from 
the airway space. Potentially contributing to the clearance of tPA in the airways, is the 
significant expression of pulmonary LRP1, which was primarily detected in the alveolar 
epithelium, at levels comparable to the liver. In addition, our data show that, in both lung and 
liver cell suspensions, the peak measured intracellular fraction tPA concentration occurred within 
1 min of the application of tPA to the cells and this concentration was reduced by half within 10 
min. This observation implies that LRP1-mediated uptake into cells occurs very quickly [16, 17] 
and likely contributes to the αt1/2 of tPA in the airways. The longer βt1/2 may be attributable to 
the diffuse distribution of tPA in the lungs that is known to occur after IT administration [36, 37] 
and involves other clearance mechanisms such as mucociliary action which is categorized as 
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slow (Figure 6) because it can take several hours for macromolecules to be cleared from the 
airway by this process. Transcellular absorptive transcytosis is also reported to occur over hours 
[38] but, to date, there is no evidence that tPA is removed from the airway via this mechanism. 
Thus, we infer that LRP1-mediated binding and uptake contributes, at least in part, to the early 
clearance of tPA from the airways. This conclusion is supported by the rapid time course of the α 
phase of BALF clearance and by two other pieces of evidence: First, using a whole lung cell 
suspension model, that lung cells are capable of taking up tPA from the surrounding media via 
LRP1 to the same extent as liver cells; and second, state-of-the-science image analysis 
techniques, which permitted measurements of a cell-associated LRP1 signal following 
immunohistochemical staining. This revealed that the expression of LRP1 protein by cells from 
the lung was comparable to that of cells from the liver in both mice and macaque monkeys. 
Western blotting also showed an abundance of LRP1 in type II alveolar epithelial cells. 
Our findings are important and relevant because they point to a potential mechanism for 
removal of inhaled tPA from the airways. The clearance mechanisms affecting the half-life of 
pulmonary delivered therapeutic macromolecules from the airways, via absorption, metabolism 
or other routes have not been fully elucidated [38–40]. However, there is evidence that these 
mechanisms are distinct from those that regulate small molecule and ion transport in the lungs 
[41, 42]. Therapeutic proteins have been successfully delivered to the lungs via inhalation but 
issues related to utility and safety have been raised [38, 43]. Nevertheless, technological 
advances in pulmonary drug formulation and devices for the delivery of macromolecules, 
including siRNA and DNA, are being made [44, 45]. This active area of drug development 
highlights the need for more mechanistic knowledge about the fate of therapeutic proteins in the 
lungs. 
Endocytosis of tPA by LRP1 in the liver has been well studied and is known to result in 
the degradation of this protein [12, 16–18]. This process is essential for the regulation of tPA 
plasma concentrations, contributes to the short elimination for the systemically administered 
drug, and is a saturable process [15, 16]. In our study, the rate of intracellular processing of tPA 
in liver cells appeared to occur at a faster rate than that in lung cells. This was evidenced by 
longer α and β elimination half-lives compared with those of systemically administered tPA [13, 
14] and the lower intracellular fraction concentrations of mtPA present in liver cells compared to 
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lung cells, with similar extracellular fraction concentrations across both cell types (see Figure 3). 
Given the functional differences of these organs, it is reasonable to expect that the 
pharmacokinetics of tPA endocytosis in the lungs will be somewhat different from that of the 
liver. However, since LRP1 appears to function in lung epithelial cells in the same manner as it 
does in hepatocytes, it is reasonable to hypothesize that RME followed by degradation of tPA 
[12, 16–18] is also active in the lung. Collectively, details of this process remain to be elucidated 
as RME of tPA in alveolar epithelium is not yet fully understood (Figure 6). 
The importance of improving understanding of the mechanisms of the fate of lung 
delivered proteins is further illustrated by the broad functions of the receptors that bind tPA 
protein and/or that participate in RME (Figure 6). While delivery of therapeutic proteins to the 
lungs can result in cellular uptake via endocytic receptors and ultimately lead to degradation in 
lysosomes, this process can also initiate subsequent cell signaling pathways. In the context of 
LRP1, which is a transmembrane receptor responsible for the endocytosis and degradation of a 
number of ligands including metalloproteinases (MMP) and apolipoproteins [22, 24], it can 
function as a signaling receptor (Figure 6). The expression of LRP1 in the airway epithelium 
suggests an important but not yet fully understood physiological role in the lungs. Its ability to 
mediate MMP endocytosis and other extracellular matrix proteins may be particularly important 
in inflammatory conditions, like acute respiratory distress syndrome, in which the extracellular 
domain is shed and results in dysregulation of MMP homeostasis [24]. It is also worth noting 
that tPA-mediated activation of LRP1 can lead to activation of the ERK1/2 pathway [46, 47] 
with consequent effects on cell physiology [48]. In fact, depending on the cell type, the tPA-
LRP1 interaction can trigger a range of different responses [12]. Activation of downstream 
signaling can also occur via other tPA receptor proteins such as annexin A2 and mannose 
receptors both of which have been detected on alveolar macrophages [23]. Accordingly, as the 
use of inhaled tPA for PB or other fibrin-inflammatory lung diseases advances, it will be 
important to assess whether LRP1 binding leads to downstream effects on cell function. 
We acknowledge that there are limitations of our study. Experimentally, it is possible that 
the intracellular fraction may contain contamination by extracellular tPA that occurred during the 
separation process. However, the purpose of our studies was to evaluate the role of LRP1-
mediated uptake in the lung rather than the specific mass action of tPA. Since any contamination 
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would likely occur to similar extent across all samples it has little impact on the interpretation of 
our results. Next, as previously mentioned, additional mechanisms likely contribute to the 
clearance of tPA in the lungs. This includes the mannose receptor which may contribute to α-
phase elimination and is prevalent on alveolar macrophages [18, 49]. The LRP1 receptor is also 
expressed by macrophages [50] and we did not separately account for macrophage-mediated 
uptake of tPA in our model. We also elected to conduct the bulk of our study in an ex vivo 
murine model using a small dose of tPA that was directly applied to the cells. This did not permit 
assessment of mucociliary clearance which likely contributes to the β-phase of airway 
elimination. While we generated evidence of LRP1 in the airway epithelium of Macaque 
monkeys, we recognize that LRP1-RME of tPA in the airways will need to be confirmed using in 
vivo models including the human model so that we can confirm this mechanism. 
In conclusion, the abundance of LRP1 in the alveolar epithelium suggests that there is a 
site accessible mechanism of elimination for inhaled tPA. Furthermore, our study found that 
exposure of whole lung cell suspensions to exogenous tPA resulted in LRP1-mediated uptake of 
tPA that followed a similar extent and time course to that which occurred in whole liver cell 
suspensions. Therefore, LRP1-mediated cellular uptake is a candidate mechanism responsible for 
the fate of tPA in the airways. 
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2.8 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Human tissue plasminogen activator versus time in bronchoalveolar lavage fluid 
 
Log10 concentration of human tissue plasminogen activator (htPA) versus time in bronchoalveolar lavage fluid 
(BALF) from mice that received a single intratracheal dose of nebulized htPA (0.3mg/kg). BALF was acquired from 
individual animals at each time point and at the same time an associated blood sample was obtained. Mice that 
received an equivalent volume of phosphate buffered saline (PBS) did not have detectable levels of htPA in the 
BALF and there was no detectable htPA in any of the blood samples from either htPA- or PBS-treated mice. The 
initial (α) elimination half-life (t1/2) was followed by a more prolonged, terminal (β) t1/2, which is indicative of a two-
compartment model. Data are the mean (±S.E.M.) of 3-4 mice at each time point. htPA concentrations were 
determined by ELISA. 
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Figure 2-2 LRP1-mediated uptake of mtPA in murine whole lung and liver cell suspensions 
 
Receptor associated protein (RAP) reduced LRP1-mediated uptake of mtPA in primary murine whole lung and liver 
cell suspensions. A total of 20,000 lung or liver cells in the presence or absence of LRP1 inhibitor, RAP (400 nM), 
were treated with mtPA (25-100 ng). A representative Western blot of intracellular fraction of mtPA and quantitated 
data from (A) primary liver cell suspension lysates and (B) primary lung cell suspension lysates show that RAP 
reduced the amount of intracellular fraction mtPA by an average of 67, 67, and 39% for 25, 50, and 100 ng of added 
mtPA, respectively, in liver cells and by an average of 20, 43, and 52% for 25, 50 and 100 ng of added mtPA, 
respectively, in lung cells. In the presence of RAP, the mean amount of mtPA (100 ng) was significantly lower in 
liver cells compared to the absence of RAP (*p=0.014 by ANOVA post-hoc Holm-Sidak test). In the lung, but not 
the liver, the mtPA dose response was significant by linear regression (r
2
=0.82; p<0.0001 and r
2
=0.19; p=0.19, 
respectively). Data are the mean (±S.E.M.) of 3-4 samples/group. 
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Figure 2-3 Concentration of intracellular mtPA in murine liver and lung cell suspensions 
 
The concentration of intracellular fraction mtPA was lower over time in the presence of LRP1 inhibitor, receptor 
associated protein (RAP) in primary liver and lung cell suspensions (20,000 cells each). Cells were exposed to mtPA 
(50ng) at time 0 in the presence or absence of RAP (400nM). Representative Western blots of intracellular fraction 
mtPA over time in (A) primary whole liver cell lysates and (B) primary whole lung cell lysates. These findings were 
corroborated by the measurement of intracellular fraction mtPA concentrations measured by ELISA in (C) liver cell 
(*p=0.0132 at 1 min) and (D) lung cell (*p=0.009; +p<0.001; #p=0.066) lysates as well as in extracellular fraction 
(supernatant) media of (E) liver (*p=0.005; +p=0.0005) and (F) lung (*p=0.024; +p=0.001) cell suspensions. Data 
are the mean (±S.E.M.) of 3-4 samples/group and p values were generated from post ANOVA Holm-Sidak tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4 LRP1 protein quantification in murine liver and lung cells 
 
Protein band density of LRP1 increases with increasing cell number in both murine whole liver and lung cells. 
Representative Western blot and quantitation of LRP1 in primary whole (A) liver cell and (B) lung cell lysates at 
cell densities from 20,000 to 500,000 cells. The correlation coefficient (r
2
) for liver and lung LRP1 and cell number 
was 0.74 and 0.92, with p values of 0.13 and 0.04, respectively. (C) Representative Western blot of LRP1 in mouse 
type II alveolar epithelial cell (AEC) lysates with actin as a loading control. Lanes 1, 2: Mouse AEC (30 μg protein); 
Lanes 3, 4: Mouse AEC (20 μg protein); Lane 5: Mouse primary whole lung cell lysate (20,000 cells). 
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Figure 2-5 LRP1 tissue staining in liver and lung sections 
 
The percent (%) tissue area with LRP1 staining in mouse liver and lung sections was similar. Representative color 
light micrographs of (A) liver and (B) lung sections (40X) stained for LRP1 using 3'3'-diaminozenzidene (DAB) as 
a chromogen lead to brown staining; see text for details. (C) Quantitative image analysis revealed that the % tissue 
area with LRP1 stain in liver and lung sections was not different (p=0.483 by unpaired Student's t-test). Data are 
mean (±S.E.M.) of 7 sections/group. 
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Figure 2-6 Macromolecular transport mechanisms within the lung 
 
A number of transport mechanisms for macromolecules exist in the airways. Panel A: Transcellular transport can 
occur as either absorptive transcytosis or via transporter proteins (e.g., OAT P2B1) [42] and often involve 
movement of molecules through the cell, which can be a slow (hours) process [38]. Paracellular transport, in which 
macromolecules move through the airway epithelial barrier between cells, is thought to be a primary transport 
mechanism for small (≤40kDa) proteins and can occur within minutes [39]. Mucociliary action is pivotal for 
maintaining the integrity of the airway environment and also serves as a mechanism for slow airway clearance of 
macromolecules [42]. Panel B: At the receptor level, membrane-associated tissue plasminogen activator (tPA) 
binding proteins include annexin A2 and p11 binding complex, LRP1 and the mannose receptor. The LRP1 and 
mannose receptors are transmembrane proteins which are the only known endocytic receptors for tPA [18, 49], the 
former of which can be blocked by receptor associated protein (RAP). Annexin A2 serves as the site where tPA 
assembles with plasminogen (PLG) for localized generation of plasmin [51]. Most abundant on endothelial cells, 
annexin A2 has been detected on macrophages and pneumocytes [23] and tPA binding to annexin A2 has been 
reported to lead to activation of downstream signaling pathways [47, 52]. The binding of tPA to LRP1, which is 
ubiquitous, and mannose receptors, which are prevalent on macrophages, is independent of tPA protease activity and 
can occur in the presence or absence of its primary physiological inhibitor, plasminogen activator inhibitor. 
Following tPA binding, the protein is endocytosed and packaged into endosomes. In the liver, this process leads to 
lysosomal degradation of tPA. Given this function and the abundance of LRP1 in the alveolar epithelium, it is 
reasonable to expect that the same occurs in the lung. In addition to the processing of macromolecules, activation of 
LRP1 and mannose receptors can trigger a cadre of downstream signaling events including the activation of ERK 
and MAP kinases [46, 53]. “Lungs diagram simple” by Patrick J. Lynch, medical illustrator - Patrick J. Lynch, 
medical illustrator. Licensed under CC BY 2.5 via Wikimedia Commons -
http://commons.wikimedia.org/wiki/File:Lungs_diagram_simple.svg#mediaviewer/File:Lu ngs_diagram_simple.svg 
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2.9 Supporting Information Available 
This material is published in Pharmaceutical Research and supplemental methods and figures 
are available in the Appendix A. 
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Chapter 3 
Massive Bioaccumulation and Self‐Assembly of Phenazine 
Compounds in Live Cells 
3.1 Relevance to Thesis 
Studying the accumulation, biotransformation, and stabilization of intracellular biocrystals of 
clofazimine within live cells encompasses the overall scope of the three aims of the dissertation 
work presented here, as well as the central hypothesis guiding the work. Thus, studying how 
chemically similar, but distinct derivatives of clofazimine both accumulate within cultured 
macrophages, and become solubilized in different media conditions is an important first step in 
designing experiments to analyze the in vivo and in vitro stability of clofazimine biocrystals. In 
this study, chemical derivatives of clofazimine were synthesized and incubated with both 
macrophages and epithelial cells, revealing distinct differences in accumulation between the two 
groups of cells. Additionally, the accumulation of these chemicals, and subsequent intracellular 
aggregate formation was studied using polarized light microscopy. Using polarized light, the 
cellular accumulation pattern for each derivative was determined (i.e. if the cell formed insoluble 
ordered aggregates of the chemical). The accumulation of clofazimine, stabilization of 
intracellular aggregates, and their analysis with quantitative polarized light microscopy is further 
elaborated on and applied in chapters 5, 6, and 7, with different applications being utilized in 
each case. The chemical changes to the core clofazimine structure, unsurprisingly, altered its 
accumulation pattern within these cultured cells. As related to this thesis, my own contribution to 
the work presented in this chapter was to relate the visual changes in accumulation pattern within 
these cells detected via quantitative polarized light microscopy (i.e. the formation of an 
intracellular amorphous or insoluble aggregate) to a physical phenomenon (i.e. changes in the 
aqueous solubility of the phenazine derivative or solubility in the cellular media). To accomplish 
this, the solubility of each phenazine derivative was determined in cell culture media both in the 
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presence and absence of serum proteins to see if the observed differences in accumulation could 
be related to precipitation in the surrounding cellular media. It was determined that there was no 
specific correlation between the solubility of the derivative within the media and the cellular 
accumulation, hinting at a potential cellular mechanism behind the accumulation and 
sequestration of these phenazine compounds. The analysis methods and knowledge obtained 
from these experiments helped guide the work discussed further in chapters 6, 7, and 8, in 
particular the in vivo experiments related to clofazimine biocrystal stability.   
3.2 Abstract 
Clofazimine is an orally administered drug that massively bioaccumulates in macrophages, 
forming membrane‐bound intracellular structures possessing nanoscale supramolecular features. 
Here, a library of phenazine compounds derived from clofazimine is synthesized and tested for 
ability to accumulate and form ordered molecular aggregates inside cells. Regardless of chemical 
structure or physicochemical properties, bioaccumulation is consistently greater in macrophages 
than in epithelial cells. Microscopically, some self‐assembled structures exhibit a pronounced, 
diattenuation anisotropy signal, evident by the differential absorption of linearly polarized light, 
at the peak absorbance wavelength of the phenazine core. The measured anisotropy is well above 
the background anisotropy of endogenous cellular components, reflecting the self‐assembly of 
condensed, insoluble complexes of ordered phenazine molecules. Chemical variations introduced 
at the R‐imino position of the phenazine core lead to idiosyncratic effects on the compounds' 
bioaccumulation behavior as well as on the morphology and organization of the resulting 
intracellular structures. Beyond clofazimine, these results demonstrate how the self‐assembly of 
membrane permeant, orally bioavailable small molecule building blocks can endow cells with 
unnatural structural elements possessing chemical, physical, and functional characteristics unlike 
those of other natural cellular components. 
3.3 Introduction 
In mammals, macrophages orchestrate many key physiological functions, including 
wound healing and regeneration, clearance of apoptotic and necrotic cells, recognition of foreign 
antigens, defense against invading pathogens, and mounting of protective immune responses [1-
4].  In addition, macrophages play a physiological role in the disposition of lipophilic, poorly 
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soluble small molecule chemical agents. In the liver, for example, Kupffer cells sequester lipids, 
cholesterol, fat soluble vitamins, xenobiotics, and drugs [5-8]. Perhaps it is not too surprising that 
clofazimine, an old but highly effective antibiotic that is included in the World Health 
Organization's list of essential medications and part of the standard treatment of leprosy[9, 10], 
has been found to massively bioaccumulate in macrophages.4 In these cells, clofazimine forms 
crystal‐like drug inclusions (CLDIs): highly organized, insoluble molecular complexes that are 
predominantly found in membrane‐bound compartments within the cytoplasm[11, 12]. Although 
drug crystal formation has generally been regarded as an unwanted side effect, clofazimine is a 
well‐tolerated, clinically useful drug. Thus, in the case of clofazimine, CLDIs may function as a 
biocompatible, intracellular drug depot mechanism. More generally, CLDI formation could be 
exploited as a means to target drugs to macrophages in living organisms and to endow these cells 
with unnatural structural and functional elements for diagnostic or therapeutic purposes. 
Related to clofazimine, Neutral Red is a phenazine compound that undergoes 
accumulation in lysosomes [13], while Janus Green B is another phenazine compound that 
undergoes electrical potential dependent accumulation in mitochondria[14] . However, neither of 
these compounds exhibits the massive intracellular bioaccumulation or intracellular self‐
assembly properties that are characteristic of clofazimine[15]. Furthermore, because of 
differences in membrane partitioning, the transport mechanisms mediating the cellular uptake 
and intracellular distribution of clofazimine may be different from that of less lipophilic, more 
soluble phenazine derivatives [16, 17]. Therefore, to explore whether other phenazine 
compounds could provide a good a starting point for developing new kinds of self‐assembling 
intracellular elements for drug delivery and bioimaging applications, we decided to examine the 
impact of variations in lipophilicity and chemical structure on the intracellular uptake and 
trafficking of phenazine compounds. For this purpose, we synthesized a small, focused library of 
phenazine derivatives of clofazimine, and assayed their bioaccumulation and self‐assembly 
properties in RAW264.7 macrophages and Madin‐Darby Canine Kidney (MDCK) epithelial 
cells. 
Because phenazines are chromophores with a broad absorbance peak in the range of 
visible wavelengths, the interaction of the phenazine ring with monochromic, polarized light 
could be useful to specifically probe the intracellular accumulation, distribution, and molecular 
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organization of the phenazine compounds. Accordingly, a quantitative polarization microscope 
(LC‐PolScope) [18-20] was adapted to assay the formation of condensed, ordered molecular 
aggregates of the compounds in live cells. With this instrument, we measured the manner in 
which the intracellular inclusions differentially influenced the transmittance of polarized light—
an optical property known as diattenuation anisotropy [21]. By relating the extent of 
bioaccumulation to the measured optical properties of the intracellular inclusions formed by 
different phenazine derivatives, we determined that certain chemical modifications at the R‐
imino group promoted the self‐assembly of phenazines, specifically in macrophages. The 
influence of these variations on bioaccumulation and structure formation seemed highly 
idiosyncratic. However, all compounds tended to preferentially accumulate in macrophages 
relative to epithelial cells, regardless of their chemical structure or physicochemical properties. 
3.4 Materials and Methods 
Materials for Chemical Synthesis. The starting materials, reagents, and solvents for the 
synthesis were purchased from Sigma Aldrich, Fisher Scientific Acros, Oakwood Products or 
Chem‐Impex and used as such without purification. Biotage Initiator Classic, single‐mode 
Microwave Synthesizer was used for Microwave Syntheses. Compounds were purified by either 
Column Chromatography using Silicycle's SiliaFlash P60 (220–240 mesh) under positive house 
nitrogen pressure or Silicycle or Biotage prepacked flash columns using Biotage SP1 Flash 
System using two solvent gradient system. Solvent/Reagent Abbreviations or Formulae used: 
DCM, dichloromethane; EtOH, ethanol; EtOAc, ethyl acetate; DMSO, dimethylsulfoxide; 
MeCN, acetonitrile; AcOH, acetic acid; K2CO3, potassium carbonate; KF, potassium fluoride; 
Na2SO4, sodium sulfate; KOH, potassium hydroxide; FeCl3, ferric chloride; HCl, hydrochloric 
acid; Pd/C, palladium on carbon. NMR spectra were recorded on either Varian MR 400 MHz, or 
Varian Inova 500 MHz spectrometer. Chemical shifts were reported in δ (parts per million) in 
reference to the hydrogen peaks of tetramethylsilane, δ = 0.00. Mass spectra were recorded on a 
Micromass LCT Time‐of‐Flight instrument utilizing electrospray ionization in the positive ion 
mode (ESI
+
). 
Synthesis of Phenazine Derivatives: Figure 1 represents the overall synthesis procedures of the 
phenazine compounds. With the previously reported methods (using reagents, (a) KF/K2CO3 or 
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(b) KOH/DMSO) [22, 23], niline derivatives 1 and 2‐fluoronitrobenzene 2 were treated to 
produce the secondary amine derivatives 3(N‐(4‐aryl)‐2‐nitroaniline). Using 10% Pd/C catalyst 
under hydrogen atmosphere, the nitro group in 3 was reduced to yield the diamine 4 (N‐
arylbenzene‐1,2‐diamine). Then, derivative 4 was oxidized[24, 25] in aqueous ferric chloride 
solution to produce the corresponding phenazine salts 5 (3‐imino‐N,5‐bis(aryl)‐3,5‐
dihydrophenazin‐2‐amine hydrochloride). Following treatments with various primary amines, the 
phenazine salts 5 yielded the corresponding phenazine derivatives 6 ((E)‐3‐(isopropylimino)‐
N,5‐bis(aryl)‐3,5‐dihydrophenazin‐2‐amine) with 10%–85% yield.  
Absorbance Measurements. Phenazine derivatives were solubilized at 0.1 mg mL
−1
 in 
methanol and in 9 M H2SO4. The UV–vis spectra of the different phenazine derivatives in 
methanol and in acidic solutions of H2SO4 were obtained in 96 well plates, using a Biotek 
microplate spectrophotometer. 
Physicochemical Property Predictions. Estimation of various physicochemical properties of 
clofazimine and its chemical derivatives which could be important for predicting their behaviors 
when those chemicals are confronted by cellular/suborganellar membranes were made as 
follows: Clog P (the calculated logarithm of lipid/water partitioning coefficient of nonionic 
(neutral) forms of the compound) were calculated by Chemaxon software from Marvin Beans 
(http://www.chemaxon.com/marvin). Clog P values of ionized species were calculated using the 
procedures described by Hansch and Leo[26]. Multiple pK a (the dissociation constant of the 
protonated functional group) values (pK a1, pK a2, or pK a3) were calculated for the ionizable 
functional groups (amines) in these weakly basic molecules. Other structure parameters were 
estimated as described in the next section [27, 28]  
Predicting Cellular Uptake and Intracellular Localization of Phenazine Compounds. 
Intracellular localization was predicted for each plausible ionic species of each phenazine 
compound as follow. For each species, structure parameter values, as estimated above, were 
inserted into published quantitative structure activity relationship (QSAR) models predicting cell 
uptake and intracellular localizations[27, 28]. The poor‐moderate‐good predictions in Tables S1, 
S3, and S5 relate to the Clog P of the major species present, usually the free base, as follows: 
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Poor: Clog P > 8 or Clog P < 0 [and/or number of rotatable bonds > 40]; moderate: 8 > Clog P > 
5; Good: 5 > Clog P > 0. 
Species close to prediction boundaries in parameter space are indicated by use of terms such as 
moderate‐good [i.e., the species falls into the moderate zone but close to the boundary with the 
good zone]. Predictions assume that pK a values of basic groups are such that for most analogues 
a large proportion of each compound will be present in solution as a free base, with rather less as 
monocations, and even less as polycations, under physiological conditions. Polycations would 
only be present within acidic organelles. In Tables S1, S3, and S5: E = endoplasmic reticulum, C 
= cytosol, G = generic biomembranes, L = lysosome, M = mitochondrion, P = plasma 
membrane. 
Cell Culture. RAW264.7 macrophages or MDCK (Madin Darby Canine Kidney) epithelial cells 
(strain II) were obtained from American Type Culture Collection (ATCC) (Manassas, VA) and 
cultured in 75 cm
2
flasks at 37 °C, 5% CO2 containing humidified incubator. RAW264.7 
macrophages (passage numbers 5–15) were grown in the medium containing Dulbecco's 
Modified Eagle Medium (DMEM (Gibco 11145); Invitrogen, Carlsbad, CA) with 2 × 10
−3
 m l‐
glutamine, 4500 mg L
−1
 of d‐glucose, 110 mg L−1 of sodium pyruvate, 1% penicillin–
streptomycin (Gibco 10378), and 10% fetal bovine serum (FBS; Gibco 10082). Confluent 
macrophage cells were detached by scraping and subcultured at 1:8 split ratios to culture flasks. 
MDCK cells (passage numbers 60–80) were cultured with growth medium consisting of DMEM 
supplemented with 1X nonessential amino acids (Gibco 11140), 1% penicillin–streptomycin, and 
10% FBS. After reaching 70–80% confluence, MDCK cells were detached from the culture 
flasks using trypsin‐ethylenediaminetetracetic acid (trypsin‐EDTA) solution and subcultured at a 
split ratio of 1:5. Media in the flask was replaced every 3 days. 
Solubility Measurements. Solutions containing the phenazine derivatives were made in cell 
culture media (DMEM) with or without FBS (10%). After a 24 h incubation, the solutions were 
centrifuged (10 000 × g, 10 min), the supernatant was removed and the precipitate was dissolved 
in 9 m H2SO4. The supernatant was diluted with 10 M NaOH to precipitate the remaining 
solubilized compound. The diluted supernatant was centrifuged (10 000 × g, 10 min) followed by 
dissolution of the precipitate in 9 m H2SO4. Both fractions were spectrophotometrically 
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measured with a Biotek microplate spectrophotometer (λ = 540 nm) and phenazine content was 
determined using calibrated clofazimine standards. 
Cytotoxicity Measurements. A 3′‐bis(4‐methoxy‐6‐nitro)benzene‐sulfonic acid hydrate (XTT) 
colorimetric assay was performed to assess the cytotoxicity of the clofazmine derivatives in 
RAW264.7 macrophages or MDCK epithelial cells using a Cell Proliferation Kit II (Roche 
Chemicals, Indianapolis, IN). Briefly, the cells were seeded in 96 well plates at a cell density of 
8 × 10
3
 cells cm
−2
 (RAW264.7 macrophages) or 1.5 × 10
4
 cells cm
−2
 (MDCK epithelial cells) 
and after a 24 h incubation (37 °C, 5% CO2), cells were exposed to media containing various 
concentrations of clofazimine or its chemical derivatives (100 μL of 0.5 × 10−6, 1 × 10−6, 2 × 
10
−6
, 4 × 10
−6
, 6 × 10
−6
, 8 × 10
−6
, 10 × 10
−6
, 15 × 10
−6
, 20 × 10
−6
, 25 × 10
−6
, 50 × 10
−6
, or 100 × 
10
−6
 m) in DMEM (no phenol red; Gibco 21063) with 5% FBS and 1 × 10
−3
 m sodium pyruvate. 
After 72 h incubation with clofazimine or its derivatives, compound‐containing media was 
removed and cells were washed twice with media. The XTT labeling reagent (3′‐bis(4‐methoxy‐
6‐nitro)benzene‐sulfonic acid hydrate) was freshly mixed with the electron coupling reagent 
(PMS: N‐methyl dibenzopyrazine methyl sulfate) before use according to the manufacturer's 
instructions. Cells were incubated in 100 μL of media (DMEM with 5% FBS) with XTT labeling 
mixture for 3 h (37 °C, 5% CO2). The absorbance value in each well was measured at 495 nm 
against a reference wavelength at 650 nm using a microplate reader (Synergy 2, BioTek 
Instruments, Winooski, VT). The experiments were repeated in three different sets for the 
various concentrations of compounds. The IC50 value for each compound was calculated from 
the concentration‐response curve generated by a nonlinear regression (curve fit) method in 
GraphPad Prism version 5.0 (GraphPad Software, Inc., San Diego, CA). The concentration of 
clofazimine or its chemical derivatives used for further in vitro cell studies was determined based 
on cell viability (%) assay results (see the next section). 
Cell Accumulation Experiments and Transmitted Light Microscopic Examination. For cell 
cultures, RAW264.7 macrophages or MDCK epithelial cells were seeded in the 8‐well Nunc 
Lab‐Tek II chambered (#1.5) coverglasses (Thermo Scientific, Pittsburgh, PA) at a cell density 
of 8 × 10
3
 cells cm
−2
 or 1.5 × 10
4
cells cm
−2
, respectively. After a 24 h incubation (37 °C, 5% 
CO2), cells were incubated with solution of clofazimine or its chemical derivatives (300 μL of 5 
× 10
−6
 m concentration; measured cell viability ranging from 85% to 97% for all compounds 
62 
 
tested at this concentration; Figure 1) in DMEM (no phenol red; plus 1 × 10
−3
 m sodium 
pyruvate and 5% FBS). For Compound “I,” 2.5 × 10−6 m of compound solution in media was 
used for the RAW 264.7 macrophages incubation because of lower cell viability at higher 
concentrations (IC50 = (3.95 ± 0.11) × 10
−6
 m). A solution of clofazimine or other chemical 
derivatives was made by a diluting stock solutions (2.5 × 10
−3
 m in DMSO; 10 × 10
−3
 m stock in 
DMSO were stored at −80 °C for further use) into DMEM with 5% FBS. Previously, we 
reported that clofazimine did not form visible precipitates in this media (DMEM with 5% FBS) 
[15]. For other phenazine derivatives, precipitates were avoided by including FBS in the media. 
The extracellular concentration of each compound in each well was maintained by daily 
replacement of the compound‐containing media. After 72 h of incubation with clofazimine or its 
derivatives, compound‐containing media were removed and cells were washed twice with media. 
Live cells in the chambered glasses were examined under inverted transmitted light microscopy 
(Nikon Eclipse Ti microscope) with a 40× objective and color camera. As a control experiment, 
fixed cells were also microscopically examined after incubation with the compounds. Cells were 
seeded on the chambered cover glasses at the density of 1.5 × 10
4
 cells cm
−2
 (RAW264.7 
macrophages) or 2.5 × 10
4
 cells cm
−2
 (MDCK epithelial cells). After an overnight incubation (37 
°C, 5% CO2), media was removed from the wells and cold methanol (−20 °C) was added to each 
well. After 30 s, remaining methanol was removed by washing with media with 5% FBS. Fixed 
cells were incubated (37 °C, 5% CO2) with clofazimine or derivatives (300 μL of 5 × 10
−6
 m; 2.5 
× 10
−6
 m for I) in media with 5% FBS. After 72 h, fixed RAW264.7 or MDCK cells were 
washed with media and examined using the same transmitted microscopy conditions as the live 
cells. 
Cell Associated Mass Measurements. RAW264.7 macrophages or MDCK epithelial cells were 
seeded in 96 well plates at the density of 8 × 10
3
 cells cm
−2
 or 1.5 × 10
4
 cells cm
−2
, respectively. 
After an overnight incubation (37 °C, 5% CO2), cells were incubated with 100 μL of the media 
(DMEM with 5% FBS) containing 5 × 10
−6
 m clofazmine or its chemical derivatives (2.5 × 
10
−6
 m of Compound “I”). Media containing each compound was replaced every day during the 
72 h incubation. After the incubation, media was removed and cells were washed with Hank's 
balanced salt solution (HBSS) buffer (No. 14025; Invitrogen) twice. RAW264.7 macrophage 
cells in buffer were scraped and MDCK epithelial cells were exposed to Trypsin‐EDTA solution 
for detachment from the plates for cell number counting and quantification of cell‐associated 
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masses. After centrifugation (650 × g), supernatant was removed and cell pellets were 
resuspended in 0.1 m citric acid/0.1 m trisodium citrate buffer (pH 5) for cell counting as 
previously reported (7).  Equal numbers of cells in 100 μL in buffer were transferred to 96 well 
plates and 100 μL of detergent (ATCC, 30‐1010K) was added into wells for cell lysis. Chemical 
absorbance from each well was measured by the UV–vis microplate reader (Synergy 2, BioTek 
Instruments, Winooski, VT) at 490 nm wavelength and cell‐associated mass of each compound 
was calculated by a standard curve generated separately using the same media and presented as 
pmole/cell by normalizing the amount of chemical in each cell population sample by the number 
of cells in each sample. 
Linear Diattenuation Microscopy Instrument Set Up. The LC‐PolScope was first developed 
as a birefringence imaging system at the Marine Biological Laboratory (Woods Hole, MA) by 
Oldenbourg and colleagues, which greatly increased the sensitivity and analytic power of the 
polarized light microscope [18-20]. Recently, the technique was extended to include quantitative 
imaging of diattenuation and polarized fluorescence in biological and man‐made specimens [21, 
29]. For our studies of absorption properties of intracellular aggregates of phenazine derivatives, 
we used the diattenuation LC‐PolScope as reported earlier[21] and described on the website 
OpenPolScope.org. The optical design was built on a Nikon Eclipse Ti microscope equipped 
with the liquid crystal universal compensator consisting of a linear polarizer and a pair of liquid 
crystal devices. The LC compensator was part of the transillumination path and was used to 
illuminate the specimen with monochromatic, linearly polarized light of varying polarization 
orientation. There was no polarization analyzer present in the imaging path. Quantitative 
intensity images were recorded by a charge‐coupled device camera and a desktop computer 
calculated the average transmittance, the differential transmittance and the polarization 
orientation leading to maximum transmittance for each optically resolved picture element (pixel). 
Acquisition and processing steps were controlled using OpenPolScope plugins for the open 
source imaging programs ImageJ and Micro‐Manager (MMStudio version 1.4.15). With the 
combination of hardware and software, polarized light images were acquired at high sensitivity 
and high spatial resolution for measuring linear diattenuation. 
Linear Diattenuation Microscopy Data Acquisition and Analysis. After RAW264.7 
macrophages or MDCK epithelial cells were incubated with the compound in the chambered 
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cover glasses for 72 h, at the same time of performing transmitted microscopic examination, cell 
specimens were examined under linear diattenuation microscopy using the Nikon Eclipse 
Ti microscope with 40×/0.75 NA objective and monochromatic light of two different center 
wavelengths, 546 and 623 nm (passband 30 nm). In the OpenPolScope software, Pol‐Acquisition 
and Pol‐Analyzer plugins (version 2.0) were used to capture, process, and analyze the attenuation 
images. Before imaging the samples, the setup was calibrated using a specially prepared slide 
featuring four small pieces of linear polarization filters. The transmission axes of the filters were 
oriented in steps of 45° providing a means to calibrate the LC universal compensator settings. 
After the calibration, a sample slide was inserted and first a sequence of polarized light images of 
a clear, fully transmitting sample area was recorded, followed by an image sequence featuring 
the cells under investigation. The images of the clear area were used to determine instrument 
factors which were needed for computing the average and the polarization dependent loss in 
transmittance in cellular components visible in the second image [21].  
Linear diattenuation is a material property that can occur in materials such as crystals, in which 
the light absorbing molecules are arranged with a preferred orientation. The molecular alignment 
creates principal axes in the material denoting polarization directions for which light is 
maximally and minimally transmitted. Diattenuation is the difference between maximal (T max) 
and minimal (T min) transmittance, divided by their sum (Equation (1). 
To simultaneously measure the attenuation of many crystals with arbitrary orientations, we 
developed algorithms based on four specimen images, each recorded using light of a different 
polarization orientation: 0°, 45°, 90°, and 135° [21]. The four raw images were used to calculate 
the average and differential transmittance and the orientation of maximum transmittance in every 
resolved image pixel. To isolate and analyze quantitative data of the objects (crystals), the 
anisotropy or maximum transmittance axis orientation image file opened in ImageJ was inverted 
(Ctrl + Shift + I) and thresholded using ImageJ's default automatic method (“Binary” → 
“Convert to Mask”). By using the ImageJ's algorithm, “Analyze Particles,” data of anisotropy or 
maximum transmittance axis orientation of objects in images could be obtained automatically. 
Diattenuation ratios were calculated by dividing anisotropy at 623 nm by that at 546 nm. For 
images obtained from cells incubated with Compounds, P, U, V, or W, maximum transmittance 
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axis orientation lines in crystals were displayed by using OpenPolScope's plugin (Orientation‐
LinesV3) installed in ImageJ. 
Confocal Fluorescent Microscopy. A Nikon A1 confocal microscope was used for further 
investigation of live cells incubated with chiral pairs of compounds (T and U) and the parent 
compound, P. Since crystals or vesicular forms containing chemicals inside the cells incubated 
with Compound P, T, or U were fluorescent when viewed with the TRITC filter sets, 
intracellular distribution of these compounds in RAW264.7 or MDCK cells were visualized 
using a Nikon A1 confocal microscopy (Nikon Instruments Inc., Melville, NY) equipped with 
diode‐based lasers and a Nikon Apo 60×/1.4 NA oil immersion lens. Briefly, RAW264.7 
macrophages or MDCK epithelial cells were seeded in the 8‐well Nunc Lab‐Tek II chambered 
(#1.5) cover glasses (Thermo Scientific, Pittsburgh, PA) at a density of 8 × 10
3
 cells 
cm
−2
 (RAW264.7 cells) or 1.5 × 10
4
 cells cm
−2
 (MDCK cells) and allowed to adhere overnight 
(37 °C, 5% CO2). Then, 5 × 10
−6
 m of Compound “P” or the related isomers, “T” or “U” in 
DMEM with 5% FBS (300 μL) was added to the cells and the cells were incubated for 72 h (37 
°C, 5% CO2). For live cell imaging, after the removal of media, cells were washed with HBSS 
buffer twice. Hoechst 33342 (Invitrogen, Carlsbad, CA) was used for staining cell nuclei and FM 
1‐43 (Molecular Probes T35356, Invitrogen) for the plasma membrane. Cells were incubated 
with 300 μL of 1:1 (v/v) dye mixtures of 5 μg mL−1 Hoechst 33342 and 7 × 10−6 mFM 1‐43 in 
HBSS for 15 min at room temperature. Without fixative, the confocal imaging of the live cells 
was performed using lasers for DAPI (excitation/emission wavelength: 405 nm/450 ± 25 nm), 
FITC (488 nm/525 ± 25 nm), and TRITC (561 nm/596 ± 25 nm) channels. Z‐stack images of the 
cells were captured along the Z‐axis (interval, 1 μm) in three fluorescence channels and analyzed 
by using the Nikon NIS‐Elements 3.2 confocal software (Nikon Instruments Inc., Melville, NY). 
In 3D reconstructions of the confocal sections assembled with the Nikon software, the cell nuclei 
fluoresced in the Hoechst/DAPI channel; the cell membranes fluoresced in the FITC channel; 
and, the intracellular inclusions fluoresced in the TRITC channel. 
Transmittance and Optical Density (OD) Calculations. For calculating the differential 
transmittance of the inclusions, images at four different angles of polarization (0°, 45°, 90°, and 
135°) were acquired by linear attenuation microscopy as described above. To measure 
transmittance, a threshold was applied to the mean transmitted image generated by the linear 
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attenuation microscopy data acquisition. This threshold was determined using the ImageJ Auto‐
thresholding protocol—Moments. Based on this threshold, a region of interest (ROI) image mask 
was generated, and then used to measure the mean transmittance (T mean) of the ROIs, expressed 
as mean pixel value. To generate transmittance image maps and for quantitative measurement of 
transmittance, pixel values were converted to absolute values by dividing the mean pixel value 
by 255 (8‐bit images). For the corresponding OD image maps and measurements, we used the 
following formula: OD = −log10(T mean). For each compound a total of five images were 
measured from experiments performed on three separate days (>200 cells analyzed per 
compound). 
Principal Component Analysis. An “optical properties score” was calculated for each replicate 
measurement (n = 5) for each compound in each cell type (RAW264.7 macrophages and MDCK 
epithelial cells), by combining the anisotropy and optical density values at 546 and 623 nm 
wavelengths. PCA plots [30] were generated using soft independent modelling in class analysis 
(SIMCA, http://www.umetrics.com/products/simca; Umeå, Sweden). 
3.5 Results and Discussion 
First, we synthesized a focused library of clofazimine derivatives (Figure 1), by replacing 
the chlorophenyl moieties of clofazimine with different aromatic substituents (Figure 1a and 
Table S1, Compounds A–G). When these compounds were incubated with cells, they exhibited 
similar or decreased intracellular staining relative to clofazimine, irrespective of their higher or 
lower lipophilicity relative to clofazimine (Figure1a' and Table S2). Small changes in the 
chemical structure of clofazimine were associated with visibly different cellular staining pattern 
in macrophages. In this first series of phenazine compounds (Compounds A–G), the 
chlorophenyl moiety of clofazimine was replaced with various other closely related substituents, 
yet most of these substituents (Compounds A–F) led to decreased cellular staining in relation to 
clofazimine. Only the replacement of chlorines with hydroxyls led to a staining pattern similar to 
that of clofazimine (Compound G). 
For comparison, we synthesized a second, focused series of derivatives, in which the 
isopropyl group at the R‐imino position of clofazimine was replaced with different achiral 
substitutents (Figure 2b and Table S3, Compounds H–Q). Compared to clofazimine, replacing 
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the isopropyl group with other functional groups at the R‐imino position generally led to similar 
or greater staining of macrophages (Figure 2b′ and Table S4, Compounds H–Q). Three 
derivatives yielded cellular staining patterns comparable in morphology and intensity to those of 
clofazimine (Compounds H, I, and M) while two derivatives yielded more prominent staining 
patterns (Compounds P and Q). The most intense staining was associated with the formation of 
condensed cytoplasmic inclusions, either amorphous or crystal‐like in morphology (Figure 2b′ 
and Table S4; Compounds P and Q). 
To assess the extent to which specific interactions with chiral components present in cells 
(or the cell culture medium) affected the bioaccumulation and self‐organization behavior of the 
compounds, we proceeded to synthesize and screen a third, focused series of phenazine 
derivatives, which incorporated a stereochemical center at the R‐imino position (Figure 2c and 
Table S5, Compounds R–W). As observed in the second series of achiral R‐imino phenazines, 
small variations in the chemical structure and physicochemical properties of these chiral R‐imino 
phenazine compounds led to pronounced differences in cellular staining (Figure 2c′ and Table 
S6). Three of the six chiral R‐imino derivatives exhibited prominent cellular staining, associated 
with the formation of yellow, orange, red, or brown cytoplasmic inclusions (Figure 2c′ and Table 
S6) Compounds U, V, and W). In control experiments, untreated cells showed no visible yellow 
or brown staining when viewed using the same optical set up under transmitted, brightfield 
illumination (Figure 2d, Control). Furthermore, staining was also not observed when cells were 
fixed prior to incubation with the compounds (Table S6), indicating that the observed staining 
patterns reflected underlying differences in physiological, small molecule transport mechanisms 
present in live cells. Because all phenazine compounds exhibited similar absorbance spectra 
under different conditions (Figure 3a, Figure 3b), the variations in cellular staining patterns most 
likely reflected differences in the accumulation and distribution of the compounds in the cells, 
independently from the compounds' optical properties. 
Next, we proceeded to characterize the optical properties of the inclusions using a 
quantitative, polarization microscope [18-20] to perform diattenuation anisotropy measurements 
on cells incubated with the different compounds [21]. By transmitting linearly polarized, 
monochromatic light of wavelengths near the absorbance maxima of the phenazine molecules, 
the diattenuation anisotropy signal can be used to detect and quantify the presence of ordered 
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aggregates of phenazine molecules in live cells. For isotropic, disordered intracellular inclusions, 
polarized light is expected to be transmitted in the same manner irrespective of the orientation of 
the polarization vector, resulting in diattenuation anisotropy close to 0. For ordered intracellular 
inclusions of phenazine molecules (as occurs when molecules are aligned with each other), the 
diattenuation anisotropy should increase, as the ordered molecular aggregates will preferentially 
transmit light that is polarized in a particular direction. Accordingly, by comparing the 
diattenuation anisotropy image maps for treated and untreated control cells, we observed clear 
diattenuation anisotropy signals in association with dense inclusions formed specifically by 
phenazine compounds (see Compounds P, U, V, and W in Figure 4). Interestingly, Compounds 
U, V, and W exhibited optically anisotropic inclusions only in macrophages, whereas Compound 
P formed optically anisotropic inclusions in both macrophages (Figure 4a) and epithelial cells 
(Figure 4b). By visual inspection, we observed significant variations in the molecular 
organization of the inclusions formed by different compounds: Some compounds formed 
monolithic aggregates comprised of a single domain with uniform orientation (Compound P; 
Figure 4a, Figure 4b), while other compounds formed complex aggregates comprised of 
segregated domains with subdomains organized in different directions (Compounds U, V, and 
W; Figure 4a). 
We quantitatively confirmed that Compounds P and Q showed higher diattenuation 
anisotropy in both macrophages and epithelial cells than seen with clofazimine (Figure 5a). 
Notably, chiral Compounds U, V, and W exhibited even higher anisotropy as compared to 
clofazimine but only in macrophages (Figure 5a). The measured diattenuation anisotropy signals 
for all chiral compounds were well above the background, diattenuation anisotropy signal of 
untreated cells (Figure 5a). On average, the anisotropy diattenuation ratio measured at a 
wavelength of 546 nm relative to 623 nm did not reveal significant wavelength‐dependent 
differences in diattenuation anisotropy (Figure 5b), although some compounds exhibited higher 
variability in the measured diattenuation anisotropy ratios in macrophages than in epithelial cells 
(Figure 5; Compounds V and W). 
 In relation to the compounds' chemical structures, the self‐assembly and resulting optical 
properties of intracellular structures formed by phenazine compounds appeared to be highly 
idiosyncratic: only one pair of enantiomers (Figure 4 and Figure 5a, Compounds T and U) 
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exhibited enantioselective differences in their optical anisotropy signal and this was observed 
only in macrophages. Compounds V and W did not show enantioselective differences in 
diattenuation anisotropy (Figure 6a, Figure 6b). The other pair of enantiomers (Compounds R 
and S) did not yield a measurable, diattenuation anisotropy signal in either macrophages or 
epithelial cells. Furthermore, Compound P, an achiral phenazine compound, formed inclusions 
with strong diattenuation anisotropy signals in both macrophages and epithelial cells (Figure 4 
and 5), indicating that the formation of ordered, R‐imino phenazine aggregates can occur 
regardless of stereochemistry. 
To confirm the intracellular localization of the inclusions, we took advantage of the 
fluorescence properties of the phenazine Compounds P, T, and U. Following intracellular 
accumulation, these compounds exhibited strong fluorescence excitation and emission signals 
that were visible through the standard (tetramethylrhodamine isothiocyate) TRITC channel of a 
fluorescence, confocal microscope. Accordingly, we acquired confocal optical sections through 
cells incubated with these compounds to confirm that the inclusions were intracellularly 
localized (Figure 6). For counterstaining, cells were also incubated with an orthogonally 
fluorescent nuclear marker (Hoechst 33342), as well as an orthogonally fluorescent, plasma 
membrane‐specific marker (FM‐143). FM‐143 yielded a green, plasma membrane signal in the 
fluorescein isothiocyanate (FITC) channel of the microscope, while Hoechst 33342 yielded a 
blue, nuclear signal in the 4′,6‐diamidino‐2‐phenylindole (DAPI) channel. In both macrophages 
and epithelial cells, optical sections through the cells clearly revealed that Compounds P, T, and 
U (red signals) were localized at the periphery of the cell nuclei (blue signal) and within the 
confines of the cells' plasma membrane (green signal) (Figure 6). 
To establish the extent to which the differences in staining and self‐assembly of 
phenazine compounds may be due to cell type‐dependent differences in bioaccumulation, the 
total amount of compounds present in macrophages (Figure 7a) and epithelial cells (Figure 7b) 
following an incubation period was measured and normalized by the number of cells. Overall, 
phenazine compounds tended to accumulate more in macrophages than in epithelial cells, 
regardless of ordered aggregate formation (Figure 7c). Nevertheless, compounds that exhibited 
the greatest accumulation in macrophages (Figure 7c, Figure 7d) also yielded the most ordered 
inclusions (Compounds P, Q, U, V, and W). To confirm the cell type‐dependence of the 
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bioaccumulation and intracellular self‐assembly properties of the phenazine compounds, 
principal component analysis (PCA) was performed on the cumulative bioaccumulation and 
diattenuation anisotropy data (Figure 8). Because the first two components of the resulting PCA 
plots captured >97% of the variation in the measured properties of the compounds in 
macrophages and epithelial cells (Figure 8) the PCA plot indicates that most of the observed 
variation was associated with cell type specific differences in bioaccumulation and diattenuation 
anisotropy, without a clear association with chirality, chemical structure or the lipophilicity of 
the compounds. 
Finally, we tested whether the bioaccumulation of the compounds was related to the 
precipitation of the compounds in cell culture media or to their solubility. In serum containing 
media, solutions of clofazimine and the other phenazine compounds were stably solubilized at 
the concentrations that were added to the cells, so the formation of extracellular precipitates is an 
unlikely explanation for the measured differences in bioaccumulation in either macrophages 
(Figure 9a) or epithelial cells (Figure 9b). Only one of the phenazine analogs (Compound J) was 
not completely solubilized under these conditions. In the absence of serum (Figure 9c, Figure 
9d), the phenazine compounds exhibited significant variation in their solubility with some of the 
compounds precipitating in the media. However, the solubility of the compounds did not show a 
correlation with the measured bioaccumulation in macrophages (Figure 9c) or epithelial cells 
(Figure 9d). 
Considering the biological mechanisms that may account for the observed variations in 
bioaccumulation properties of phenazine compounds, clofazimine and other small molecule 
drugs can be subject to chemical transformation by metabolic enzymes. Furthermore, small 
organic molecules can also be substrates of active transport mechanisms. These metabolic and 
active transport mechanisms are differentially expressed in macrophages and epithelial cells and 
they are highly specific and sensitive to the presence of different functional groups on the 
compounds. 
3.6 Conclusions 
To conclude, our results demonstrate that, in addition to clofazimine, other membrane‐
permeant small molecule phenazine compounds can bioaccumulate and self‐assemble in 
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macrophages, to a greater extent than in epithelial cells. Our results also demonstrate the use of 
monochromatic polarized light to measure diattenuation for monitoring the formation of ordered, 
insoluble complexes, which can be useful for assaying intracellular self‐assembly of phenazine 
compounds. This is an advantage of this approach compared to other types of optical techniques 
that have been developed to detect the presence of insoluble drug complexes inside cells [31]. 
Indeed, with the quantitative polarization microscope, the presence of ordered molecular 
aggregates accompanying bioaccumulation of phenazine compounds was readily measurable and 
analyzable. Independently, we confirmed the bioaccumulation of the molecules by chemical 
analysis and the intracellular localization of the inclusions was confirmed with confocal 
microscopy by taking advantage of the compounds' fluorescence signals. 
Similar to other structure–property relationship studies, our results demonstrate how the 
molecular organization of self‐assembling intracellular elements can be analyzed in relation to 
specific chemical features of the individual, small molecule building blocks. Based on staining 
patterns, the uptake of clofazimine was inhibited by replacing its chlorophenyl group with 
different aromatic functionalities. Notably, modification of the R‐imino group did not suppress 
intracellular inclusion formation. Instead, several R‐imino phenazine derivatives exhibited 
greater bioaccumulation than clofazimine, forming highly condensed cytoplasmic inclusions, 
which exhibited strong diattenuation anisotropy signals. In addition, biological factors affecting 
the preferential bioaccumulation of phenazine molecules in macrophages exerted the most 
dominant effect on self‐organization and intracellular inclusion formation, independently of the 
lipophilicity, solubility, and chirality of the molecules. 
The condensation and phase separation of phenazine compounds into insoluble 
aggregates especially influences the bioaccumulation and retention of these compounds inside 
macrophages. In this regard, it is important to note that the measured concentration of phenazine 
compounds inside cells is far greater than one would expect from a nonspecific partitioning or a 
specific binding mechanism. For all the compounds that bioaccumulated inside cells, the 
measured numbers of phenazine molecules per cell (>0.03 ± 0.01 picomoles) exceeded the 
amounts of the most concentrated, endogenous biomolecules and metabolites (e.g., adenosine 
triphosphate [32] or glutathione [33].  Only potassium and water are expected to be present in 
greater amounts [34, 35]. Considering the possibility that bioaccumulation may reflect the 
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partitioning of the molecules in membranes, there are in the order of 15 picograms of total lipids 
per leukocyte [36, 37]. This corresponds to 0.03 picomoles of total lipids per cell (calculated 
based on 500 g mol
−1
 of phospholipid). Interestingly, such intracellular precipitation behavior 
has been reported for other kinds of drugs [38]. In fact, the size, faceted shapes, and overall 
morphology of these inclusions are inconsistent with the typical size, shapes and morphology of 
natural organelles[31] and do not resemble the typical staining patterns of mitochondria[39, 40] 
or other cellular components stained with fluorescent probes[41]. Therefore, one can infer that in 
addition to cell type‐specific differences in bioaccumulation, the propensity of poorly soluble 
phenazine molecules to aggregate into insoluble molecular complexes and phase separate from 
other cellular components also exerts an important influence on their intracellular disposition 
properties. 
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3.8 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Synthesis scheme for phenazine derivatives 
 
Synthesis of phenazine derivatives. Treatment of aniline derivatives 1 with 2‐fluoronitrobenzene 2 (using reagents: 
a) KF/K2CO3 or b) KOH/DMSO) gave the secondary amine derivatives 3 in 22–63% yield. Reduction of the nitro 
group was carried out using 10% Pd/C catalyst under hydrogen atmosphere to yield the diamine 4 in 55–99% yield. 
Then the diamine 4 was oxidized in aqueous ferric chloride solution to give the corresponding phenazine salts 5 in 
70–96% yield. The phenazine salts 5 on treatment with variety of primary amines gave the corresponding phenazine 
derivatives 6 in 10–85% yield. These methods are elaborated in detail in the Supporting Information. 
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Figure 3-2 Phenazine derivatives and cellular staining patterns 
 
Three series of phenazine derivatives of clofazimine were synthesized to probe the relationship between 
clofazimine's chemical structure a–c) and its cellular staining patterns a′–c′). The common phenazine core shared by 
all phenazine compounds is shown in the top left corner of the figure. In the first series of derivatives a,a′), the 
chlorophenyl groups of clofazimine were substituted with different functionalities. In the second series b,b′), the 
isopropyl R‐imino group of clofazimine was substituted with achiral functional groups. In the third series c,c′), the 
isopropyl R‐imino group of clofazimine was substituted with additional functional groups that probed the effects of 
an added stereochemical center. Scale bar = 20 μm. 
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Figure 3-3 Absorbance spectra of phenazine compounds in methanol and sulfuric acid 
 
Absorbance spectra of phenazine compounds were very similar to that of clofazimine. Absorption peaks were 
between 450 and 490 nm when measured in methanol and between 510 and 540 nm when measured in H2SO4. 
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Figure 3-4 Quantitative polarization microscopy of cells incubated with phenazine derivatives 
 
Quantitative polarization microscopy of macrophages and epithelial cells incubated with the different phenazine 
compounds revealed cell type‐specific differences in transmittance, diattenuation anisotropy, and the orientation of 
the polarization axis maximal transmittance of the intracellular inclusions. For the experiments, live RAW264.7 
macrophages a) or MDCK epithelial cells b) were incubated for 72 h with clofazimine or other phenazine analogs 
and analyzed with the diattenuation anisotropy microscope imaging set up, using monochromatic light of 546 nm 
wavelength. Transmittance corresponds to the image map of the transmitted light intensity at 546 nm wavelength 
(white corresponds to 100% transmittance and black corresponds to 0% transmittance) and orientation corresponds 
to the measured direction of maximal light transmittance of linearly polarized light across the sample, indicated with 
a grid of red lines superimposed on the image. Diattenuation corresponds to the quantitative diattenuation anisotropy 
image map measured using linearly polarized light of 546 nm wavelength. The color‐gradient calibration bar 
corresponds to diattenuation anisotropy values ranging from 0 to 0.6. Scale bar = 20 μm. 
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Figure 3-5 Quantitative comparison of diattenuation of intracellular inclusions 
 
Quantitative comparison of the diattenuation anisotropy measurements of intracellular inclusions formed by 
clofazimine and other phenazine derivatives showing the most prominent diattenuation anisotropy signals 
(Compounds P, U, V, and W). Compound T was included as well, since it corresponds to the mirror image (chiral 
pair) of Compound U. a) Compared to clofazimine, Compounds U, V, and W show stronger diattenuation 
anisotropy signals in macrophages, while Compound P shows stronger diattenuation anisotropy signals in both 
macrophages and epithelial cells. b) The ratio of 623 nm/546 nm diattenuation anisotropy signals of the phenazine 
compounds was similar to that of clofazimine. Suggesting greater variability in the organization of the intracellular 
inclusions, Compounds V and W exhibited greater standard deviations, corresponding to greater differences in the 
measured diattenuation anisotropy ratios amongst individual inclusions. 
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Figure 3-6 Confocal fluorescence microscopy of cells incubated with fluorescent phenazine derivatives 
 
Confocal fluorescence microscopy of RAW264.7 macrophages or MDCK epithelial cells after incubation with 
fluorescent phenazine Compounds, P, T, or U. 2D images in xy planes show the location of cell nuclei (blue) and 
plasma membranes (green), together with the corresponding, intracellular location of phenazine compounds (red). 
3D reconstructions of optical sections through orthogonal planes (xzand yz planes) confirm intracellular, cytoplasmic 
signals of compounds (red), in relation to the position of the nuclei and plasma membrane signals. Scale bar = 20 
μm. 
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Figure 3-7 Cellular accumulation of phenazine compounds 
 
Measured differences in the accumulation of clofazimine or its phenazine derivatives (in pmols per cell) in 
RAW264.7 macrophages or MDCK epithelial cells following a 72 h incubation period. a) Measurements indicate 
significant differences in the accumulation of the compounds in live versus fixed macrophages. b) Measurements 
also indicate significant differences in the accumulation of the compounds in live versus fixed epithelial cells. c) 
Plot of mass accumulation of compounds in macrophages versus epithelial cells reveals overall trend towards higher 
accumulation of the compounds in macrophages. d) Plot of the cellular accumulation of phenazine compounds in 
macrophages and epithelial cells in relation to the diattenuation anisotropy of the resulting intracellular inclusions, 
measured using linearly polarized light at 546 nm wavelength. 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8 PCA plot of optical properties of phenazine inclusions within cells 
 
PCA confirms that the cell‐associated staining patterns of phenazine compounds corresponded with a greater 
variation in bioaccumulation and optical signals in macrophages. PCA was performed based on all optical properties 
analyzed for each phenazine compound in series 2 and 3, using five replicate measurements at 546 and 623 nm. In 
the plot, X(M) corresponds to Compound X in macrophages (red) and X(E) corresponds to Compound X in 
epithelial cells (blue). In this PCA plot, only the two main principal components are shown. These first two 
components of the PCA plot explained 97% of the variance in the data. 
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Figure 3-9 Solubility of phenazine compounds in cell culture media related to intracellular accumulation 
 
The solubility of phenazine compounds in cell culture media a,b) with FBS (+FBS) and c,d) without FBS (−FBS) 
plotted in relation to their cellular accumulation in a,c) RAW264.7 macrophages and b,d) MDCK epithelial cells. 
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3.9 Supporting Information Available 
This material is published in Advanced Science and supplemental figures and tables are available 
in Appendix B. 
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Chapter 4 
Clofazimine Biocrystal Accumulation in Macrophages Upregulates 
Interleukin 1 Receptor Antagonist Production to Induce a Systemic 
Anti-Inflammatory State 
4.1 Relevance to Thesis 
The accumulation of clofazimine and CLDIs within a mouse model, and experiments related to 
that are the primary experimental methodology that is utilized in the thesis work of this 
dissertation. Relating the physiological changes brought about to the body (i.e., weight gain or 
loss, changes in body temperature, and heart rate) to treatment with the drug can prove to be a 
useful marker for numerous clinical endpoints, among the most important for the work discussed 
in chapter 8 is systemic toxicity or damage to the overall health of the animal. In the studies 
presented here, the accumulation and presence of clofazimine biocrystals within mice was tested 
for its ability to protect against inflammatory agents, in particular, LPS-induced lung injury and a 
carrageenan-induced paw injury. As related to this thesis, my own contribution to the work 
presented in this chapter was  monitoring the body weight, temperature, heart rate, breathing rate, 
oxygen saturation, and pulse distention of mice daily to  determine the effect that the lung-injury 
and drug therapy had on the general health of the animal, and in turn, if the animal was 
moribund. The knowledge and skills obtained from assisting with this work helped provide the 
necessary hands-on animal training and experience needed to design and perform the in vivo 
experiments that were performed in chapters 6, 7, and 8. Additionally, these experiments guide 
the experimental design and techniques utilized in the macrophage-depletion and toxicity 
experiments that are performed in chapters 7 and 8, and how this relates to a systemic toxic 
event. The key finding discussed in this manuscript is related to the upregulation of anti-
inflammatory activity related to the accumulation of insoluble drug, rather than treatment with 
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the soluble form of clofazimine. To that end, my contributions also included quantifying these 
anti-inflammatory cytokines using enzyme-linked immunosorbent assay (ELISA), which were 
thoroughly utilized in chapter 8. Through these analyses, the relationship between anti-
inflammatory activity and insoluble drug aggregate accumulation was determined, and helped 
guide the work that is discussed in chapter 8, in particular the link between macrophage-
dependent drug bioaccumulation, granuloma formation, production of anti-inflammatory 
cytokines, and a potential protective mechanism behind CLDI accumulation.  
4.2 Abstract 
Clofazimine (CFZ) is a poorly soluble antibiotic and anti-inflammatory drug indicated for 
the treatment of leprosy. In spite of its therapeutic value, CFZ therapy is accompanied by the 
formation of drug biocrystals that accumulate within resident tissue macrophages, without 
obvious toxicological manifestations. Therefore, to specifically elucidate the off-target 
consequences of drug bioaccumulation in macrophages, we compared the level of inflammasome 
activation in CFZ-accumulating organs (spleen, liver and lung) in mice after 2 and 8 weeks of 
CFZ treatment when the drug exists in soluble and insoluble (biocrystalline) forms, respectively. 
Surprisingly, the results showed a drastic reduction in caspase 1 and interleukin-1β (IL-1β) 
cleavage in the livers of mice treated with CFZ for 8 weeks (8-week-CFZ-treated mice) 
compared to 2-week-CFZ-treated and control mice, which was accompanied by a 3-fold increase 
in hepatic IL-1 receptor antagonist (IL-1RA) production and a 21-fold increase in serum IL-1RA 
levels. In the lung and spleen, IL-1β cleavage and tumor necrosis factor alpha expression were 
unaffected by soluble or biocrystal CFZ forms. Functionally, there was a drastic reduction of 
carrageenan- and lipopolysaccharide-induced inflammation in the footpads and lungs, 
respectively, of 8-week-CFZ-treated mice. This immunomodulatory activity of CFZ biocrystal 
accumulation was attributable to the upregulation of IL-1RA, since CFZ accumulation had 
minimal effect in IL-1RA knockout mice or 2-week-CFZ-treated mice. In conclusion, CFZ 
accumulation and biocrystal formation in resident tissue macrophages profoundly altered the 
host's immune system and prompted an IL-1RA-dependent, systemic anti-inflammatory 
response. 
4.3 Introduction 
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Clofazimine (CFZ) is an antimycobacterial agent listed in the World Health 
Organization's List of Essential Medicines that has been in use as part of the standard treatment 
of leprosy since the 1960s [1, 2]. The number of leprosy cases has drastically dropped from 12 
million/year in 1981 to 216,000/year in 2013 [3], a testament to the effectiveness of CFZ, which 
has gained considerable attention recently as part of a treatment regimen for drug-resistant 
tuberculosis [4–6]. The efficacy of oral CFZ against leprosy is due, in part, to its well-
documented anti-inflammatory activity [2]. However, CFZ's mechanism of anti-inflammatory 
action and atypical pharmacokinetic properties are not well understood, and its high oral 
bioavailability and poor solubility leads to significant bioaccumulation in tissues [7]. 
In previous studies, it has been shown that following prolonged oral administration of 
CFZ, the drug massively bioaccumulates as intracellular biocrystals in resident tissue 
macrophages [8–12]. Therefore, it is natural to assume that this bioaccumulation phenomenon 
contributes to the drug's toxicity, whereas the soluble form of CFZ, which circulates and 
partitions to and from the different organs, is responsible for CFZ's mechanism of action. Indeed, 
insoluble particles and crystals that accumulate in macrophages under various pathological 
conditions are known to activate immune signaling pathways that lead to caspase 1 (Casp 1) 
activation and increased interleukin-1β (IL-1β) secretion [13–16]. This so-called 
“inflammasome” activation pathway is often associated with many downstream pathological 
changes, as has been shown by the accumulation of cholesterol monohydrate crystals in 
atherosclerosis [13], monosodium urate crystals in gout [14], and inhaled foreign particles in the 
case of asthma and other chronic inflammatory lung diseases [15, 16]. 
In spite of its bioaccumulation, several clinical trials have established CFZ as a 
potentially useful therapeutic agent for treating a variety of chronic inflammatory diseases [17,–
22]. Furthermore, in vitro studies have shown that intracellular CFZ biocrystals dampen pro-
inflammatory pathways while enhancing anti-inflammatory signals [23]. 
In order to distinguish between the potential adverse effects of insoluble drug biocrystals 
from those of the soluble molecules, we designed an experimental strategy to compare how the 
accumulation of insoluble drug biocrystals might influence the immune signaling response of 
macrophages in live mice. We reasoned that macrophages exposed to the soluble form of CFZ 
(after 2 weeks of treatment) may behave differently from those that are exposed to its 
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biocrystalline form (after 8 weeks of treatment). Accordingly, we tested the specific hypothesis 
that CFZ biocrystals that accumulate in resident tissue macrophages can modulate (or activate) 
these cells' inflammatory signaling pathways in vivo that lead to systemic changes in the 
inflammatory response. By assessing tumor necrosis factor alpha (TNF-α) and IL-1 receptor 
antagonist (IL-1RA) expression, as well as Casp 1 and IL-1β maturation, in the vital organs and 
blood of CFZ-treated mice, our results demonstrate that CFZ biocrystals in macrophages, but not 
the soluble form, is specifically associated with an IL-1RA-mediated anti-inflammatory 
response. 
4.4 Materials and Methods 
Reagents. Anti-caspase 1 and anti-IL-1β antibodies were purchased from Thermo Pierce 
(Rockford, IL) and Novus Biologicals (Littleton, CO), respectively. Anti-F4/80 and anti-CD68 
antibodies were purchased from Abcam (Cambridge, MA). Anti-actin antibody and 
lipopolysaccharide (LPS; from E. coli O55:B5) were purchased from Sigma (St. Louis, MO). 
Mice clofazimine treatment. Clofazimine (CFZ; Sigma-Aldrich, catalog no. C8895) was 
prepared in sesame oil (Shirakiku, Japan, or Roland, China) and Powdered Lab Diet 5001 (PMI 
International, Inc., St. Louis, MO) and orally administered to wild-type (WT) C57BL/6 mice or 
IL-1RA knockout mice (4 to 5 weeks old; Jackson Laboratory, Bar Harbor, ME) for up to 8 
weeks ad libitum as previously described [8, 24]. Control mice were fed with the same diet 
without CFZ. The animal protocol was approved by the University of Michigan's Animal Care 
and Use Committee in accordance with the National Institutes of Health guidelines (UCUCA, 
no. PRO00005542). 
Carrageenan footpad edema test. Footpad edema in response to carrageenan (CAR; Sigma) 
injection was measured in CFZ-treated and control mice as previously described [25]. In IL-1RA 
knockout (KO) mice, these experiments were performed at 6 weeks and not at 8 weeks because 
the IL-1RA KO mice weighed less than the WT mice and their livers were smaller (see Fig. S4). 
In brief, the volume of each hind paw was measured before and after the intraplantar injection of 
30 μl of 2% CAR (60 μg per paw) in phosphate-buffered saline (PBS) or an equal volume of 
PBS in the contralateral paw. Paw swelling was measured at 4 and 48 h after injection, after 
which the animals were euthanized by exsanguination while deeply anesthetized with an 
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intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), and the skin tissues 
of the plantar region were harvested for cytokine assay (see the Materials and Methods in 
Appendix C). 
Acute lung injury and infrared pulse oximetry. Since C57BL/6 mice are relatively resistant 
toward a single dose of intratracheal (i.t.) LPS instillation [26], two i.t. injections of LPS (16 
mg/kg; 50 μl) were administered, one on day 0 and the second on day 3. Briefly, mice treated 
with CFZ for 8 weeks (8-week-CFZ-treated mice) and control mice were anesthetized using 
intraperitoneal injections of xylazine (50 mg/kg) and ketamine (5 mg/kg). Under direct 
visualization of the vocal cords using an otoscope, either LPS or an equivalent volume of PBS in 
a 1-ml syringe attached to an oral gavage needle (22G) was instilled into the lungs via the oral 
route. The mouse was then placed in a temperature-controlled cage (37°C) for recovery from 
anesthesia. The general health status of each PBS/LPS-instilled mice was monitored by 
measuring body weight and rectal temperature (microprobe thermometer; Physitemp 
Instruments, Clifton, NJ), and cardiopulmonary function (arterial oxygen saturation, respiratory 
rate, heart rate, and pulse distention) was monitored using MouseOx with a collar clip sensor 
(Starr Life Sciences Corp., Oakmont, PA) as previously described [27, 28]. In brief, 1 day before 
i.t. instillations (day −1), the hair around the neck of each mouse was removed using Nair 
(Church & Dwight, Princeton, NJ) to enable data acquisition using the collar clip sensor. The 
next day (day 0), immediately prior to the first LPS/PBS dose, and every 24 h afterward until day 
6, the body weight, temperature, and MouseOx readings were recorded. MouseOx data were 
acquired by very brief anesthesia of the mouse using 5% isoflurane to facilitate the placement of 
the collar clip sensor. The mouse was then placed in an enclosed chamber with ambient light and 
allowed to acclimatize for 5 min, at which point the animals had recovered normal activities and 
physiological readings. Arterial oxygen saturation, respiratory rate, heart rate, and pulse 
distention measurements were then simultaneously recorded for 6 min (15 readings/s), and any 
errors caused by motion during recording were excluded, after which the mean value of each 
parameter was used for further data analysis. 
Terminal endpoint assessment. To objectively assess LPS-induced mortality, we used a 
multiparametric scoring system that relied on the daily changes in vital signs associated with 
inflammatory injury progression and mortality, which included arterial oxygen saturation [27], 
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body weight, and temperature [29, 30]. First, the percent change from baseline (day 0) in arterial 
oxygen saturation, body weight, and temperature in each mouse caused by i.t. instillation of 
PBS/LPS were measured and calculated daily until day 6 after instillation. These data were then 
used in a vector equation to calculate the distance between each LPS-treated mouse and the mean 
of the PBS-treated mice to assess the terminal endpoint for each LPS-instilled mouse (see 
Materials and Methods in Appendix C). CFZ-treated and control mice were calculated 
separately, and LPS-instilled mice that scored a total of 18 or higher were determined as 
terminal, since these mice also displayed severe signs of sickness evidenced by impaired 
mobility, lack of grooming, hunched posture, and muscle weakness that could be felt while 
handling the mice. These mice were immediately euthanized with ketamine-xylazine (100 
mg/kg, 10 mg/kg) and the bronchoalveolar lavage (BAL) fluid and lungs were harvested for 
cellular and biochemical analysis (see below). Remaining mice that did not reach terminal 
endpoint were all euthanized on day 6 after PBS/LPS instillation. 
Cytokine measurements. The harvested organs (liver, spleen, lungs, and kidneys) and footpads 
designated for cytokine assays were cut and homogenized by sonication (2-s pulses repeated five 
times on ice, level 5; Fisher model 100) in radioimmunoprecipitation assay buffer (Sigma) with 
added protease inhibitors (Halt protease and phosphatase inhibitor cocktail and 0.5 M EDTA; 
Thermo Pierce, Rockford, IL). After centrifugation (18,000 × g, 15 min, 4°C), the supernatants 
were assayed for IL-1β, IL-1RA, and TNF-α by enzyme-linked immunosorbent assay (ELISA; 
Duoset; R&D Systems, Minneapolis, MN) in duplicate wells according to the manufacturer's 
instructions. Cytokines in the BAL were measured after the removal of the cells. Albumin was 
assayed by ELISA (Innovative Research, Novi, MI). The cytokine concentrations were expressed 
(i) as pico-, nano-, or micrograms per milligram of protein for the organs, (ii) as pico-, nano-, or 
micrograms of paw weight, or (iii) as pico- or micrograms per milliliter of BAL fluid. 
Mouse BAL fluid harvesting, immunohistochemistry and imaging, and SDS-PAGE and 
Western blotting. The mouse BAL fluid harvesting, immunohistochemistry and imaging, and 
SDS-PAGE and Western blotting procedures are described in Appendix C. 
Data processing and statistics. All data are expressed as means ± the standard deviations (SD). 
For multiple comparisons, statistical analysis was performed with one-way analysis of variance 
(ANOVA) and Tukey's post hoc comparisons. For two-group comparisons, an unpaired 
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Student t test was used. All statistical analyses employed the Sigmaplot version 13 (Systat 
Software, San Jose, CA) software and P ≤ 0.05 was considered statistically significant. 
4.5 Results 
4.5.1 CFZ crystallization and bioaccumulation in the liver occurs after 2 weeks 
During the first 2 weeks of CFZ treatment, CFZ-associated diffuse red staining was 
present throughout the liver (Fig. 1A, brightfield). However, by 4 weeks, CFZ accumulated in 
the biocrystalline form. At 8 weeks, red CFZ biocrystals were evident throughout the liver (Fig. 
1A, top panel). Taking advantage of solvatochromic changes in the fluorescent excitation and 
emission spectra of CFZ [31, 32], fluorescence microscopy enabled in vivo detection of the 
soluble and biocrystalline forms of CFZ. After 2 weeks of CFZ treatment, the drug was mostly 
present in the soluble form with its fluorescence mostly detectable in the FITC channel (Fig. 1A, 
fluorescein isothiocyanate [FITC] and Cy5 panels; Fig. 1B). At later time points, the 
fluorescence signal in the FITC channel declined, while the fluorescence signal in the Cy5 
channel increased, indicating the relative accumulation of the biocrystalline form (Fig. 1A and 
and B). By 8 weeks, most of the fluorescence signal was detectable in the Cy5 channel (Fig. 1 A 
and B), indicating that CFZ was present almost entirely in biocrystalline form. 
Immunohistochemistry of 8-week-CFZ-treated liver sections showed that CFZ biocrystals are 
sequestered inside F4/80-positive macrophages (Fig. 1C). Such targeted accumulation of CFZ 
biocrystals was also detected in other organs such as CD68
+
 alveolar macrophages (see Fig. SI. 
7), and F4/80
+
 splenic macrophages [8, 31]. 
4.5.2 CFZ biocrystal formation in the liver downregulates Casp 1/IL-1β processing while 
enhancing IL-1RA expression 
Intracellular crystals, such as those formed by cholesterol or uric acid, have been 
implicated in the activation of the NLRP3-Casp 1 inflammasome, which plays a major role in the 
pathogenesis of chronic inflammatory disorders [14, 33, 34]. The uptake of other nano- and 
microparticles has also been reported to cause inflammasome activation in macrophages [35–37]. 
Therefore, to assess whether the bioaccumulation of CFZ crystals leads to activation of the 
inflammasome, we measured and compared cleaved Casp 1 and IL-1β in organs that 
bioaccumulate CFZ—i.e., the liver, spleen, and lungs—and kidneys, that do not accumulate 
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CFZ, after 2 and 8 weeks of either CFZ or control treatment. Two weeks of CFZ exposure 
resulted in only moderate cleavage of hepatic Casp 1 and IL-1β (Fig. 2A, left panel, and Fig. 
2B). However, by 8 weeks, Casp 1 and IL-1β cleavage was significantly reduced by CFZ 
treatment (Fig. 2A, right panel, and Fig. 2B); IL-1β levels in the spleen, lung, and kidneys did 
not change (see Fig. SI. 8). The expression of the proinflammatory cytokine, TNF-α, was 
unchanged by CFZ at both 2 and 8 weeks (Fig. 2C), except in the liver, where it was decreased at 
2 weeks compared to control livers. 
Similar to previous observations [8], we found that after 8 weeks of oral administration 
CFZ caused a major upregulation of IL-1RA expression in CFZ biocrystal-accumulating organs, 
such as the spleen, the lungs, and especially the liver, which increased by 3-fold (Fig. 2D). IL-
1RA levels in the kidney were unaffected (Fig. 2D). In contrast, after 2 weeks of oral CFZ 
administration there were more modest increases in only the spleen and lungs, while the liver 
was unaffected (Fig. 2D). Since the liver is known to be the major source of circulating IL-1RA 
[38, 39], we observed a corresponding increase in serum IL-1RA levels in CFZ-treated mice at 8 
weeks but not at 2 weeks (Fig. 2E). Under all conditions, neither TNF-α nor IL-1β was detected 
in the serum. In aggregate, these findings suggest that crystallized CFZ, which is evident after 8 
weeks of CFZ administration, decreased the activation of the inflammasome in vivo. In parallel 
with this decline, crystallized CFZ induced an upregulation of endogenous IL-1RA. 
4.5.3 Systemic CFZ bioaccumulation and crystallization dampens CAR-mediated acute 
footpad inflammation 
To test the physiological impact of the CFZ-induced serum IL-1RA levels, we tested the 
acute inflammatory response of CFZ-treated mice by using a well-established footpad injury 
model [25]. The paws of 8-week-CFZ-treated mice displayed strikingly reduced swelling at 48 h 
after the injection of CAR compared to the paws of untreated CAR-injected mice (Fig. 3A). Paw 
volume measurements showed that there was a significant reduction (57%) in footpad swelling 
as early as 4 h after the injection of CAR in 8-week-CFZ-treated mice compared to control mice, 
and the animals continued to exhibit reduced swelling over the 48-h study period (Fig. 3B). 
CAR-induced increases in footpad IL-1β and TNF-α levels were dramatically reduced by 8-
week-CFZ treatment (Fig. 3C and 3D). In contrast to the 8-week-treated mice, 2-week-CFZ-
treated mice produced only a modest reduction in paw swelling compared to control mice (Fig. 
95 
 
3E and 3 F). The IL-1β and TNF-α levels in footpad homogenates from these animals were 
similar in both CFZ-treated and control mice at 48 h (Fig. 3G and 3H). Accordingly, these results 
suggest that the accumulation of CFZ biocrystals modulated the immune response to profoundly 
dampen CAR-induced footpad inflammation, and this action is not evident for the soluble form 
of the drug after 2 weeks of treatment. 
4.5.4 CFZ biocrystals dampen the acute inflammatory response in the footpad by 
increasing blood IL-1RA 
IL-1RA is known to be an early-acting acute-phase anti-inflammatory cytokine [38], and 
circulating IL-1RA has been reported to dampen a broad spectrum of inflammatory conditions 
by inhibiting the activity of IL-1β at the site of injury [40, 41]. Therefore, we hypothesized that 
the anti-inflammatory response observed after 8 weeks of CFZ treatment may be mediated by 
increased serum IL-1RA concentrations, which are not evident after 2 weeks of CFZ treatment 
(Fig. 2E). Detection of serum IL-1RA in 2-week-CFZ-treated and control mice showed 
comparable IL-1RA levels before (0 h) and after (48 h) CAR injection (Fig. 4A). However, 
serum IL-1RA levels in 8-week-CFZ-treated mice rapidly declined 4 h after CAR injection (Fig. 
4B). After 48 h, IL-1RA returned to similar levels in the plasma of control and 8-week-CFZ-
treated mice (Fig. 4B). For all mice, the plasma levels of TNF-α and IL-1β were below the 
detection limit of ELISAs (15 pg/ml). These results suggest that increased circulating IL-1RA 
levels associated with CFZ bioaccumulation and crystallization could be responsible for the anti-
inflammatory activity observed in 8-week-CFZ-treated mice. 
In order to test the possibility that elevated IL-1RA expression mediates the anti-
inflammatory activity of CFZ after crystal formation, we administered oral CFZ to age-matched 
IL-1RA KO and WT mice and then subjected the animals to the CAR footpad injury model. IL-
1RA KO mouse livers also increased in weight to an extent similar to that of WT mice after 6 
weeks of CFZ treatment (see Fig. SI. 9B). Also, IL-1RA KO mice formed and accumulated CFZ 
biocrystals in the liver at a level similar to WT animals without noticeable differences in crystal 
shape or Cy5 fluorescence intensity (see Fig. SI. 9C and SI. 9D). Remarkably, the anti-
inflammatory action of CFZ bioaccumulation was greatly diminished in IL-1RA KO mice, since 
CFZ-treated and CAR-injected IL-1RA KO mice displayed similar swelling compared to 
untreated and CAR-injected IL-1RA KO mice (Fig. 4C and 4D, right panels). In the CFZ-treated 
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WT mice, we observed significantly reduced CAR-induced swelling compared to control mice at 
4 and 48 h postinjury (Fig. 4C and  4D, WT panels). As expected, the footpad IL-1β and TNF-α 
levels were significantly reduced in WT CFZ-treated and CAR-injected mice compared to WT 
untreated and CAR-injected mice (Fig. 4E). However, the IL-1β and TNF-α levels were 
comparable in the CAR-injected IL-1RA KO mice with or without CFZ treatment (Fig. 4F). IL-
1RA KO mice with or without CFZ treatment showed higher cytokine levels than the control 
WT mice after CAR injection (Fig. 4E versus Fig. 4F), but the footpad swelling was similar (Fig. 
4D). These results are consistent with CFZ bioaccumulation exerting a systemic anti-
inflammatory action via the elevation of blood IL-1RA levels. 
4.5.5 CFZ bioaccumulation enhances resistance to acute lung injury and improves mouse 
survival 
Given the massive bioaccumulation of CFZ observed in the lungs, we proceeded to 
determine whether the presence of CFZ biocrystals in these organs may sensitize mice to a 
sublethal pro-inflammatory injury. Although CFZ treatment and bioaccumulation did cause some 
physiological changes, these changes were within ranges of normal physiological readings and 
overall mouse health was normal (see Table S7). 
To determine whether CFZ bioaccumulation induced a latent proinflammatory state in 
mouse lungs, a sublethal dose of LPS (16 mg/kg) was delivered i.t. to control and CFZ-treated 
mice. Strikingly, CFZ-treated mice were highly resistant to LPS-induced acute lung injury, with 
a 92% survival rate compared to the 42% survival rate of control mice (Fig. 5A). The difference 
in the arterial oxygen saturation levels between control and CFZ-treated mice was more 
prominent after the second LPS injection. CFZ-treated mice displayed significantly higher 
arterial oxygen levels at days 5 and 6 than control mice because most control mice experienced 
levels of hypoxia that required euthanasia, indicating that control mice showed progressive 
deterioration in lung function compared to CFZ-treated mice (see Fig. SI. 10A). Paralleling the 
impaired lung function, LPS-injected control mice lost weight more rapidly than CFZ-treated 
mice, such that six control mice lost >15% of their body weight compared to a similar weight 
loss in one CFZ-treated mouse (see Fig. SI. 10B). Both control and CFZ-treated LPS-injected 
mice displayed large drops in body temperature one day after LPS injection (days 1 and 4). 
However, CFZ-treated mice were more resistant to a decline in body temperature after the 
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second injection compared to control mice (day 4) (see Fig. SI. 10C). CFZ-treated mice also 
displayed less reduction in heart rate, respiratory rate, and pulse distention after the second LPS 
injection (see Fig. SI. 10D to 10F) compared to control mice. Gross lung examination lungs after 
LPS-induced injury showed a notable reduction of hemorrhaging in CFZ-treated mice compared 
to control mice (Fig. 5B). Cellular and biochemical analyses of BAL fluid to assess lung injury 
revealed that CFZ treatment reduced the LPS-induced BAL fluid cell count (Fig. 5C) and 
reduced the BAL fluid albumin concentrations (Fig. 5D). This CFZ-mediated reduction in lung 
injury was corroborated by CFZ-induced reductions in LPS-induced levels of BAL fluid TNF-α 
and IL-1β (Fig. 5E and 5F). These results demonstrate that CFZ biocrystal accumulation in the 
lungs did not impair lung function but instead increased resistance to LPS-induced inflammatory 
lung injury. 
4.6 Discussion 
Previously, CFZ bioaccumulation has been associated with atypical pharmacokinetics, as 
well as more serious side effects, ranging from gastrointestinal problems to splenic infarcts [42]. 
Although expecting that CFZ bioaccumulation would lead to an upregulation of proinflammatory 
signaling pathways in macrophages, we were surprised to find the opposite. Instead, our 
experimental results indicate that long-term oral administration of CFZ and its sequestration as 
biocrystals within the macrophages of the lung, the spleen, and especially the liver can 
dramatically suppress inflammation in peripheral tissues and increase mouse survival in response 
to acute lung injury. This systemic anti-inflammatory response parallels the accumulation of 
CFZ biocrystals throughout the animal and is accompanied by elevated IL-1RA levels in these 
organs and a corresponding boost in IL-1RA levels in serum. Of noteworthy significance, the 
formation and accumulation of cholesterol monohydrate and monosodium urate crystals have 
been implicated in the pathogenesis of chronic inflammatory diseases, such as atherosclerosis, 
nonalcoholic steatohepatitis (NASH) [34], and gout [43]. Moreover, other artificial nano- and 
microparticles, such as silica crystals [37], aluminum salt crystals [44], silver nanoparticles [35], 
poly(lactide-co-glycolide) (PLG), and polystyrene microparticles [36], have also been reported to 
cause inflammasome activation in macrophages. At the cellular level, the aforementioned 
particles or crystals are known to augment Toll-like receptor signaling and activate the NLRP3 
inflammasome via lysosomal destabilization, which leads to Casp 1 activation and the 
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production of cleaved IL-1β [13, 14]. Therefore, the finding that inflammasome activity was 
inhibited in the CFZ biocrystal-containing liver, evidenced by the suppression of Casp 1 
activation and mature IL-1β processing, was unexpected. Moreover, the presence of CFZ 
biocrystals in the lung, spleen, or liver did not alter the TNF-α levels, a finding consistent with a 
lack of proinflammatory signaling. 
These results prompt us to question whether CFZ bioaccumulation is an inherently toxic 
phenomenon. It is well known that soluble CFZ is toxic in vitro, with a 50% inhibitory 
concentration of approximately 5 μM, whereas the insoluble crystalline form of CFZ that 
bioaccumulates in macrophages leads to very few signs of toxicity even at 100 μM [23]. Indeed, 
in spite of its massive accumulation in the liver, the hepatotoxicity of CFZ in mice and human 
patients has not been a significant concern [45–47]. Like humans, mice treated with therapeutic 
CFZ doses (10 mg/kg/day) did not show signs of deteriorated health. In fact, the CFZ-induced 
reduction of heart rate could be linked with increased longevity in mice [48]. Also, hypothermia, 
which is most often used as an indicator of drug toxicity in mice [49], was not seen in 8-week-
CFZ-treated mice. 
Regarding the therapeutic implications of these results, CFZ has proven to be highly 
effective for treating leprosy and active against a broad range of Gram-positive bacteria strains 
(Staphylococcus, Streptococcus, Bacillus, and Listeria spp.) [50] and even against drug-
resistant Staphylococcus aureus clinical isolates that are methicillin resistant (MRSA) and 
vancomycin intermediate resistant (VISA) [51]. Indeed, CFZ has been clinically used since the 
1960s and has helped cure over 16 million leprosy patients. Many of these microorganisms tend 
to infect and reside within macrophages. Interestingly, chemical analysis of CFZ biocrystals has 
revealed that they are composed of protonated hydrochloride salt of CFZ (CFZ-HCl) within 
membrane-bound intracellular compartments [9]. Therefore, the bioaccumulation of CFZ 
biocrystals in macrophages could serve to maximize the therapeutic efficacy of CFZ without 
significant side effects. Accordingly, it may be possible to reformulate CFZ as injectable micro- 
or nanocrystals to specifically target macrophages at sites of infection. Targeted local delivery 
could maximize CFZ benefit as a therapeutic agent while minimizing the systemic side effects 
that have curtailed the more widespread use of CFZ. 
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Considering possible signal transduction mechanisms underlying the anti-inflammatory 
activity of CFZ biocrystals, the cellular integrated stress response pathway is a candidate 
[52, 53]. Although soluble CFZ can cause membrane destabilization and cell death at high 
concentrations [54], lower concentrations of CFZ lead to accumulation within intracellular 
compartments. Previously, we observed that CFZ biocrystals can also be phagocytosed by 
macrophages, where they are stable inside low-pH [4, 5] and counterion (Cl
−
)-containing [9] 
membrane-bound compartments. As a weakly basic lysosomotropic drug, CFZ is prone to pH-
dependent ion trapping in lysosomes and could therefore activate transcription factor EB (TFEB 
[55], a master transcription factor of lysosomal biogenesis and homeostasis [56,–58]. In turn, this 
could attenuate inflammasome activation pathways and IL-1β processing [59]. Alternatively, like 
intracellular protein aggregates and other crystalline inclusions that form in the endoplasmic 
reticulum (60), CFZ biocrystals may activate the unfolded protein response pathway, which 
could lead to downstream effects on inflammatory signaling [61, 62]. 
Our experiments indicate that CFZ biocrystals induce a considerable upregulation of IL-
1RA production without triggering pro-inflammatory signaling. Since the evidence points to IL-
1RA mediating the anti-inflammatory effects downstream of CFZ bioaccumulation in 
macrophages, future experiments aimed at elucidating the signaling pathway leading from CFZ 
biocrystals to IL-1RA expression should reveal further mechanistic details about the mechanism 
of action of CFZ and perhaps serve as the starting point for the development of new kinds of 
anti-inflammatory drugs. Thus, the present study strongly warrants further investigation into the 
mechanisms and therapeutic potential of CFZ for treating inflammatory and infectious diseases 
in humans. To conclude, CFZ biocrystal accumulation in macrophages could be triggering a 
previously unknown anti-inflammatory/immunomodulatory signaling pathway(s) of potential 
therapeutic value. 
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4.8 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 CFZ bioaccumulation and crystallization within the liver 
 
CFZ bioaccumulation and crystal formation in the liver occurs after 2 weeks. (A) Representative bright-field and 
fluorescence (FITC for soluble CFZ and Cy5 for crystalline CFZ) images of liver sections from control mice and 
mice treated with CFZ for 2, 4, and 8 weeks. Scale bar, 50 μm. (B) Fluorescence intensity values (FITC and Cy5 
channels) of liver sections from control and CFZ-treated mice. Baseline (0 week) intensity values of controls were 
subtracted from CFZ-treated sections. The data are the means ± the SD of results from three to four images/time 
point. One-way ANOVA was used to compare fluorescence intensity between time points and P ≤ 0.05 was 
considered statistically significant. *, P ≤ 0.05; **, P ≤ 0.01. (C) F4/80 (DAB) immunohistochemistry of a 
representative liver section from an 8-week-CFZ-treated mouse in which CFZ crystals (Cy5) are sequestered inside 
F4/80
+
 macrophages. CV, central vein. Scale bar, 100 μm. 
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Figure 4-2 CFZ bioaccumulation and pro- and anti-inflammatory signaling  
 
CFZ bioaccumulation reduces Casp 1 and IL-1β cleavage levels in the liver but increases IL-1RA expression. (A) 
Representative Western blots of liver homogenates showing that Casp 1 and IL-1β cleavage was not altered by 2 
weeks of CFZ treatment but that 8 weeks of treatment reduced the detection of Casp 1 and IL-1β cleavage. (B) 
Densitometry of cleaved Casp 1 and IL-1β protein in 2- and 8-week-treated liver blots, normalized to actin (n = 4). 
Hepatic Casp 1 and IL-1β cleavage were reduced by 86 and 78%, respectively, in 8-week-CFZ-treated mice. (C) 
The levels of TNF-α in the spleen, lungs, and kidneys were unchanged by CFZ treatment, but there was a significant 
decrease in liver TNF-α from 2-week-CFZ-treated mice (n = 4 to 5). (D) The organs that bioaccumulate CFZ 
crystals—liver, spleen, and lung—displayed increased IL-1RA expression, whereas the kidney, which does not 
accumulate CFZ, did not show changes in IL-1RA expression (n = 4 to 5). (E) Serum IL-1RA levels were 
unchanged after 2 weeks but were increased 21-fold after 8 weeks of CFZ treatment. The serum TNF-α and IL-1β 
levels were below the limit of detection of the assay (n = 6). *, P ≤ 0.05; **, P ≤ 0.01; #, P ≤ 0.001. Data are means 
± the SD, and an unpaired Student t test was used to compare control mice versus CFZ-treated mice. 
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Figure 4-3 CFZ bioaccumulation and crystallization dampens inflammatory response in mouse footpad 
 
Systemic CFZ bioaccumulation and crystal formation dampens CAR-induced inflammatory response in the mouse 
footpad. (A) Representative photographs of paws 48 h after CAR or PBS footpad injection show markedly reduced 
paw swelling in 8-week-CFZ-treated mice compared to control mice. Scale bar, 5 mm. (B) Paw swelling, as 
measured by foot volume, was reduced on average by 57% as early as 4 h after CAR injection in 8-week-CFZ-
treated mice compared to control mice and was sustained through 48 h. The footpad homogenate cytokine levels of 
IL-1β (C) and TNF-α (D) were reduced in 8-week-CFZ-treated mice at 48 h compared to untreated and injured 
paws. (E and F) Representative photographs of paws 48 h after CAR or PBS footpad injection in 2-week-CFZ-
treated or control mice (E), which resulted in only a minor reduction in swelling at 4 and 48 h (F). Scale bar, 5 mm. 
(G and H) Associated footpad homogenate TNF-α (G) and IL-1β (H) levels were unchanged. PBS-injected paws did 
not show any difference in cytokine expression between CFZ-treated or control paws. Data are means ± the SD 
of n = 5 to 6/experiment. An unpaired Student t test was used to compare control versus CFZ-treated mice. *, P ≤ 
0.05; **, P ≤ 0.01. 
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Figure 4-4 IL-1RA mediated anti-inflammatory activity 
 
The CFZ-induced dampening of the acute inflammatory response in the CAR footpad model is mediated by 
circulating IL-1RA. (A) Two-week-CFZ-treated and control wild-type (WT) mice displayed similar serum IL-1RA 
levels before (0 h) and after (48 h) CAR injection. (B) Serum IL-1RA concentrations were significantly increased 
after 8 weeks of CFZ treatment compared to controls in WT mice (0 h). CAR injection in 8-week-CFZ-treated mice 
caused a sharp decline in serum IL-1RA concentrations by 4 h, whereas the levels in control CAR mice remained 
constant. At 48 h after CAR injection, the serum IL-1RA increased to similar levels in both control and CFZ-treated 
WT mice (data are means ± the SD of n = 5 to 8 animals/group/time point). (C) Representative images of inflamed 
paws of 6-week-CFZ-treated WT mice and IL-1RA KO mice at 48 h after CAR injection. (D) Footpad swelling, as 
measured by foot volume, was reduced by 27 and 38% at 4 and 48 h after CAR injection, respectively, in 6-week-
CFZ-treated WT mice compared to control WT mice. In IL-1RA KO mice with CFZ treatment, paw swelling was 
similar at 4 h compared to untreated littermates, and at 48 h, swelling was marginally reduced (17%) compared to 
untreated IL-1RA KO mice. (E) Footpad homogenate levels of IL-1β and TNF-α were dampened in 6-week-CFZ-
treated and CAR-injected WT mice at 48 h compared to control and CAR-injected paws. (F) Footpad homogenate 
levels of IL-1β and TNF-α were unaffected in 6-week-CFZ-treated and CAR-injected IL-1RA KO mice at 48 h 
compared to control and CAR-injected paws. Data are the compilation of two separate experiments and are 
presented as means ± the SD (n = 7 to 9). A Student t test was used to compare untreated versus CFZ-treated mice at 
each time point. *, P ≤ 0.05; **, P ≤ 0.01. Scale bar, 5 mm. 
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Figure 4-5 CFZ bioaccumulation enhances resistance to LPS-induced lung injury and improves survival 
 
CFZ bioaccumulation enhances resistance to LPS-induced lung injury and improves mouse survival. (A) Kaplan-
Meier survival curve showing the 92% survival rate of 8-week-CFZ-treated mice after LPS-induced acute lung 
injury compared to the 42% survival rate of control mice with LPS-induced injury. (B) A representative photograph 
shows the gross appearance of the lungs after PBS or LPS injection in control and CFZ-treated mice. Hemorrhaged 
areas caused by LPS injection are outlined in black lines. (C to F) CFZ treatment reduced LPS-induced increases in 
the BAL fluid cell count (C), albumin level (D), TNF-α level (E), and IL-1β level (F). The data are the compilation 
of two separate experiments and are presented as means ± the SD (PBS, n = 4; LPS, n = 12). One-way ANOVA was 
used to compare control versus CFZ-treated mice with PBS or LPS injections, and P ≤ 0.05 was considered 
statistically significant. *, P ≤ 0.05; **, P ≤ 0.01. 
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4.9 Supporting Information Available 
This material is published in Antimicrobial Agents and Chemotherapy and supplemental 
methods, figures and tables are available in Appendix C. 
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Chapter 5 
Elasticity in Macrophage-Synthesized Biocrystals 
5.1 Relevance to Thesis 
The accumulation and stability of clofazimine biocrystals within macrophages forms the basis 
for the central hypothesis of this work, and studying CLDIs with a quantitative, microscopic 
imaging methodology is one of the three aims guiding this research. To that end, this work is a 
study of the biomechanical properties of clofazimine-hydrochloride, and how this relates to the 
underlying crystal structure of the biocrystal. As related to this thesis, my own contribution to the 
work presented in this chapter involved the utilization of the quantitative polarized light 
microscope within our laboratory. Live CLDI containing macrophages and isolated CLDIs were 
imaged under polarized light to study the curvature of the crystals both inside of and outside of a 
cellular environment. Following this analysis, we determined that intracellular CLDIs show a 
significant curvature, which may be actively controlled by cellular processes, while CLDIs that 
have been removed from a cellular environment show significantly less curvature. Based off of 
this, we hypothesized that is due to intracellular forces acting on the CLDI that causes this 
bending, which may be a result of an active process being performed by the macrophage to 
stabilize the crystal. Additionally, using the polarized light microscope, we revealed that these 
crystals are highly flexible and that upon application of an external stress (i.e. manual bending of 
the crystal), the internal stress brought about by this external bending force alters the orientation 
of maximum transmission of polarized light through the crystal. This alteration in the orientation 
of maximum transmission of polarized light resulted from minute changes to the underlying 
molecular organization of the clofazimine hydrochloride due to the bending and subsequent 
return to an unbent state, which is a result of the flexible packaging of the clofazimine-
hydrochloride within the unit cell of the crystal. Further chemical analysis showed that no 
chemical change occurred within the crystal following bending. The quantitative polarized light 
microscopy that was performed here was the first attempt at analysis of these crystals, revealing 
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their high degrees of diattenuation anisotropy and extensive underlying molecular organization, 
resulting from a cellular self-assembly. The techniques developed to both image and analyze 
these crystals were further refined and utilized throughout chapters 6, 7, and 8 to analyze CLDIs 
within live cells and in tissue cryosections. 
5.2 Abstract 
Supramolecular crystalline assembly constitutes a rational approach to bioengineer intracellular 
structures. Here, biocrystals of clofazimine (CFZ) that form in vivo within macrophages were 
measured to have marked curvature. Isolated crystals, however, showed reduced curvature 
suggesting that intracellular forces bend these drug crystals. Consistent with the ability of 
biocrystals to elastically deform, the inherent crystal structure of the principal molecular 
component of the biocrystals—the hydrochloride salt of CFZ (CFZ-HCl)—has a corrugated 
packing along the (001) face and weak dispersive bonding in multiple directions. These 
characteristics were previously found to be linked to the elasticity of other organic crystals. 
Internal stress in bent CFZ-HCl led to photoelastic effects on the azimuthal orientation of 
polarized light transmittance. We propose that elastic, intracellular crystals can serve as 
templates to construct functional microdevices with different applications. 
5.3 Results and Discussion 
Abnormal morphology of crystals has been a subject of significant study over the last 
century [1-6]. Particularly, crystalline growth and distribution within living organisms such as 
cells, tissues and clinically in humans has allowed an understanding of how solid-state crystal 
chemistry can modulate biological and biophysical environments [7-12]. Specifically, the 
interaction of crystalline matter with cells such as macrophages within clinical 
microenvironments has garnered much attention [13-15]. Macrophages (Mϕs) are critical self–
non-self-recognizing immune cells capable of maintaining mammalian homeostasis and 
resolving inflammatory conditions responsible for many diseases. Concurrently, Mϕs are cellular 
“vacuum cleaners” eliminating foreign matter, typically referred to as xenobiotics. Such 
elimination may also be preceded by massive bioaccumulation, self-assembly and intracellular 
crystallization of sequestered foreign molecular agents such as clofazimine (CFZ), a red-
pigmented, anti-inflammatory, antimycobacterial, FDA-approved drug molecule [16, 17]. 
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Specifically, CFZ accumulates within Mϕs upon prolonged oral dosage in humans [18-21] and 
rodent models [13, 22-24] (protocol in Appendix D) to form biocrystals containing clofazimine 
hydrochloride (CFZ-HCl) crystalline domains [25]. 
In order to characterize the crystal structure and physical morphology of biocrystals, 
peritoneal and alveolar Mϕs from an 8-week CFZ-fed mouse were harvested. Through 
brightfield microscopy, several cell-associated dark red crystals were identified, some of which 
were surprisingly curved (Figure 1a). Moreover, after 10 minutes, the crystals turned over likely 
due to mechanical forces exerted by its parent Mϕ (Figure 1a). Upon closer inspection, we 
observed that another biocrystal in close proximity to the curved biocrystal also had a minor 
curvature that straightened out when the curved biocrystal flipped (Figure 1 a). In light of this 
empirical evidence, we further characterized the biocrystals for their curvature (κ) within or 
isolated from Mϕs (Figure 1 b and SI. 11). The curvature per unit length (κ/L) of biocrystals was 
significantly higher when present in peritoneal Mϕs (4.8-fold change in mean, p<0.005) or 
alveolar Mϕs (3.6-fold change in mean, p<0.005) compared to when isolated from Mϕs. A 
greater number of biocrystals were found to be inherently straight or having zero curvature when 
isolated (26) than when present in peritoneal Mϕs (10) or alveolar Mϕs (18) (Figure 1b, Figure 
SI. 11). Such a reduction in curvature of isolated biocrystals are indicative of forces acting on the 
crystals curving them when present inside Mϕs and secondly of inherent elasticity of the 
biocrystals. 
Mechanical properties of crystals (moduli, plasticity, and elasticity) are known to be 
dependent on the atoms, ions or molecules forming the crystals and the interactions between 
these particles (molecular packing and intramolecular bonding) [26-30]. Further, recent work has 
explored the relationship between elasticity in organic crystals and their molecular and structural 
properties. Ghosh and Reddy reported an elastic and bendable organic cocrystal solvate formed 
from caffeine, 4-chloro-3-nitrobenzoic acid and methanol with weak and dispersive C−H⋅⋅⋅π 
interactions in three nearly perpendicular directions, suggesting that elastic deformation is due to 
isotropic molecular packing [28, 29]. Subsequently, Ghosh et al. studied n-benzylideneanilines 
and elucidated design rules for elastic organic crystals [26-28]. Accordingly, elastic organic 
crystals should have 1) multi-directional weak dispersive bonds that can be easily broken to 
dissipate energy as the crystal is bending and that can be easily formed when no force is applied 
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and 2) corrugated packing along a crystallographic face to prevent long range dislocation within 
the crystal [26-28]. In these studies, when crystals did not align with these design rules, they did 
not demonstrate elastic behavior. As such, we explored if elasticity and curvature of biocrystals 
could be explained via these design parameters. 
As the primary component of the biocrystals is CFZ-HCl, we hypothesized that the 
inherent crystal structure of CFZ-HCl plays a role in the flexibility (being able to adopt non-
linear morphologies) and elasticity (being able to return to linear conformations upon removal of 
force) of the biocrystals. A synthetic crystallization route was developed to grow CFZ-HCl 
crystals with similar crystal structure to the biocrystals (protocol in Appendix D). The synthetic 
CFZ-HCl crystals form dark red rectangular plates (Figure 2a) that closely resemble the crystal 
habit and color of the biocrystals (Figure 2b) as observed with brightfield microscopy. The CFZ-
HCl crystals can grow to be much larger than the biocrystals allowing for optimal structural 
characterization. The powder XRD (Figure 2c) suggests a strong agreement in the observed 
peaks of CFZ-HCl with those from the biocrystals as previously reported [25]. Both samples 
show strong preferential orientation of the crystals along the (001) face, consistent with face 
indexing of single crystals (Figure SI. 12). The most intense peak on the p-XRD spectra is the 
(002) peak due to a systematic absence at (00l) when l=2n for Pbca space groups. Thus, the 
synthesized CFZ-HCl crystals are a suitable model for characterizing the mechanical behavior of 
the biocrystals. 
Single-crystal XRD was also performed to determine the crystal structure of CFZ-HCl. 
The CFZ-HCl crystals grow in an orthorhombic Pbca space group with unit cell 
parameters; a=10.266 Å, b=19.828 Å, and c=24.156 Å, α=β=γ=90° and Z=8 (CCDC 
number: 1497722). One CFZ and one HCl molecule make up the asymmetric unit (Figure 3 a). 
Cl3 (the Cl associated with the HCl) associates with the CFZ through two N−H⋅⋅⋅Cl hydrogen 
bond interactions between N3−H⋅⋅⋅Cl3 and N4−H⋅⋅⋅Cl3 (D, d, θ: 3.172 Å, 2.376 Å, 166.45°, and 
3.104 Å, 2.243 Å, 174.51°). The data set was solved to 99.8 % completeness. Water was 
incorporated into the crystal structure at an occupancy of 0.13, and there was some disorder in 
the isopropyl group. The presence of water likely caused a change in the orientation of the 
isopropyl group, thereby contributing to the observed disorder (Figure SI. 13). A summary of the 
unit cell parameters and diffraction data can be found in Table S8. 
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A key design feature of the CFZ-HCl crystal structure is the corrugated packing along the 
(001) face (Figure 3 b,c). One CFZ-HCl molecule makes up one step of the zig-zag and together 
the steps make up one corrugated sheet. The steps of the zig-zag are held together with weak 
C−H⋅⋅⋅π and C−H⋅⋅⋅Cl interactions, highlighted by light blue dotted lines and orange solid lines, 
respectively (Figure 3 b). Cl3 is situated in the crease of the zig-zags and serves an anchor by 
coordinating with 3 additional molecules strengthening interactions within the crease and 
coordinating with adjacent sheets. Bond distances and angles are as follows: C14−H⋅⋅⋅Cl3, 3.503 
Å, 2.724 Å, 139.72°, C24−H⋅⋅⋅Cl3, 3.457 Å, 2.757 Å, 131.19°, and C4−H⋅⋅⋅Cl3, 3.625 Å, 2.900 
Å, 133.9°. These interactions are in 3 nearly perpendicular directions. Weak dispersive bonding 
between the sheets of the zig-zags from π⋅⋅⋅π interactions between the aromatic rings is also 
present (grey dotted lines, Figure 3 b). Cl1 interacts with C5 (C5−H⋅⋅⋅Cl1, 3.516 Å, 2.937 Å, 
120.48°) to create a ribbon of CFZ molecules down the b-axis (Figure SI. 14). When viewed 
along the c-axis this interaction is located in the crease and it stabilizes interactions between the 
sheets of the zig zag. As such, the weak multi-directional interactions are located at critical parts 
of the zig-zag, particularly associated with Cl3 and support the previously proposed design rules 
for crystal elasticity [26]. The angle between the corrugated steps is 82°. All intermolecular 
interactions are listed in Table S9. Face indexing of the crystal during XRD showed that the 
(001) face is the largest surface which corresponds to the previous p-XRD data. The projection 
of the (001) face is shown in Figure 3 c to better show the corrugated packing. Projections of all 
the crystallographic faces can be found in Figure SI. 15. 
Interestingly, while harvesting CFZ-HCl crystals for single crystals XRD, the crystals 
would noticeably bend when force was applied to pick up the crystals. As soon as the force was 
removed the crystals would promptly return to their original linear morphologies. Subsequently, 
video microscopy of bending crystals with tweezers was performed to further demonstrate their 
observed elastic response (Movie 1). Crystallization experiments yielded a very wide size 
distribution of crystals out of which crystals between 500 μm and 2 mm long and ca. 20 μm thick 
were chosen. The CFZ-HCl crystals typically lie with the (001) face normal to the substrate 
(Figure 4 a). When a slight force was applied, the crystal rotated 90° about the a-axis (Figure 
4 b). When a force was applied to the (001) face, the crystal bent (Figure 4 c,d) and assumed its 
original shape upon removal of the force (Figure 4 e). The crystal arched again when a second 
force was applied, Figure 4 f. As such, the crystals can be bent many times without noticeable 
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deformation to the crystal. In one experiment, a crystal was bent 8 times without noticeable 
deformation (Movie 2). However, upon applying a larger force, the crystal snapped and the 
crystalline fragments adopted the original straight configuration (Movies 1 and 2). 
To confirm the elastic deformation of CFZ-HCl, polarization microscopy was performed 
as a way of measuring the photoelastic phenomena that is commonly observed with application 
of stress and development of strain [31]. In this particular study, linear dichroism could be 
measured using hardware configured on an epifluorescence-brightfield microscope [32, 33] (see 
the Appendix D for protocol). Crystals were imaged under polarized light following which the 
anisotropy in transmittance and importantly, the azimuth (the polarization orientation that results 
in maximum transmittance) were computed (Figure 5) [34]. Crystals were first identified as 
regions with low transmittance (Figure 5 a,c). Given the structural packing of the CFZ-HCl 
lattice and absence of polycrystalline elements in the biocrystals, the azimuth distribution was 
expectedly isotropic across the crystal plane when unstressed and straight (Figure 5 b). In 
contrast, the azimuth was anisotropic in the elastically deformed region of the crystal wherein 
two approximately orthogonal azimuthal orientations were measured (Figure 5 d). In the concave 
region, the azimuth was perpendicular to the long axis of the crystal whereas in the convex 
region, the azimuth was retained along the long-axis of the crystal as observed in the straight 
crystals. Such anisotropy is clearly indicative of a stress network resulting in the development of 
an elastic strain through the crystal [35]. As such, given the extent of cross-interactions within 
the crystal lattice as described before (Figure 3, SI.11–SI.14), the development of an elastic 
stress–strain network through an expectedly isotropic crystal structure was accomplished and 
verified through photoelastic azimuth measurements. 
Further, no differences in vibrational spectra (Raman) were evident before and after 
bending at the point of maximum curvature in these crystals (Figure SI. 16). Naturally curved 
crystals also showed no differences in molecular vibrations compared to the reference CFZ-HCl 
crystals. Finally, the melting point for CFZ-HCl was measured to be 275 °C (Figure SI. 17), 
which is 53 °C degrees higher than CFZ while other salts of CFZ also have melting points 
<246 °C [36]. As indicated by their melting points, the salts of CFZ are more stable than CFZ. 
The stabilization of CFZ as CFZ-HCl within mammalian cells therefore favors the formation of a 
highly stable crystalline polymorph and as reported here has appropriate structural packing 
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features, reinforced by the additional Cl from HCl (Cl3 in Figure 3 a) that allow it to adapt to 
intracellular mechanical stressors. 
In summary, we show that the inherent structural packing features of CFZ-HCl within 
biocrystals indeed contribute to their elasticity and naturally adjustable curvature. As such, 
formation of biocrystals mediated by Mϕs leads to the development of elastic and curved 
crystalline elements with structural packing features that showcase the classical design rules 
designated for organic crystal flexibility [26-29]. The presence of CFZ biocrystals in the Mϕ 
endows them with potent anti-inflammatory characteristics [37, 38] and specific fluorescent [39] 
and photoacoustic [40, 41] signatures for cellular optical tracking. Such dual therapeutic and 
diagnostic (theranostic) applications make biocrystals a potent cellular device that could be 
harnessed for biomedical applications. Mϕ-mediated crystallization is an important example of 
how these cells self-assemble a crystal with features that allow for easier adaptability to the 
mechanical environment of the cell, thereby allowing a massive drug loading within the cell. 
Importantly, the additional Cl (in HCl) is most likely reinforced within CFZ biocrystals through 
the presence of multiple chloride channels in macrophages and their highly regulated role in 
cellular physiology [42-44]. Here, we show that the salt chloride also plays an integral role in the 
structural stability and intracellular mechanical adaptation of biocrystals via elasticity. 
Furthermore, mechanical flexibility of exogenous elements within cells could be a critical 
design parameter toward engineering organic intracellular constructs to endow cells with 
unnatural yet stable and beneficial features for therapeutic applications. Finally, viscoelasticity, 
pressures and connected mechano-transductive elements are connected to inflammatory cell 
phenotypes [45-49]. As such, the mechanochemical characterization of intracellular properties 
could be important for cell-based mechano-biological applications leading to a new class of 
pharmaceutics: mechano-pharmaceutics. 
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5.5 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Curvature of CLDIs within macrophages and isolated CLDIs 
 
a) Peritoneal macrophages from a CFZ-fed mouse with the curvature of the curved biocrystal marked with dotted 
lines (white arrows show cell membrane, black arrows mark the crystal in physical contact with the first curved 
crystal). Scale bar: 10 μm. b) Curvature per unit arc length (κ/L) of biocrystals in peritoneal Mϕs or alveolar Mϕs or 
when isolated from splenic Mϕs. (n=100 biocrystals, *: p<0.005. The wider and thick horizontal line indicates the 
mean of the distribution whereas the other smaller two lines indicate the mean ± SE. Number in brackets indicates 
the number of biocrystals measured to have zero curvature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Images and powder X-ray diffraction of CLDIs and CFZ-HCl 
 
Optical micrograph of a) synthesized CFZ-HCl crystals, scale bar: 50 μm and b) harvested biocrystals from a 8-
week CFZ-fed mouse spleen, scale bar: 10 μm. c) Powder X-ray diffraction data from biocrystals and CFZ-HCl 
crystals. Both samples display preferential orientation favoring the (001) face. The diffraction data from 2θ= 8–40° 
is zoomed in for convenient comparisons. 
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Figure 5-3 CFZ-HCl structure and crystal packing 
 
a) Asymmetric unit of CFZ-HCl displayed as an ellipsoid plot with 50 % probability. The atomic positions for all 
non-hydrogen atoms are labeled. b) One section of the corrugated packing with solid orange lines indicating 
C−H⋅⋅⋅Cl interactions, C−H⋅⋅⋅π indicated with a light blue dotted line and π⋅⋅⋅π interactions indicated by light grey 
dotted lines (unit cell looking along the c-axis). The molecules are displayed as capped sticks with the hydrogen 
atoms removed for better visualization of the crystals packing. c) Crystallographic projections of packing along the 
(001) face showing the corrugated packing. The projection is made up of 2×2×0.5 (a×b×c) unit cells. 
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Figure 5-4 Bending of synthetic CFZ-HCl crystal 
 
a–d) A CFZ-HCl crystal was bent by applying a force with a crystallization probe while the crystal was held 
stationary against a pair of tweezers. e) The force was removed and the crystal quickly regained the original position 
before f) another force was applied to the crystal. Scale bar is 100 μm. The bottom schematic shows how the angle 
of corrugation would look like on the convex and concave edges of the crystal during bending. 
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Figure 5-5 Azimuth of CFZ-HCl before and after bending 
 
a) Computed transmittance image of a a,b) straight vs. c,d) bent crystal. Calibration bar in (a,c) shows the range of 
transmittance. Dark regions (with low transmittance) follow the crystal with the dotted tangential line from one edge 
of the crystal confirming the curvature in the crystal. Azimuth: polarization orientation of maximum transmittance 
overlaid on the transmittance image indicating unidirectional axes in the b) straight crystal while in the d) bent 
crystal, there is a bidirectional axes depending on the direction of compressional (inward bending edge leads to an 
orthogonal axes) or tensile stress (outward bending edge leading to a longitudinal axis). Scale bar in (a,b) is 100 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
5.6 Supporting Information Available 
This material is published in Angewandte Chemie and supplemental figures and tables are 
available in Appendix D. Supplemental videos are also available online. 
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Chapter 6 
Detecting Ordered Small Molecule Drug Aggregates in Live 
Macrophages: A Multi-Parameter Microscope Image Data 
Acquisition and Analysis Strategy 
6.1 Abstract 
Following prolonged administration, certain orally bioavailable but poorly soluble small 
molecule drugs are prone to precipitate out and form crystal-like drug inclusions (CLDIs) within 
the cells of living organisms. In this research, we present a quantitative multi-parameter imaging 
platform for measuring the fluorescence and polarization diattenuation signals of cells harboring 
intracellular CLDIs. To validate the imaging system, the FDA-approved drug clofazimine (CFZ) 
was used as a model compound. Our results demonstrated that a quantitative multi-parameter 
microscopy image analysis platform can be used to study drug sequestering macrophages, and to 
detect the formation of ordered molecular aggregates formed by poorly soluble small molecule 
drugs in animals. 
6.2 Introduction 
For studying complex cell populations, fluorescence-based multi-parameter cytometric 
analysis techniques are routinely used for monitoring the expression of multiple phenotypic 
markers at a single cell level. For this purpose, fluorescence-based flow and image cytometry 
instruments can be used to quantify the expression of different molecular markers down to the 
level of individual cells, using fluorescently tagged antibodies that recognize specific cell surface 
receptors, intracellular proteins or other cellular targets of interest. These antibodies are labeled 
with fluorophores that are excited and emit light specific wavelengths, allowing for simultaneous 
detection of multiple different fluorescence signals at different excitation and emission 
wavelengths [1]. 
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While many multi-parameter, cytometric analysis instruments are available for analyzing 
samples based on a single optical modality (e.g. fluorescence), the development of multi-
parameter imaging platforms for phenotypic analysis of cell populations based on various optical 
properties (e.g. fluorescence, transmittance, and birefringence) is an emerging area of research. 
For example, the combination of polarization, transmittance and fluorescence imaging modalities 
could be useful to study protein aggregation at a single cell level [2].  
Indeed, the ability to combine fluorescence, transmittance, and polarization microscopy 
measurements could be useful in obtaining new insights into the organization of molecules in 
biological specimens [3]. Similar to conventional, transmitted light microscopy, polarization 
microscopy instruments can employ polarized, transmitted light to study the structure of 
supramolecular aggregates within individual cells [4-7]. Because of the manner in which 
polarized light interacts with ordered molecular structures, differences in the organization of 
molecular components can be detected and quantified based on the fraction of light that is 
transmitted through the material when it is illuminated with polarized light [8]. At the simplest 
level, the diattenuation anisotropy of a material can be measured as the maximal difference in 
light transmittance of a perpendicular pair of planes of polarized light passing through a material, 
as the material is rotated in the direction perpendicular to both polarized planes of light. These 
measurements allow distinguishing between homogenous and heterogeneous materials 
comprised of subdomains of molecules arranged in a particular direction. Polarization 
microscopy can also be used to obtain information about how the molecules within these 
subdomains are oriented, providing insight into the underlying molecular order of the material 
[9-11].  
Previously, polarization microscopy has been used extensively to image ordered 
supramolecular structures in live cells [12-16], as well as to study the formation of intracellular 
aggregates [17]. This led us to consider combining quantitative polarization microscopy together 
with fluorescence and transmittance measurements to facilitate multi-parameter cytometric 
analysis of molecular aggregates formation at a single cell level. 
Here, we present a multi-parameter imaging instrument and analysis platform for the 
analysis of live cell populations, at a single cell level. For demonstration purposes, we used this 
imaging platform to study the formation of intracellular crystal-like drug inclusions (CLDIs) 
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formed by clofazimine (CFZ) -an FDA-approved drug that accumulates as highly ordered 
supramolecular aggregates in macrophages of drug-treated mice [18, 19]. In flow cytometric 
experiments, CLDIs have been shown to exhibit a strong signal in the Cy5 fluorescence range 
(650 nm excitation/670 nm emission) [20]. Taking advantage of this intrinsic fluorescence of 
these biocrystals, we proceeded to analyze the optical anisotropy and fluorescent properties of 
live cells containing CLDIs, and probe for any relationship between these properties within cells. 
Our results demonstrate how this multi-parameter imaging platform can be used to study drug 
accumulation and detect ordered aggregates within live-cells. 
6.3 Materials and Methods 
Clofazimine administration to mice. Mice (4 week old, male C57Bl6) were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and acclimatized for 1 week in a specific-pathogen-free 
animal facility.  Clofazimine (CFZ) (C8895; Sigma, St. Louis, MO) was dissolved in sesame oil 
(Roland, China, or Shirakiku, Japan) to achieve a concentration of 3 mg/ml, which was mixed 
with Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) to produce a 0.03% drug 
to powdered feed mix, and orally administered ad libitum for 8 weeks. A corresponding amount 
of sesame oil was mixed with chow for vehicle treatment (control). Animal care was provided by 
the University of Michigan’s Unit for Laboratory Animal Medicine (ULAM), and the 
experimental protocol was approved by the Committee on Use and Care of Animals (Protocol 
PRO00005542).  
Isolation of spleen CLDIs. CLDIs were isolated from the spleen of 8 week CFZ fed mice using 
a previously described method [21]. In brief, the spleens were homogenized with a syringe 
plunger and then filtered through a 40 μm cell strainer to remove connective tissue debris.  The 
spleen filtrate was centrifuged (300 x g for 10 min) to remove large cell debris and the pelleted 
CLDIs were resuspended in 10% sucrose in Dulbecco’s PBS (DPBS; Life Technologies, 
Carlsbad, CA) without CaCl2 and MgCl2, pH 7.4. CLDIs were further purified using a 3-layer 
discontinuous gradient (50%, 30% and 10% sucrose in DPBS) centrifugation method (3200 ᵡ g 
for 30 min). 
Isolation of alveolar macrophages. CFZ or control chow-fed mice (n=3 per group) were 
euthanized by carbon dioxide asphyxiation followed by exsanguination. The trachea was 
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surgically exposed and cannulated with an 18G needle and the lungs were lavaged by instilling 
DPBS  containing 0.5 mM EDTA (Sigma) in 1 ml aliquots for a total of 6 ml. Approximately 
90% of the bronchoalveolar lavage (BAL) was retrieved. BAL was then centrifuged for 10 min 
at 400 x g, 4°C, resuspended in RPMI 1640 media (Life Technologies) and the cells were pooled 
together. The cells were then plated onto 4 or 8 chamber coverglass (#1.5, Lab-Tek II, Nunc, 
Rochester, NY) for imaging studies. The cells were allowed to attach for 45 min and then 
washed with media, enabling the isolation of alveolar macrophages by adherence.  
Multi-parameter Imaging Instrument Set Up. The multi-parameter imaging instrument 
utilized by our laboratory combines three imaging separate imaging modalities onto a single 
instrument, allowing for the fluorescence, transmittance, and polarization properties of a sample 
to be rapidly acquired. Polarization measurements are acquired utilizing the diattenuation LC-
Pol-Scope microscope, a custom built microscopic imaging system similar to the birefringence 
LC-PolScope designed by Oldenbourg et al [4], but without the polarization analyzer. Our LC-
PolScope is built on the Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, 
New York), with the computer-controlled universal compensator (Hinds Instrumentation, 
Hillsboro, Oregon) placed between the interference filter (623±23 nm, Semrock Optics, 
Rochester, New York) and condenser lens (Figure 1). Illuminating light is narrowed to 623 nm 
by the interference filter, and the light is linearly polarized by passing through a universal 
compensator, allowing for the diattenuation of the sample to be measured. The LC in the 
universal compensator is controlled by Image J “Micro-manager” software (Vale Laboratory, 
UCSF) [22] and is automatically rotated to produce polarized light at 0°, 45°, 90° and 135° 
angles, respective to the horizontal, during image acquisition. The image maps of diattenuation, 
mean transmittance, and angle of high transmittance are then generated by image analysis 
algorithms. 
Brightfield and fluorescence images are captured using the Nikon DS-U3 camera (Nikon 
Instruments) and Photometrics CoolSnap MYO camera system (Photometrics, Tucson, Arizona), 
respectively, under the control of Nikon NIS-Elements AR software (Nikon Instruments). The 
software allows for multiple fluorescent filters to be readily switched back and forth, and 
controls the exposure time for each fluorescent filter. Illumination for the fluorescence imaging 
is generated using the X-Cite 120Q Widefield Fluorescence Microscope Excitation Light Source 
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(Excelitas Technology, Waltham, MA). Light generated from the mercury lamp enters the filter 
cube, and a dichroic mirror filters this light to the appropriate wavelength, which then passes 
through the sample. This current set-up allows for the acquisition of polarization, brightfield and 
fluorescence images of the same sample at the same field of illumination. 
Calibration of LC-PolScope for Diattenuation Measurements. Prior to sample analysis, the 
LC-PolScope was calibrated using a reference standard consisting of a microscope slide 
comprised of four squares of perfectly polarized glass, oriented at 0, 45, 90, or 135 degrees. The 
PolScope software utilizes an individual region of interest (ROI) calibration method. In order to 
calibrate each polarization setting, the glass that is polarized orthogonally to that angle setting 
was chosen - for example, to calibrate 0° polarized light, an ROI square on the glass oriented 90° 
relative to the horizontal was selected. To verify the calibration, a blank region of the slide was 
visualized, brought out of focus, and a background image was taken. The calibration slide was 
then visualized and brought back into focus, and a sample image data set of the reference slide 
standards was generated (Figure 2B-E) and the PolScope measurements were analyzed in 
relation to the known optical properties of the reference standards. The mean transmittance 
image map of the slide (Figure 2B) is the average transmittance of each of the four polarization 
orientations (Figure 2E). As this material is highly anisotropic, each of the four sheets gives a 
strong diattenuation signal (Figure 2C).  The high transmittance angle is measured with respect 
to the horizontal axis, or in this case, the surface of the slide, and is represented as a pixel 
intensity value [23]. The angle of high transmittance corresponds to the angle to which the sheet 
is polarized, i.e. the high transmittance angle of the 0 degree polarized sheet is 0 degrees (Figure 
2D, top left, yellow   square).   As   previously   described, the   mean   transmittance   (Figure   
2B), diattenuation (Figure 2C), and high transmittance angle (Figure 2D) image maps are all 
calculated using the four polarization orientation images (Figure 2E).  
Multi-parameter image acquisition of isolated CLDIs and alveolar macrophages. Isolated 
CLDIs and alveolar macrophage samples were imaged using a 40x objective lens. The LC-
PolScope was used to capture the linear diattenuation of the sample using a 623±23 nm 
interference filter (Semrock Optics, Rochester, New York). Once the polarized light images were 
captured, the filter and universal compensator were removed, and the color camera was used to 
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take a brightfield image of the sample. The fluorescence camera was then used to assess the 
fluorescent properties of the sample, using a standard Cy5 filter set.  
Multi-parameter Cytometric Image Analysis. All images generated using the LC-PolScope 
software were analyzed using ImageJ [24-26]. These images are 8-bit images, yielding intensity 
values from 0-255. The values for diattenuation, mean transmittance, and fluorescence are 
obtained by extracting the pixel values from the image maps at exact locations, denoted as (x,y) 
coordinates. Each pixel will have an intensity value z associated with it, located such that 1≤x≤X 
and 1≤y≤Y, where X and Y define the total dimensions of the image such that the resolution of 
the image is defined as R=X*Y. The image maps generated represent the values of diattenuation, 
mean transmittance, and Cy5 fluorescence as such: 
Diattenuation: Dλ(x,y) is the diattenuation signal at wavelength λ for the pixel located at (x,y) 
Mean Transmittance: TM,λ(x,y) is the mean transmittance at wavelength λ for the pixel located at 
(x,y) 
Fluorescence: FCy5(x,y) is the Cy5 fluorescence of the pixel located at (x,y) 
To compare the diattenuation, optical density, and Cy5 fluorescence of cells at a whole 
cell level, an automated data acquisition strategy was put in place, and is summarized in figure 3. 
First, the zero-degree polarization state image was selected (Figure 3, Panel A), and the 
brightness and contrast are manually adjusted to allow for cells to stand out from the well-plate 
background (Figure 3, Panel B). Following this, the adjusted image was then subjected to a 
manual thresholding, which generates a binary mask to discriminate between objects and 
background (Figure 3, Panel C). The binary mask was then subjected to the “Fill Holes” function 
in ImageJ, which fills holes within each object, allowing for a more complete cellular mask to be 
generated (Figure 3, Panel D). Once the mask has been generated, the dichroism, mean 
transmittance, and fluorescence image maps for a single field of view were opened and the cells 
in the image were analyzed using the “Analyze Particles” function within ImageJ, and, using the 
previously generated binary image as a mask, a region of interest (ROI) was selected to analyze 
the pixels contained within the cell, and is denoted as p(c). The objects across each image were 
analyzed, with objects greater than 250 pixels
2
 in area being selected for, measuring the total, 
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integrated signal intensity of diattenuation, mean transmittance, and Cy5 fluorescence for the 
same cell ‘c’ in the following manner: 
(1)  𝐷𝜆(𝑐) = ∑ 𝐷𝜆(𝑥, 𝑦)
(𝑥,𝑦)∈𝑝(𝑐)
 
 
(2) 𝑇𝑚,𝜆(𝑐) = ∑ 𝑇𝑚,𝜆(𝑥, 𝑦)
(𝑥,𝑦)∈𝑝(𝑐)
 
 
(3) 𝐹𝐶𝑦5(𝑐) = ∑ 𝐹𝐶𝑦5(𝑥, 𝑦)
(𝑥,𝑦)∈𝑝(𝑐)
 
                                                                                
The integrated optical density (OD) of the drug crystals was determined using the integrated 
mean transmittance as follows: 
(4) 𝑂𝐷𝜆(𝑐) =  ∑ − log10( 𝑇𝑚,𝜆(𝑥, 𝑦))
(𝑥,𝑦)∈𝑝(𝑐)
 
 
To correct for background signal, the integrated OD was corrected by subtracting the average 
integrated background optical density as follows: 
(5) 𝑂𝐷𝜆(𝑐) =  ∑ − log10( 𝑇𝑚,𝜆(𝑥, 𝑦))
(𝑥,𝑦)∈𝑝(𝑐)
−  ∑ − log10( 𝑇𝑚,𝜆(𝐵𝐺))
(𝑥,𝑦)∈𝑝(𝑐)
 
 
To obtain the average diattenuation, optical density, or Cy5 fluorescence within an object of 
interest, the values obtained from equations (1), (3), and (5) are divided by the total area 
analyzed, as such: 
138 
 
(6) ?̅?𝜆(𝑐) =
∑ 𝐷𝜆(𝑥, 𝑦)(𝑥,𝑦)∈𝑝(𝑐)
𝐴
 
 
(7) 𝑂𝐷̅̅ ̅̅ 𝜆(𝑐) =  
∑ − log10( 𝑇𝑚,𝜆(𝑥, 𝑦))(𝑥,𝑦)∈𝑝(𝑐) −  ∑ − log10( 𝑇𝑚,𝜆(𝐵𝐺))(𝑥,𝑦)∈𝑝(𝑐)
𝐴
 
 
(8) ?̅?𝐶𝑦5(𝑐) =
∑ 𝐹𝐶𝑦5(𝑥, 𝑦)(𝑥,𝑦)∈𝑝(𝑐)
𝐴
 
 
All average values are reported on a 0-1 scale by dividing by 255. All integrated signal values 
are reported as the total signal value, with each individual pixel ranging from 0-255. 
Statistical analysis. Statistical tests were performed with IBM SPSS Statistics version 24.0 
(IBM Software, Armonk, New York). Results are reported as average ± standard deviation. P 
values less than 0.05 were considered statistically significant. 
6.4 Results 
6.4.1 Imaging and Quantification of Diattenuation, Optical Density, and Cy5 
Fluorescence of CLDIs using Multi-parameter imaging system 
To demonstrate the capabilities of this multi-parameter imaging system, the drug 
clofazimine was chosen as a model compound. Clofazimine (CFZ) is a bright red phenazine drug 
that accumulates extensively in tissues throughout the organism, leading to the formation of deep 
red, crystal-like drug inclusions in vivo [27]. Following eight weeks of CFZ treatment, CLDIs 
were isolated from the spleen of a mouse and imaged with the polarization and fluorescence 
imaging system. These CLDIs are deep red, and have a rod-like polygonal shape, with an 
average size of 17.6 ± 10.9 µm
2
 (Figure 4A). These crystals strongly absorbed linearly polarized 
light of 623 nm wavelength, and had an average optical density (OD) of 0.31±0.12 (Figure 4B). 
Interestingly, CLDIs are able to interact with different orientation states of polarized light, 
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resulting in a strong diattenuation signal. As a result of the crystallinity and molecular order 
present in the CLDI, different orientations of polarized light are absorbed to different extents by 
the crystal, yielding an average diattenuation signal of 0.26±0.05 (Figure 4C). The CLDIs are 
also highly fluorescent in the Cy5 channel (excitation/emission), which occurs due to the 
formation of a mono-protonated, hydrochloride salt during the process of clofazimine 
accumulation and biocrystallization [20] (Figure 4D). The crystals had an average Cy5 
fluorescence of 0.06±0.02. After analyzing isolated CLDIs from mice treated with CFZ, we 
decided to probe the utility of this instrument in studying live cells isolated from animals fed the 
drug for a period of eight weeks. 
6.4.2 Multi-Parameter Live Cell Imaging and Quantification of Diattenuation, Optical 
Density, and Fluorescence of Drug-Treated Alveolar Macrophages  
Based off of previous work, it has been shown that CLDIs tend to be found within tissue 
macrophages, such as Kupffer cells of the liver, red pulp macrophages of the spleen, and alveolar 
macrophages within the lung [18, 28, 29]. Due to the extensive accumulation within alveolar 
macrophages, these cells were chosen to test this multi-parameter imaging and analysis system in 
live cells. These cells serve as the first barrier to incoming airborne pathogens and other inhaled 
xenobiotics, and have been shown to be greatly impacted by the accumulation of these materials 
[30]. Alveolar macrophages were isolated from mice treated with CFZ for eight weeks or mice 
fed a control diet, and imaged using the combined polarization and fluorescence imaging system.  
Upon visual inspection of the brightfield image, control diet-fed macrophages are small, 
rounded cells, ranging in size from 10 to 25 microns in diameter. Imaging of these cells using the 
multi-parameter imaging system revealed a low, but detectable, dichroism signal of 0.018 ± 
0.005 (Table 1). This signal arises due to interactions of the polarized light with cellular 
components, such as membranes and organelles, which have some degree of molecular 
organization. The mean transmittance image shows cells with very low optical density, with an 
average intensity of 0.021 ± 0.029.These cells are, by and large, transparent, with occasional 
dark spots, which may correspond to cellular components, such as lysosomes or other 
membrane-bound organelles. Control alveolar macrophages show little to no fluorescence in the 
Cy5 channel, as is expected (0.0002 ± 0.00005). Representative images of the untreated alveolar 
macrophages are seen in figure 5, top panel. 
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Following eight weeks of sustained therapy with CFZ, the alveolar macrophages are 
loaded with large amounts of intracellular crystals of the drug, consistent with previous reports 
from our laboratory [29]. As a result of the accumulation of intracellular drug complexes, 
intracellular dichroism increased significantly (0.042 ± 0.013, p<0.01, Two-Tailed Student’s T-
Test), revealing that CLDIs are highly organized, self-assembling supra-molecular entities, and 
that the dichroism of these crystals can be detected within a cell. CLDI accumulation and 
formation also resulted in a significant increase in the optical density of the macrophages (0.054 
± 0.071, p<0.01, Two-Tailed Student’s T-Test), as a result of the deep red color associated with 
these biocrystals. Consistent with previous reports [20], CLDI accumulation also resulted in a 
concomitant increase in the Cy5 fluorescence associated with the macrophages as well (0.012 ± 
0.019, p<0.01, Two-Tailed Student’s T-Test). 
The analyses performed also studied how each of these three properties related to one 
another in both control and CFZ-treated cells. By plotting the total integrated dichroism, optical 
density, and fluorescence of the cells, one can gain further understanding on how the molecular 
order (represented by dichroism), degree of accumulation (represented by optical density), and 
protonation state (represented by fluorescence) of the drug relate to one another following eight 
weeks of sustained therapy. Performing this analysis also allows for the study of the optical 
properties of an entire population of cells to be observed, which can be a useful analysis when 
determining how different cell populations accumulate drugs both in vitro and in vivo. Figure 6 
compares the optical properties from both control alveolar macrophages (A, D) and those from a 
mouse fed 8 weeks (B, C). In Panel A, one can see that, on a whole population level, these cells 
display very low fluorescence and optical density, with a more varied dichroism signal. In all, the 
control cells display little variability with respect to their optical signals, and this is captured in 
the plots shown in Panels A and D. On the other hand, treatment with CFZ, and the subsequent 
accumulation and biocrystal formation which occurs as a result, causes there to be three 
populations of cells which can be segregated. In Panel B, there is a population of cells 
aggregated very near the origin, showing low fluorescence, optical density, and dichroism. These 
cells are most likely red blood cells which were not eliminated during the collection and plating 
of the macrophages. The second population of cells shows an elevated fluorescence, optical 
density, and dichroism compared to the previously described population; these cells are most 
likely macrophages which have accumulated soluble CFZ, but have not yet formed a CLDI 
141 
 
(Panel B). The final population of cells can be seen in Panel C. These cells display very high 
fluorescence, optical density, and dichroism, indicating that these cells are most likely alveolar 
macrophages which contain at least one intracellular crystal. 
6.5 Discussion 
The development and refinement of polarized light microscopy measurements to study 
changes in the organization of molecular components in individual cells has had many 
applications in cell biology and beyond [4, 31, 32]. To study the bioaccumulation of small 
molecule drugs inside cells, the experiments presented here indicate how a quantitative multi-
parameter imaging system combining polarization, transmittance and fluorescence measurements 
can be useful for studying the cellular mechanisms of drug disposition from the cellular to the 
molecular level. Previously, our lab has used polarization microscopy to study the optical 
properties of drug inclusions formed in vitro. Cells were incubated with CFZ and other 
phenazine derivatives to study the self-assembly of drug aggregates in live cells, revealing that, 
even after 72 hours, the self-assembly of CFZ aggregates within cells yields a measurable 
diattenuation signal [33]. Cultured cells, however, are not the optimal model for studying 
intracellular drug crystallization for a variety of factors, namely the length of time necessary for 
the crystals to form. Thus, a long term in vivo study was performed to develop a method to 
accurately quantify changes in intracellular dichroism, absorbance, and fluorescence induced 
following eight weeks of CFZ therapy.   
 Through the development of this multi-parameter imaging and analysis system, drug 
accumulation, as well as the changes this accumulation has within the cell with respect to 
molecular order can be studied at the level of single cells in a rapid manner. Further applications 
of this instrument can potentially be used to study large populations of cells which can allow for 
researchers to discriminate which cells have a propensity to accumulate and sequester soluble 
drug, or potentially form an insoluble aggregate. Due to the automated nature of the analysis, all 
of the objects analyzed may not be macrophages, but rather red blood cells or other immune 
cells, such as B cells. However, by analyzing each of the three cellular properties measured using 
this method, one can place each cell in a category on the basis of the intensity of the signals 
measured. For example, cells which display a high level of fluorescence, dichroism, and optical 
density are most likely macrophages containing an intracellular crystal. Red blood cells, on the 
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other hand, would show low levels of fluorescence and optical density.  Further refinement of the 
imaging and analysis technique can be used to rapidly image and analyze large populations of 
live cells from drug treated animals, allowing for investigators to determine how, if at all, various 
drugs accumulate within these cells without the need for time-consuming chemical analyses. 
 Previously, we have characterized the molecular organization and chemical composition 
of CLDIs following biochemical isolation, using nuclear magnetic resonance, powder X-ray 
diffraction, transmitted electron microscopy, freeze fracture electron microscopy, liquid 
chromatography and mass spectrometry [18, 19, 34].  Our results demonstrated that CLDIs are 
comprised of subdomains of pure CFZ-hydrochloride crystals [34], bounded by multilamellar 
membrane structure of biological origin [18, 19]. Consistent with these previous results, 
quantitative polarization microscopy revealed the manner in which microscopic domains of 
ordered CFZ molecules within CLDIs of live macrophages obtained from CFZ-treated mice 
differentially interact with polarized light.  Nevertheless, unlike the aforementioned chemical 
analysis techniques, quantitative multi-parameter observations were performed on functional, 
viable cells.  
 In terms of its implications for drug targeting and delivery, the formation and fate of 
intracellular drug biocrystals has remained a poorly understood aspect of pharmacokinetics, 
precisely because of the lack of practical, quantitative techniques to study intracellular drug 
bioaccumulation. Nevertheless, understanding the mechanisms responsible for the accumulation 
of drugs within intracellular compartments is important as it may explain why some drugs fail to 
reach proper therapeutic concentrations at a site of action or to explain unfavorable drug-drug 
interactions that may occur through bioaccumulation dependent pathways [35]. Drug trapping 
and accumulation can lead to alterations in the structure and function of organelles, affecting cell 
physiology [36]. Accumulation of small molecule drugs in organs such as the liver and kidney 
are particularly concerning as a potential cause of toxicity [37, 38]. For example, the antiviral 
drug cidofovir (Gilead Sciences) tends to accumulate in the kidneys, leading to nephrotoxicity 
[39]. Yet, there are also specific cases in which drug bioaccumulation may be beneficial.  Many 
of the anti-malarial drugs in the 4-aminoquinolone class have been shown to be more effective in 
treating the illness due to preferential accumulation within an acidic compartment of the parasite 
[40, 41].  
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 The development and refinement of a multi-parameter imaging system which combines 
polarization and fluorescence microscopy may further the understanding of intracellular drug 
bioaccumulation via the mechanism of CLDI formation in macrophages and potentially other 
cell types.  In addition to CLDIs formed by clofazimine, this quantitative multi-parameter 
imaging set up could be used to detect ordered molecular aggregates formed inside cells by other 
drugs. Imaging systems such as this can also be applied in drug discovery: by looking for drugs 
which induce similar changes in intracellular molecular organization, drugs that potentially 
crystallize intracellularly can be identified as potential target molecules for therapeutics. While 
CFZ and CLDIs are deeply red and fluorescent, other drugs which accumulate may not be as 
easy to detect with the naked eye. Through the use of polarization microscopy, minute changes 
in the underlying structure which may be induced by drug accumulation can potentially be 
detected; this may provide information about the subcellular localization of drug. Indeed, much 
remains to be discovered about the physiological function of xenobiotic sequestering 
macrophages, and the underlying biological mechanisms responsible for CLDI formation. 
Furthermore, beyond the study of drug transport phenomena, a quantitative multi-parameter 
imaging set up could also be used for studying many other kinds of phenomena associated with 
the formation of ordered molecular aggregates, such as the formation of hemoglobin crystals in 
sickled red blood cells [42]; the formation of atherosclerotic plaques [43]; the formation of 
misfolded protein fibrils as seen in Parkinson’s and Alzheimer’s disease and other forms of 
dementia [44, 45]; and the formation of lipid aggregates as is characteristic of certain lysosomal 
storage diseases [46].  
6.6 Conclusions 
To conclude, this research describes how a quantitative, fluorescence-transmittance-
polarization multi-parameter imaging system can be used for detecting and studying CLDIs in 
isolation, as well as studying the accumulation of drug in live macrophages obtained from drug 
treated animals at differing stages in treatment. CLDI formation leads to the development of a 
highly organized molecular structure that homogenously interacts with linearly polarized light. 
While all experiments reported herein were performed with alveolar macrophages, other 
macrophage populations, such as those in the spleen, liver, bone marrow and in the peritoneal 
cavity have been previously implicated in the disposition of clofazimine, and should also be 
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amenable for comparative analysis. In the future, establishing how the optical properties of 
CLDIs vary amongst different macrophage populations, as a function of clofazimine dose, and in 
mouse mutants harboring mutations that affect macrophage function, will be especially useful to 
elucidate the molecular mechanisms driving the pharmacokinetics of clofazimine accumulation. 
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6.8 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 Schematic of multi-parameter imaging system 
 
Schematic diagram of multi-parameter instrument used for live alveolar macrophage diattenuation imaging at 
623nm or 546nm wavelengths and fluorescence microscopy. Adapted from Mehta et al. 2010 Journal of Optics. 
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Figure 6-2 Slide used to calibrate diattenuation polarization instrument 
 
Calibration of the LC-PolScope instrumentation and software. A slide comprised of four sheets of perfectly 
polarized glass, with each sheet polarized to light at either 0°, 45°, 90°, or 135° relative to the horizontal is used for 
calibration. (A) Brightfield image, (B) mean transmittance and (C) diattenuation image map of the calibration slide. 
(D) Colored schematic representing the angle of high transmittance, or the orientation of light which is most 
transmitted by the object. (E) Images generated from passing linearly polarized light at 0°, 45°, 90°, and 135°, from 
left to right, which are used to calculate the angle of high transmittance, diattenuation, and mean transmittance 
image maps. 
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Figure 6-3 Generation of mask for automated data collection 
 
Representative schematic of mask generation for data collection. The 0-degree polarization state image is selected 
(Panel A) and has the brightness and contrast adjusted (Panel B). Following this, the image undergoes a manual 
threshold in ImageJ, delineating between objects and background (Panel C). The image then undergoes the “Fill 
Holes” function, generating the mask for data analysis (Panel D) 
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Figure 6-4 Multi-parameter imaging of isolated spleen CLDIs 
 
Pol-Scope images of CLDIs isolated from the spleen of 8wk CFZ-treated mice. (A) Brightfield image displaying 
deep red color, rod-like shape of CLDIs. (B) Diattenuation, (C) mean transmittance and (D) Cy5 fluorescence of 
CLDIs with illuminating light at 623 nm. The high degree of diattenuation and Cy5 fluorescence of the CLDIs is 
readily visible. Scale bar is 50 μm. 
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Figure 6-5 Multi-parameter images of CFZ and untreated alveolar macrophages 
 
Comparison of CFZ treated and control alveolar macrophages. Macrophages from mice following 8 weeks of 
treatment, displayed the characteristic CLDI formation. Brightfield (A, B), diattenuation (C, D), mean transmittance 
(E, F), and Cy5 fluorescence (G,H) images of isolated alveolar macrophages from treated and non-treated (control) 
mice. Both diattenuation and mean transmittance images were generated using illuminating light at 623nm. Note 
that the diattenuation and mean transmittance signal is entirely contained within the CLDIs. Scale bar is 15 μm. 
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 Control Alveolar 
Macrophage (n=215) 
8 Week CFZ Fed Alveolar 
Macrophage (n=201) 
D623   
0.017 ± 0.004 0.042 ± 0.013 * 
OD623   
0.017 ± 0.019 0.054 ± 0.071 * 
FCy5   
0.0002 ± 0.00004 0.012 ± 0.019 * 
 
Table 6-1 Multi-parameter optical properties of untreated and 8 week CFZ treated alveolar macrophages 
 
Average Signal Intensity of Macrophages (*=p<0.001, Two-Tailed Student’s T-Test) 
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Figure 6-6 Scatter plot of relating optical properties of untreated and 8 week CFZ treated alveolar macrophages 
 
Scatter plot displaying relationship between Cy5 fluorescence, optical density, and dichroism in control alveolar 
macrophage populations (A, D) and 8 week CFZ fed alveolar macrophage populations (B,C). Panels A and B show 
the same population of cells shown in panels D and C, but zoomed into the lower signal values. Treatment with CFZ 
results in a heterogeneous population of macrophages on basis of optical signals, while untreated cells remain 
homogenous. 
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6.9 Supporting Information Available 
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Chapter 7 
The Adaptive Cargo Carrying Capacity of Macrophages Expands 
the Drug Volume of Distribution 
7.1 Abstract 
Through phagocytosis or fluid phase pinocytosis, cultured macrophages are capable of 
internalizing massive amounts of solids and solutes from the extracellular medium (‘massive’ 
defined as surpassing every other cellular component, except water). Nevertheless, the cargo 
carrying capacity of macrophages has never been measured in vivo.  Here, we used an orally 
bioavailable drug -clofazimine- as a molecular reporter of the extent of macrophage loading. 
Upon increasing the whole body drug cargo load, macrophages adjusted their size, number and 
membrane organization to accommodate an increasing cargo volume. Ultimately, the total 
volume of intracellular cargo exceeded 5% of the total cell volume across the entire macrophage 
population. Most interestingly, macrophages adaptively maximized their cargo capacity, not only 
by stabilizing and reshaping the intracellular cargo space, but also by remodeling their 
intracellular membrane architecture to minimize the surface area of the cargo space while 
maximizing the cargo volume. By stabilizing a solute-to-solid phase transition, the apparent 
volume of distribution of the reporter probe continuously increased through treatment, and 
exceeded the cell volume by more than ten thousand-fold. As expected from an active 
sequestration mechanism, experimentally depleting macrophages in liver and spleen reduced the 
total amount of drug cargo accumulated in those organs, without affecting the loading of the 
remaining cells. Altogether, the results indicate a coordinated, immunological response 
mechanism across the entire macrophage population, which expands their endolysosomal cargo 
carrying capacity to accommodate an increasingly massive load of drug cargo.   
7.2 Introduction
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Throughout the body, macrophages are especially equipped to internalize extracellular 
solutes and particles through pinocytosis and phagocytosis, respectively.  This allows them to 
carry out a number of critical cellular immune functions ranging from destruction of pathogens 
to removal and recycling of dead cells and aged tissue components [1-3]. In addition to being 
highly phagocytic, the endolysosomal system of the macrophage is especially capable of 
accommodating and degrading foreign material due to higher expression levels of lysosomal 
acidification mechanisms [4], particularly the vacuolar-type proton ATP-ase (V-ATPase) [5]. 
Little is known about the in vivo phagocytic capacity of macrophages, with the majority of work 
having been performed in vitro using fluorescent tracer molecules [6] or inert beads of varying 
sizes [7]. For example, Cannon et al performed a study to determine the extent to which murine 
bone marrow macrophages were able to phagocytose polystyrene beads of various sizes, 
revealing that the phagocytic capacity of these cells is limited by the amount of membrane that is 
available to spread out and engulf the particle, rather than the volume of the cell [8].  
Even though the macrophage is a major immune regulator, its role as a determinant of 
drug distribution is underappreciated. Due to their high rates of endocytosis, pinocytosis and 
phagocytosis, and because of their ubiquitous presence throughout the body, they are poised to 
impact the performance and efficacy of many therapeutic agents. For example, liposomal 
formulations must be optimized to avoid phagocytosis of particles and removal of drug from the 
systemic circulation, increasing therapeutic efficiency [9, 10]. The action of macrophages may 
also impact small molecule drugs, such as antibiotics [11-13]. Many antibiotics will display large 
volumes of distribution and long elimination half-lives [14], causing them to linger within the 
body for extended periods of time. The accumulation of weakly basic, hydrophobic drug 
molecules within acidic subcellular compartments is a well-documented phenomenon, referred to 
as ion-trapping [15]. Cationic, amphiphilic molecules, particularly weakly basic molecules, tend 
to become trapped within lysosomes following protonation within the acidic lysosomal 
microenvironment [15-17]. Because macrophages have very active endolysosomal systems and 
express high levels of biomolecular ion transporters, they could significantly impact the volumes 
of distribution of many weakly basic drugs.  
Here, in order to study both how macrophages impact the volume of distribution of a 
therapeutic agent, and to determine the in vivo cargo carrying capacity of the macrophage, the 
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FDA-approved and biocompatible antibiotic clofazimine was chosen as a reporter probe. 
Clofazimine is an anti-mycobacterial agent clinically used to treat leprosy and multi-drug 
resistant tuberculosis [18-20]. It exhibits extensive accumulation throughout the body following 
oral administration, in both humans and in animal models [21-23]. Because clofazimine is both 
highly lipophilic (LogP>7) and contains a weakly basic, ionizable amine group, it is expected to 
accumulate in adipose tissue, intracellular membranes and in acidic organelles such as 
lysosomes. In both human and animal models, it has been shown that following prolonged oral 
dosing, CFZ accumulates extensively within macrophages [24].  
Previously, we have shown that the accumulation of clofazimine within macrophages 
leads to the formation of large, insoluble crystal-like drug inclusions (CLDIs) within these cells 
comprised of highly organized domains of clofazimine hydrochloride [25, 26]. In this manner, 
CLDIs can provide a solid, stable volume marker to assess the macrophage’s cargo carrying 
capacity and its contribution to the drug’s volume of distribution.  Because of the crystallinity 
and low solubility, CLDIs are easily isolated and are readily detectable through a variety of 
analytical techniques [24, 26]. Thus, we proceeded to study the cargo loading capacity of 
different macrophage populations to probe the patterns of macrophage loading in different 
organs, and to determine how the macrophages impact the volume of distribution. Additionally, 
the effects of macrophage depletion on cargo loading was probed, and the theoretical 
macrophage loading capacity within different tissues was calculated and related to the measured, 
tissue-specific variations in macrophage loading and its contribution to the volume of 
distribution.  
7.3 Materials and Methods 
Clofazimine Administration to Mice. Animal care was provided by the University of 
Michigan’s Unit for Laboratory Animal Medicine (ULAM), and the experimental protocol was 
approved by the Committee on Use and Care of Animals (Protocol PRO00005542). Mice (4 
week old, male C57Bl6) were purchased from the Jackson Laboratory (Bar Harbor, ME) and 
acclimatized for 1 week in a specific-pathogen-free animal facility.  Clofazimine (C8895; Sigma, 
St. Louis, MO) was dissolved in sesame oil (Shirakiku, Japan) to achieve a concentration of 3 
mg/ml, which was mixed with Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) 
to produce a 0.03% drug to powdered feed mix, and orally administered ad libitum for up to 
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eight weeks. A corresponding amount of sesame oil was mixed with chow for vehicle treatment 
(control). For washout experiments, mice were fed the vehicle-containing diet for eight weeks, 
after an eight week loading period with the CFZ-containing diet. Mice were euthanized via 
carbon dioxide asphyxiation and exsanguination.  
Alveolar Macrophage Isolation. Following euthanasia, the trachea was surgically exposed and 
cannulated with an 20G needle and the lungs were lavaged by instilling DPBS (Life 
Technologies) containing 0.5 mM EDTA (Sigma) in 1 ml aliquots for a total of 6 ml. 
Approximately 90% of the bronchoalveolar lavage (BAL) was retrieved. The BALwas then 
centrifuged for 10 min at 400 x g, 4°C, resuspended in RPMI 1640 media (Life Technologies) 
with 5% FBS (Life Technologies) and Penicillin/Streptomycin (Thermofisher), macrophages 
were counted, and an aliquot of cells were then plated onto 4 or 8 chamber coverglass (#1.5, 
Lab-Tek II, Nunc, Rochester, NY) for imaging studies. The cells were allowed to attach 
overnight and then washed with media. The remaining cells were analyzed for drug content. 
Peritoneal Macrophage Isolation. Following euthanasia, a small incision was made in the 
lower abdomen. The peritoneal cavity was then flushed 10 mL of ice cold DPBS containing 5% 
FBS (Sigma) and collected. The peritoneal lavage was centrifuged for 10 min at 400 x g, 4°C, 
and then resuspended in DMEM media (Life Technologies) with 5% FBS and Penicillin 
/Streptomycin, macrophages were counted, and an aliquot of cells were then plated onto 4 or 8 
chamber coverglass (#1.5, Lab-Tek II, Nunc, Rochester, NY) for imaging. The cells were 
allowed to attach overnight and then washed with media. The remaining cells were analyzed for 
drug content. 
Bone Marrow Monocyte Isolation. Following euthanasia, an incision was made above the hip 
bone and the skin was removed down the entire leg. The femur was then cut from the knee joint 
and the hip, the muscle was removed, and the bone was placed in ice cold DPBS. The tips of the 
femur were then cut, and the bone was flushed with 5 mL of ice cold PBS to collect the bone 
marrow monocytes. The suspension was centrifuged for 10 min at 400 x g, 4°C, and resuspended 
in RPMI 1640 media with 5% FBS and Penicillin/Streptomycin, counted with a hemocytometer, 
and an aliquot of cells were plated onto 4 or 8 chamber coverglass  (#1.5, Lab-Tek II, Nunc, 
Rochester, NY) for imaging. The cells were allowed to attach overnight and then washed with 
media. The remaining cells were analyzed for drug content. 
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Kupffer Cell Isolation. Following euthanasia, the portal vein was injected with 10 mL of 1 
mg/mL Collagenase D (Worthington  Biochemical Corporation, Lakewood, NJ) in DMEM-low 
glucose (Life Technologies) with 15 mM HEPES (Life Technologies). The tissue was then 
removed, placed in a sterile petri dish, and minced into small (2-4 mm) pieces using a sterile 
scalpel blade. 15 mL of the Collagenase solution was added, and the tissue was incubated for 40 
minutes at 37°C, with occasional pipetting to dissociate tissue. The suspension was then filtered 
through a 100 µm cell strainer (Fisher Scientific, Waltham, MA) and centrifuged at 200 x g for 5 
minutes. The supernatant was discarded, and the cells were resuspended in 15 mL DMEM-low 
glucose with 15 mM HEPES, and centrifuged at 200 x g for 5 minutes. This was repeated for two 
additional washes. After the final wash, the cells were suspended in DMEM:F/12 (1:1) (Life 
Technologies) with 10% FBS and Penicillin/Streptomycin, macrophages were counted, and an 
aliquot was plated onto 4 or 8 chamber coverglass(#1.5, Lab-Tek II, Nunc, Rochester, NY) 
coated with Collagen 1 (Corning, Corning, New York) for imaging. The cells were allowed to 
attach overnight and then washed with media. 
Multi-parameter Microscope Imaging and Analysis of Xenobiotic Sequestering 
Macrophage Populations. Multi-parameter polarization, brightfield, and fluorescence imaging 
and analysis were performed using the imaging method previously described by Rzeczycki et al 
[26]. Briefly, cells were plated on chamber slides and allowed to attach overnight. Following 
attachment, cells were imaged with brightfield, fluorescence, and polarization imaging 
modalities. Images were then analyzed using ImageJ software [27, 28]. Values for dichroism and 
optical density are reported as an average signal per cell, from 0-1. At least 150 cells of each type 
were analyzed at each time point.  Following loading with 7 and 14 mg of cargo, macrophages 
were classified as xenobiotic sequestering based on whether or not they contained a detectable 
Cy5 signal from clofazimine hydrochloride [24] using a K-means clustering analysis, with the 
clusters set to 2 based off of the Log10(Intracellular Cy5 fluorescence).  
Biochemical Analysis of Clofazimine in Cells. The concentration of clofazimine in cells was 
determined after measuring clofazimine content in isolated macrophage populations and organ 
homogenates using established methods [22, 24, 25, 29]. For isolated macrophage populations, 
cells were counted within each cell sample using a hemocytometer to determine the total 
recovered macrophage population. The cells were then centrifuged and the media was removed. 
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The cell pellet was suspended in 1 mL of DI water, and the drug was extracted with three passes 
of 1 mL of xylenes. The drug was then extracted from the xylene with three 1 mL passes of 9M 
sulfuric acid. The concentration of clofazimine present in the cell sample was then determined 
using a plate reader (Biotek Synergy 2, Winooksi, VT) at wavelength 450 nm, and background 
corrected at wavelength 750 nm, with the concentration determined using a standard curve made 
of standards with known concentrations of clofazimine, and is reported as fmol 
clofazimine/xenobiotic sequestering cell. 
Sample Preparation for Microscopy. Cryosectioning was carried out using a Leica 3050S 
Cryostat (Leica Biosystems Inc., Buffalo Grove, IL). Samples were sectioned to 5 µm. In 
preparation for cryosectioning, portions of the organ were removed, immediately submerged in 
OCT (Tissue-Tek catalog no. 4583; Sakura), and frozen (-80°C). For transmission electron 
microscopy, organs were submerged in fixative and cut into small (<1 mm) sized pieces. The 
organs were preserved in a glass vial with fixative and stored at 4°C. After three rinses with 
Sorensen's buffer (0.1 M), tissues were stained with 1% osmium tetroxide in Sorensen's buffer 
and washed three times in Sorensen's buffer. Dehydration was carried out with a graded ethanol-
water series (50, 70, and 90% and two changes of 100%) for 15 min each. After washing with 
three changes of propylene oxide, the tissues were treated with Epon resin (Electron Microscopy 
Sciences) and polymerized at 60°C for 24 hours. The blocks were then sectioned to 70 nm using 
an ultramicrotome and mounted on a copper EM grid (Electron Microscopy Sciences), which 
was then stained with uranyl acetate and lead citrate before imaging. Immunohistochemistry of 
F4/80 (Abcam, 1:500 dilution) was performed using Alexa-Fluor 488 (Abcam, 1:500 dilution). 
Clofazimine Volume Occupancy. The volume that clofazimine occupies within the macrophage 
was determined using the reported crystal-packing density of 1.36 g/mL [25] for clofazimine-
HCl, which was then converted to a molar volume of 0.377 µm
3
/ fmol. Cellular volume 
occupancy was then estimated using the measured drug loading per cell and this calculated molar 
volume. 
Determination of Vesicle Size and Shape. Vesicle loading per cell was performed using the 
Cy5 fluorescence of the alveolar macrophage. Using ImageJ [27, 28], the radius of each vesicle 
was determined. Vesicles which showed Cy5 fluorescence were counted as clofazimine 
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sequestering. Volume of the vesicle for 3.5 and 7 mg treated cells was estimated assuming 
spherical shape, while CLDI volume was estimated assuming a cylindrical shape. 
Macrophage Expansion Analysis. To determine the expansion in macrophage population in 
lung, liver and spleen from animals treated with clofazimine, cryosections were obtained of the 
same thickness.  The relative number of macrophages in a volume of tissue was determined by 
dividing the total F4/80 signal staining intensity between 8 week clofazimine-treated sample by 
the total F4/80 signal staining intensity of a vehicle-treated sample (the area and thickness of the 
sections analyzed was kept the same).  The expanded macrophage population was then 
determined by multiplying literature reported (baseline) macrophage population values for each 
organ [30] by the relative  expansion factor.  To determine the percentage of xenobiotic 
sequestering cells, the total number of cells which showed Cy5 fluorescence and F4/80 staining 
were determined using a mask of the F4/80 staining. 5 images per organ per animal were 
analyzed, for each measurement.    
Measurement of CLDI Mass within Tissues. The CLDI mass present in lung, liver, and spleen 
tissues at eight weeks of treatment was determined using established protocols [29]. Tissues 
(n=3) were removed, weighed, and placed in a sterile petri dish, where it was manually minced 
and homogenized using a scalpel and syringe plunger. The tissue homogenate was filtered 
through a 40 µm cell strainer to remove larger cellular debris. The filtrate was then centrifuged 
for 10 min at 300 x g to pellet the CLDIs. The supernatant was removed and the pellet was 
resuspended in 10% sucrose in DPBS (Life Technologies, Carlsbad, CA) without calcium 
chloride or magnesium chloride, pH=7.4. CLDIs were further purified using a 3-layer sucrose 
gradient (50%, 30%, and 10% sucrose in DPBS) centrifugation method (3200 x g for 60 
minutes). The pelleted CLDIs were then dissolved in 9M H2SO4 and the mass of drug was 
determined using a plate reader (Biotek Synergy 2, Winooksi, VT) at wavelength 450 nm, and 
background corrected at wavelength 750 nm, determined using a standard curve with solutions of 
known concentration. 
CLDI Loading Within Individual Macrophages. Using the total recovered mass of CLDIs 
within the liver, lung, and spleen, the CLDI loading within individual xenobiotic-sequestering 
macrophages was estimated using the total expanded macrophage population, corrected for the 
percentage of cells which contained a CLDI. Using literature reported values for cellular volume 
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of the macrophage [31], the percentage of cellular volume that is occupied by the CLDI was 
estimated. 
Macrophage Depletion. To deplete tissue macrophages, mice were treated with liposomes 
containing either 7 mg/mL of clodronate or phosphate-buffered saline (PBS) (FormuMax 
Scientific Inc., Sunnyvale, CA). Liposomes were injected intraperitoneally, as previously 
described [32]. Mice were initially treated with 200 µL of liposomes followed by 100 µL 
injections twice per week to ensure continual macrophage depletion. Mice were fed clofazimine 
or control diet continuously for a four week period. Following two weeks of feeding, liposome 
administration began for two weeks. After completing four weeks of feeding and two weeks of 
liposome treatment, mice were sacrificed and tissues were collected. 
Biochemical Analysis of Clofazimine in Tissues. After loading with clofazimine, mice were 
euthanized via CO2 asphyxiation, and organs removed and weighed. Tissue (20-30 mg) was 
homogenized in 500 µL of radioimmunoprecipitation assay buffer (Sigma) with added protease 
inhibitors (Halt protease and phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, 
Rockford, IL), and 350 µL of homogenate was removed drug was extracted with three passes of 
1 mL of xylenes. The drug was then extracted from the xylene with three 1 mL passes of 9M 
sulfuric acid. The recovery yield was determined by spiking samples with a known concentration 
of clofazimine. The concentration of clofazimine present in the tissue was then determined using 
the plate reader assay (Biotek Synergy 2, Winooksi, VT) at wavelength 450 nm, and background 
corrected at wavelength 750 nm, with the aid of a standard curve made with solutions of known 
concentration. 
Biochemical Analysis of Clofazimine in Plasma. Blood was collected and centrifuged (7,000 × 
g for 5 minutes). The resulting supernatant serum was extracted with acetonitrile (90% extraction 
efficiency) for 10 min at 4°C with vortexing. After centrifugation (15,000 rpm, 4°C), the 
supernatant was injected into a Waters Acquity UPLC H-Class (Waters, Milford, MA) equipped 
with an Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm [inner diameter] by 100 mm; Waters, 
Milford, MA). Mobile phase A was 5 mM ammonium acetate, adjusted to pH 9.9 with 
ammonium hydroxide, and mobile phase B was acetonitrile. The flow rate was 0.35 ml/min, with 
a linear gradient from 50 to 100% phase B over 1.5 min, followed by holding at 100% for 1.5 
min, a return to 50% phase B, and then re-equilibration for 2.5 min. Standards were prepared by 
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spiking untreated plasma samples with known amounts of clofazimine, ranging from 0 to 30 µM. 
Peak area was determined using Empower 3 Software (Waters, Milford, MA). 
Determination of the Volume of Distribution of Clofazimine at Various Stages of Drug 
Loading. Following treatment with 5.25 or 14 mg of clofazimine, mice (n=3 per time point) 
were euthanized and the liver, spleen, small intestine, fat, kidney, and lung were removed, 
weighed, and the mass of clofazimine within each tissue and concentration within plasma was 
determined using the previously described protocols. The volume of distribution of the drug 
within macrophages, tissue and the whole body at the different loading amounts was determined 
using the ratio between the total drug within tissues or individual cells and the measured plasma 
concentration, and is reported as L/kg tissue or L/kg body weight, assuming a 25 gram mouse. 
CLDI Injection and Stabilization Assay. To determine how macrophages stabilize CLDIs, 
mice were treated with either liposomal PBS or liposomal clodronate, as previously described 
[32]. 48 hours after liposome administration, mice were injected I.P. with 200 µg of CLDIs 
suspended in 1 mL of PBS (n=3 mice per group per time point). At time points ranging from 0 to 
48 hours, the mice were euthanized, the peritoneal lavage was collected and pelleted, and the 
drug content within the pellet was analyzed using the previously described spectrophotometric 
analysis method. Using a simple exponential regression with recovered drug content, the half-life 
was estimated. 
Statistical Analysis. All data are expressed as means ± the standard deviations (SD). For 
multiple comparisons, statistical analysis was performed with one-way analysis of variance 
(ANOVA) and Tukey's post hoc comparisons. The half-life of injected CLDIs was determined 
using a simple, first order exponential regression of the recovered drug mass. All statistical 
analyses were performed using IBM SPSS Statistics version 24.0 (IBM Software, Armonk, New 
York). P values less than 0.05 were considered statistically significant. 
7.4 Results 
7.4.1 Macrophages adjusted internal membrane arrangement to maximize cargo loading 
Experimentally, a moderate, whole body cargo load (3.5 mg, Figure 1) mostly led to 
accumulation in alveolar macrophages (Figure 1a).  This cargo was associated with red, optically 
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dense cytoplasmic vesicles which exhibited little dichroism signal, corresponding to a 
disordered, amorphous supramolecular organization [33, 34] (Figure 1b). A larger cargo load 
resulted in a modest increase in accumulation in the alveolar macrophages (Figure 1c), plus a 
fraction of peritoneal and liver macrophages were also loaded; however, the structure of the 
intracellular cargo became more organized (Figure 1b) as reflected in the elevated optical density 
and dichroism of peritoneal and liver macrophages (Figure 1b-d).  Doubling the whole body 
cargo load caused all macrophages to redistribute their internal cargo loads into large, highly 
ordered CLDIs exhibiting strong dichroism signals (Figure 1b). Under all loading conditions, the 
less mature bone marrow monocytes were free of cargo. At a population level, these trends were 
confirmed by multi-parameter image-based cytometric analyses (Figure 1c, d).  
The results of chemical analyses confirmed the observed, uneven distribution of cargo 
amongst the different macrophage populations. At low (3.5 mg) cargo loading, alveolar 
macrophages sequestered 29.9 ± 12.4 fmol of cargo/cell, with the other populations showing 
minimal loading (Figure 1e). Within the alveolar macrophages, after a whole body load of 3.5 
mg, less than 0.3% of the maximal phagocytic capacity of the cells was reached (Figure 1f). At a 
larger (7 mgs) whole body cargo load, alveolar macrophages accumulated 34.0 ± 20.3 fmol 
cargo/cell, which primarily remained in disordered form as reflected in the low dichroism signal 
(Figure 1b,d). Peritoneal and liver macrophage populations, due to their differential 
accumulation pattern (Figure 1b), increased their cargo loading per cell to 105.7 ± 10.0 and 63.5 
± 16.2 fmol/cell, respectively. At the highest loads of cargo (14 mgs), alveolar, peritoneal, and 
liver macrophage populations showed similar levels of cargo loading (Figure 1e). By 
accumulating cargo as CLDIs, the macrophages maximized intracellular cargo loading. The 
highest cargo volume corresponded to ~1% of the reported, maximal phagocytic capacity of 
macrophages (Figure 1f) [8]. Thus, with CLDI formation, only a small fraction of the potential, 
intracellular cargo space was occupied at the highest loading capacity measured in vivo.  
In order to efficiently accommodate this massive cargo load, macrophages also adjusted 
their intracellular membrane organization. At low levels of loading (3.5 mgs), the alveolar 
macrophage population accumulated an average of 21.6 ± 5.0 vesicles per cell, with each vesicle 
occupying a mean volume of 0.43 ± 0.29 µm
3
 (Table 1).  Transmission electron micrographs of 
alveolar macrophages revealed numerous dark, lipid bound inclusions within the cytoplasm 
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(Figure 2a). An even larger (7 mgs) whole body cargo load resulted in the cytoplasmic vesicles 
increasing to 32.6 ± 6.8 per cell (n=30 cells, p<0.05, ANOVA, Tukey’s HSD), with the vesicular 
volume increasing slightly to 0.97 ± 0.96 µm
3
 (Table 1). Nevertheless, at 14 mg of cargo 
loading, the AMΦ’s membrane bound cargo compartment was visibly expanded (Figure 2b). At 
this point, the number of loaded vesicles per cell dropped to 18.4 ± 11.1 and their volume 
increased to 13.8 ± 10.4 µm
3
.  The larger, solid, membrane bound compartments were stable and 
remained within the macrophage even after an eight-week cargo washout period (Figure 2c).  
7.4.2 Insoluble cargo accounts for majority of intracellular loading, and leads to 
increased volume of distribution 
Of noteworthy significance, the amount of cargo in the isolated macrophage populations 
effectively accounted for most of the total cargo load measured in whole organ homogenates 
(Table 2). Based on the amount of cargo within each organ, the volume of blood that was cleared 
by the macrophages in the different organs was estimated (the organ-specific Volume of 
Distribution, VoD; Table 3). In pharmacokinetic terms, the whole body VD of a molecule is the 
ratio between the amount of drug in the organism and the plasma concentration of the drug [35].  
VD represents the extent of tissue distribution [36] as reflected in the theoretical volume required 
to contain an administered amount of drug, at the same concentration as found in the plasma. 
With an increasing cargo load, each macrophage population significantly contributed to the 
increase in VOD and hence, to VD (Table 3). Given that the volume of a single macrophage is ~1 
pL, the macrophages’ contribution to VD was mostly due to the solute-to-solid phase transition 
that accompanied CLDI formation. At the whole organ level, there was a nearly 100-fold 
increase in the VOD within the liver and small intestine, a 60-fold increase within the spleen and 
10-fold increase within the lung upon increasing the whole body cargo loading from 5.25 to 14 
mg (Table 4). Within the fat and kidney, which do not contain the large populations of tissue 
macrophages typical of the previously mentioned organs, there were modest increases in the 
VOD, but nowhere near the increases in VOD observed in liver, spleen, lung and intestine (Table 
4). 
7.4.3 Macrophages are necessary to acquire and stabilize intracellular cargo 
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Interestingly, the number of macrophages in various organs increased following loading 
with the maximum cargo treatment (Figure 3a). Thus, to test whether macrophages played an 
active role in determining cargo accumulation and distribution, liposomal clodronate injections 
were used to deplete hepatic and splenic macrophages [32]. Following clodronate treatment, the 
cargo carrying capacity of liver and spleen was significantly reduced; however, within the 
kidney, which did not undergo depletion, there was no significant reduction in cargo load (Figure 
3b). Quantitatively, due to the reduction in macrophage numbers (Figure 3c), there was a 
concomitant reduction in CLDI accumulation within the liver and spleen (Figure 3d). Most 
interestingly, cargo loading within liver and spleen macrophages was similar between the two 
treatment groups (Figure 3e).  Furthermore, the serum concentration of clofazimine was similar 
between the groups (Figure 3f), indicating that the effects of clodronate on cargo accumulation 
were specifically due to macrophage depletion, and not to a decrease in circulating drug 
concentrations or an associated decrease in drug bioavailability, absorption or macrophage 
loading, which would have been apparent as a decrease in drug accumulation in the remaining 
macrophages. Finally, injecting CLDIs directly into the peritoneal cavity of macrophage-
depleted mice led to a significant reduction in half-life compared to their control, PBS-treated 
counterparts (Figure 3g). The peritoneal macrophages imparted stability to the injected CLDI by 
internalizing them via phagocytosis, while extracellular CLDIs more rapidly degraded (Figure 
3h). These results indicate that the macrophages are actively involved in the sequestration and 
stabilization of cargo as insoluble, highly organized and biocompatible supramolecular 
complexes. 
7.5 Discussion  
While the volume of distribution of most hydrophobic drugs is typically ascribed to drug 
partitioning into adipose tissue, the experimental results presented in this study indicate how 
macrophages can account for most of the accumulation and distribution of the reporter probe in 
vivo, with macrophage cargo carrying capacity increasing in parallel to the increase in whole 
body load. In the experiments reported in this study, the mass and volume of cargo per cell was 
nowhere near the maximal cargo capacity of macrophages, as determined in vitro following 
phagocytosis of spherical beads of increasing size [8]. When macrophages of the liver and spleen 
were depleted, there was a reduction in the whole-organ cargo carrying capacity in proportion to 
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the decrease in the macrophage population, but the cargo carrying capacity of the remaining 
macrophages was unaffected. There has been extensive research in the past on how therapeutic 
agents can impact the immune system [37]; however, few, if any small molecule drugs have been 
shown to have their ADME properties dependent on the action of macrophages or other specific  
populations of immune cells. Using clofazimine as a weakly basic reporter molecule [38], we 
found that the extent of tissue distribution was actively impacted by the action of tissue 
macrophages. Lung and liver macrophages are often where bacteria reside during persistent 
bacterial infections (particularly with infections of Mycobacterium tuberculosis [39] and 
Mycobacterium leprae [40]). By extension, the efficacy of many of the antibiotics used to treat 
these infections may be dependent on a synergistic interaction between the macrophages, which 
harbor these intracellular pathogens, and the antibiotic, which is accumulated by these cells and 
ultimately destroys these pathogens. 
Most interestingly, our results indicate that macrophage-mediated small molecule drug 
sequestration can have a profound impact on pharmacokinetics. While it is often assumed that 
the volume of distribution of a therapeutic is a constant, and is only significantly impacted by 
disease states affecting organ function [41, 42], our measurements indicate that this is not 
necessarily the case.  Rather, in the case of drugs that show significant levels of bioaccumulation, 
that undergo phase transitions (solute-solid or solute-amorphous), or that are able to become 
concentrated within particular cellular populations, it is possible that the volume that the drug 
distributes can change significantly as treatment progresses. With clofazimine, this remarkable 
phenomenon was first evident as a significant reduction in the plasma concentration of the drug 
from weeks 3 to 8 in treatment [22]. Concurrently, in this study we found a ~100-fold increase in 
the organ-specific volume of distribution (VOD) within the liver and spleen, and a ~10-fold 
increase of VOD within the lung. The blood volume cleared by different organs corresponded to 
the extent of loading of the macrophages in those organs, with the spleen showing the highest 
loading per unit tissue weight, followed by liver and lung [22].  The preferential accumulation of 
the cargo in spleen was primarily associated with the accumulation of drug molecules as an  
insoluble, ordered supramolecular aggregates[43]. By depleting the macrophages of the liver and 
spleen with clodronate, we deduce that this phenomenon is largely due to the action of 
macrophages. Beyond clofazimine, it is known that the intracellular sequestration of other 
hydrophobic, cationic drugs such as amiodarone [44] or quinacrine [45] is highly dependent on 
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the proton pump V-ATPase, which is expressed at higher levels within macrophages [5]. Thus, 
beyond clofazimine, this mechanism is likely to impact the pharmacokinetics of other therapeutic 
agents.  
 In terms of the biological mechanisms that underpin their ability to sequester an 
increasingly massive load of cargo, the macrophage endolysosomal system is particularly adept 
at accommodating an increasing cargo load due to the low-pH and high chloride environment of 
their lysosome [43]. The high levels of V-ATPase expressed in macrophage lysosomes are a 
likely explanation for the active solute to solid transition that seems to occur selectively within 
these cells. Due to the active concentrative proton and chloride pumping [46] within the 
endolysosomal system, massive amounts of solid cargo can be sequestered and accommodated 
within membrane bound intracellular compartments. In addition to the activity of lysosomal 
proton and chloride transporters present in macrophage lysosomes, these cells can also alter their 
internal membrane architecture to maximize the volume of cargo within a minimal amount of 
membrane surface area. As our results indicate, at low levels of cargo treatment, macrophages 
acquired soluble cargo in the form of small, spherical vesicles. Continued accumulation of cargo 
led to the formation of larger volume vesicles and to the disappearance of the smaller vesicles. 
We infer that, by expanding the volume of intracellular vesicles, macrophages maximized the 
available cargo space while minimizing the overall membrane surface area delimiting the cargo 
compartments [47, 48], allowing for increased cargo accumulation within the cell, and 
consequently, an increase in VOD. 
In addition to the adaptive changes that were observed to occur at the level of the 
individual macrophages, measurements of the entire cell population of liver, lung, and spleen 
indicated an increase in the number of macrophages occurring in parallel to the increase in cargo 
loading. Pathologically, an expansion in the macrophage population is typically associated with a 
pro-inflammatory response [49, 50]. However, the accumulation of insoluble intracellular drug 
cargo in macrophages of clofazimine-treated animals was accompanied by the activation of anti-
inflammatory signaling pathways and was not associated with obvious toxicological 
manifestations [29, 51]. As a candidate, anti-inflammatory signaling mechanism, it is possible 
that the lysosomal accumulation of weakly basic molecules may induce activation of 
transcription factor EB (TFEB) [52, 53]. Increased cargo loading can therefore lead to TFEB 
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becoming  chronically activated, resulting in increased lysosomal biogenesis, which would 
reduce lysosomal stress and actively allow for increased intracellular cargo sequestration. 
Nevertheless, because this macrophage-mediated drug sequestration phenomenon is also linked 
to concomitant changes in organ mass (e.g. splenomegaly [22]) and histological organization 
(e.g. granuloma formation [22, 54]), these results warrant additional studies into the functional 
sequelae of the pro- and anti-inflammatory signaling mechanisms that are activated in response 
to a massive intracellular cargo load. 
7.6 Conclusion 
To conclude, the results presented in this study point to a stimulus-dependent, 
macrophage-mediated biological response mechanism that is activated by the extent of cargo 
accumulation in these cells. In this process, macrophages actively stabilize intracellular drug as 
insoluble complexes that are trapped within membrane-bound compartments. To accommodate 
increasingly massive loads of cargo, macrophages increase in numbers and adapt their 
intracellular membrane organization so as to maximize the intracellular cargo space.   While 
resident macrophages of different organs demonstrated significant variations in their response to 
increasing loads of cargo, all differentiated macrophage populations were capable of 
sequestering large loads of cargo.  The adaptive cargo carrying capacity of macrophages 
ultimately accounted for the observed expansion in the drug volume of distribution, which was 
directly measured based on the amount of drug cargo sequestered within each organ.  Of 
noteworthy significance, to our knowledge, this is the first time that the volume of distribution of 
a small molecule drug has been directly measured and associated with an adaptive, immune 
system-mediated biological response. 
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7.8 Figures 
 
 
 
 
 
Figure 7-1 Microscopic imaging cytometry reveals variations in cargo loading of macrophage and monocyte 
populations 
 
a, Brightfield images of isolated macrophage and monocytes following increasing whole-body cargo loading. b, 
Linear diattenuation images of isolated macrophage and monocytes following increasing whole-body cargo loading. 
c, Mean optical density of alveolar macrophage (black), peritoneal macrophage (red), bone marrow monocyte 
(green), and Kupffer cell (blue) at increasing cargo loading. d, Mean linear diattenuation of alveolar macrophage 
(black), peritoneal macrophage (red), bone marrow monocyte (green), and Kupffer cell  at increasing cargo loading. 
e, Mean cargo loading per xenobiotic-sequestering cell at increasing cargo loading. f, Percentage of maximal cargo 
loading within each cell type at increasing cargo loading. Error bars represent standard deviation. (n=150 cells per 
time point for imaging studies, n=3 mice per cargo treatment for drug accumulation, *=p<0.05, ANOVA, Tukey’s 
HSD) (Scale bar is 10 µm). 
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Figure 7-2 Cargo accumulation induces reorganization in the internal membrane architecture of macrophages 
 
a, Following whole-body loading of 3.5 mg of the cargo volume marker, macrophages of the lung are loaded with 
small vesicles that fill the cytoplasm. b, Increasing doses of the marker results in accumulation of crystal-like drug 
inclusions (CLDIs) throughout the cytoplasm. c, These larger aggregates remain stable intracellularly even 
following an eight week washout period. Black arrows denote cargo-laden vesicles and red arrows denote cavities 
left from CLDIs removed during sample preparation. Scale bar is 2000 nm. 
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Cargo Loading Mean number of 
vesicles per cell 
(n=30 cells) 
Mean vesicle 
volume (n=50 
vesicles) 
Mean total volume 
occupied by 
vesicles (n=50 
vesicles) 
3.5 mg 21.6 ± 5.0 0.43 ± 0.29 µm
3 
9.2 ± 6.7 µm
3 
7 mg 32.6 ± 6.8* 0.97 ± 0.96 µm
3 
31.7 ± 32.1 µm
3 
14 mg 18.4 ± 11.1 13.8 ± 10.4 µm
3
* 253.8 ± 244.5 µm
3 
 
 
Table 7-1 Cellular vesicular volume and occupancy within alveolar macrophages 
 
Changes in vesicle number, size, and volume occupancy in cargo-treated alveolar macrophages. (*=p<0.05, 
ANOVA, Tukey’s HSD). 
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Table 7-2 Insoluble cargo loading within various macrophage populations 
 
Estimated cargo loading within liver, spleen, and lung macrophages following 14 mg of cargo loading. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Macrophage 
Population 
Cargo mass 
(mg) 
Percent 
Xenobiotic 
Sequestering 
Total Xenobiotic 
Sequestering 
Population 
Fmol 
Cargo/Xenobiotic 
Sequestering Cell 
% Cell Volume Occupied 
by Cargo 
Liver 4.57 ± 0.78 88.5 ± 3.3% 8.0 x 107 ± 1.9 x 
107 
120.9 ± 35.3 2.11 ± 0.62%  
Spleen 3.23 ± 0.27 83.9 ± 12.5% 2.2 x 107 ± 5.9 x 
106 
310.5 ± 86.9 5.42 ± 1.52% 
Lung 0.32 ± 0.06 81.1 ± 3.2% 3.7 x 106 ± 1.7 x 
106 
183.2 ± 91.5 3.20 ± 1.60% 
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Macrophage Population 5.25 mg cargo VOD (nL/macrophage) 14 mg cargo VOD (nL/macrophage) 
Liver 0.66 ± 9.8x10-5 33.51 ± 0.01* 
Lung 5.51 ± 9.5x10-5 42.73 ± 0.01* 
Spleen 0.49 ± 2.5x10-4 64.25 ± 0.01* 
 
Table 7-3 Estimated volume of distribution within various macrophage populations following increased drug 
therapy 
 
Volume of distribution of cargo marker in liver, lung, and spleen macrophage, at 5.25 and 14 mg of whole-body 
loading (*=p<0.05, Two-Tailed Student’s T-Test) 
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Tissue (n=3 per treatment) 5.25 mg cargo VOD (L/kg tissue) 14 mg cargo VOD (L/kg tissue) 
Liver 33.9 ± 13.1 2232.5 ± 958.2* 
Spleen 118.8 ± 85.4 6139.3 ± 2637.0* 
Fat 91.8 ± 15.2 129.1 ± 61.1 
Jejunum and Ileum 11.1 ± 6.3 1085.2 ± 606.2* 
Lung 91.2 ± 12.0 902.3 ± 524.1 
Kidney 31.1 ± 7.3 125.6 ± 55.5 
Table 7-4 Estimated volume of distribution within various organs following increased drug therapy 
 
Volume of distribution of cargo marker in various organs, at 5.25 and 14 mg of whole-body loading (*=p<0.05, 
Two-Tailed Student’s T-Test) 
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Figure 7-3 Macrophages increase in number and actively sequester cargo primarily by stabilizing it in an insoluble 
form 
a, Comparison of total F4/80 macrophage signal in untreated (grey) and 14 mg cargo loading (red) tissue sections. b, 
Total cargo loading in PBS- (red) and clodronate-liposome (green) tissues. c, Quantification of tissue macrophage 
population in PBS-vehicle diet (grey), clodronate-vehicle diet (black), PBS-cargo diet (red), and clodronate-cargo 
diet (green) using F4/80 signal. d, Quantification of insoluble cargo accumulation in P BS-vehicle diet (grey), 
clodronate-vehicle diet (black), PBS-cargo diet (red), and clodronate-cargo diet (green) using Cy5 fluorescence. e, 
Individual macrophage cargo loading in PBS-cargo diet (red) and clodronate-cargo diet (green). f, Serum 
concentration of clofazimine in clodronate- and PBS-cargo diet treatment groups. g, Estimated half-life of injected 
CLDIs within peritoneal cavity of clodronate and PBS liposome treated mice. h, Peritoneal lavage of PBS and 
clodronate treated liposome groups 48 hours post injection, scale bar is 50 um. Error bars represent standard 
deviation (*=p<0.05, Student’s Two-tailed T-test or ANOVA, Tukey’s HSD). 
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Chapter 8 
Liver Granulomas Function as Drug Sequestering Hepatoprotective 
Organoids 
8.1 Abstract 
The liver is the major organ affecting the metabolism and disposition of drugs in the body. Here, 
we aimed to determine how the liver adapts to long term bioaccumulation of a poorly soluble, 
weakly basic drug. We also sought to determine whether granuloma macrophages played a 
distinct role in drug disposition, compared to Kupffer cells. The ability of granuloma-associated 
macrophages and resting Kupffer cells to accumulate a weakly basic drug and a related analog 
with different solubility properties was studied. The expression of proteins related to intracellular 
accumulation of the weakly basic drug molecule within acidic organelles was characterized. 
Additionally, macrophage-depletion via liposomal clodronate was used to inhibit granuloma 
formation and assess its effect on the health status of the liver in response to drug 
bioaccumulation. Granuloma-associated macrophages were distinctively different from other 
macrophages of the same liver, which resembled resting Kupffer cells of untreated animals, 
exhibiting signs of high turnover. They were specifically drug-induced, and were not evident in 
animals treated with a related derivative that is less prone to intralysosomal precipitation. 
Granuloma-associated macrophages accumulated massive amounts of insoluble drug, 
specifically as the protonated, hydrochloride salt form. These cells exhibited increased TFEB 
activation, enlarged endolysosomal compartment and showed signs of mitochondrial 
degeneration. Liposomal clodronate inhibited granuloma formation, which was accompanied by 
increased hepatic necrosis and systemic toxicity. Granuloma-associated macrophages possessed 
distinctive, differentiated features that make them uniquely different from other drug-exposed 
macrophages and untreated Kupffer cells. Granuloma-associated macrophages are especially 
equipped to stabilize insoluble drug aggregates within an enlarged endolysosomal compartment. 
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As such, granulomas function as drug sequestering “organoids” –organs within an organ that 
protect neighboring hepatocytes by sequestering drug and confining the drug’s toxicity.   
8.2 Introduction 
Macrophages mediate inflammatory responses and have been implicated in a multitude of 
disease states, ranging from obesity [1, 2] to some types of cancers [3, 4]. One particular 
inflammatory response, granuloma formation, has been observed to occur almost everywhere in 
the body, from the skin to the lungs. A granuloma is a specialized collection of macrophages that 
functions to compartmentalize a foreign body, away from the surrounding tissues [5-7]. This 
reaction is commonly seen in bacterial and fungal infections. In leprosy, granulomas form within 
the skin and near nerves, causing severe neuropathy [8]. In tuberculosis, granulomas form 
“tuber”-like structures around the bacteria, to limit their spread [9]. Other inflammatory diseases 
of unknown origins can also be accompanied by the formation of granulomas. For example, 
Crohn’s disease is an inflammatory condition in which chronic inflammation induces granuloma 
formation throughout the gut [10]. Yet another kind of granuloma are the so called “foreign body 
granulomas”, which are formed by macrophages attempting to engulf exogenous materials, from 
splinters to surgical equipment, that are accidentally introduced in the body [11].  
Hepatic granulomas are often observed in human liver biopsy samples, and can arise due 
to tuberculosis, brucellosis [12], or treatment with certain classes of drugs, such as sulfonamides 
[13] and quinidine [14]. Drug-induced liver granulomas are especially perplexing, in part, 
because the mechanisms by which drugs trigger granuloma formation are unknown. Kupffer 
cells, the macrophages of the liver, are among the first cells to interact with foreign substances 
ingested through the gut and have been implicated in protecting the host from harmful 
xenobiotics [15]. Kupffer cells have also been shown to play a major role in regulating the 
activity of drug-metabolizing enzymes such as the cytochrome P450 complex [16, 17], which 
can lead to drug-induced liver injury. Drugs like acetaminophen or bacterial products like 
lipopolysaccharide can activate Kupffer cells [18, 19]. The activation of Kupffer cells can lead to 
an inflammatory response, resulting in tissue damage and hepatotoxicity [20].  
Here, we hypothesized that granuloma-associated macrophages play a specific role in 
ameliorating drug-induced liver damage and toxicity. To test this hypothesis, we turned to the 
FDA-approved antibiotic, clofazimine (CFZ), a highly lipophilic, poorly soluble, weakly basic 
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phenazine drug. CFZ, which has been used to successfully treat and cure leprosy since the 1950s 
[21] and is currently recommended as a treatment for multi-drug resistant tuberculosis [22] is 
known to induce liver granulomas.  Due to its lipophilicity and unique pharmacokinetic 
properties [23], it bioaccumulates extensively during long term oral administration. Aside from 
causing skin pigmentation, prolonged oral administration of CFZ (>3 weeks) [24, 25] leads to its 
precipitation within liver, lung and spleen [26, 27]. These precipitates can be ingested by 
phagocytosis [28] and accumulate within macrophage lysosomes, as microscopic, insoluble 
aggregates of protonated CFZ hydrochloride [29]. While the soluble form of CFZ is cytotoxic in 
vitro [28], the insoluble, protonated hydrochloride salt form is significantly less toxic to cells. 
Importantly, the drug is well tolerated by patients and is relatively nontoxic in animal models 
[30, 31].  Thus, we decided to further explore the drug’s effect on the liver, especially in regards 
to its pronounced ability to induce granuloma formation.  
8.3 Materials and Methods 
Drug Administration to Mice. Animal care was provided by the University of Michigan’s Unit 
for Laboratory Animal Medicine (ULAM), and the experimental protocol was approved by the 
Committee on Use and Care of Animals (Protocol PRO00005542). Mice (4 week old, male 
C57Bl6) were purchased from the Jackson Laboratory (Bar Harbor, ME) and acclimatized for 1 
week in a specific-pathogen-free animal facility.  CFZ (C8895; Sigma, St. Louis, MO) was 
dissolved in sesame oil (Shirakiku, Japan) to achieve a concentration of 3 mg/ml, which was 
mixed with Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) to produce a 
0.03% drug to powdered feed mix, which was orally administered ad libitum for up to eight 
weeks. A corresponding amount of sesame oil was mixed with chow for vehicle treatment 
(control). Mice were euthanized via carbon dioxide asphyxiation and exsanguination at the time 
of organ harvesting. 
Kupffer Cell Isolation. Kupffer cells were isolated from the livers of untreated mice as follows. 
After euthanasia, the heart was perfused with 10 mL of pre-cooled Hank’s buffered salt solution 
(HBSS) without magnesium or calcium, with 0.5 mM EGTA and 25 mM HEPES, pH adjusted to 
7.4. The portal vein was then injected with 10 mL of 1 mg/mL collagenase D (Worthington 
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Biochemical Corporation, Lakewood, NJ) in DMEM-low glucose (Life Technologies) with 15 
mM HEPES (Life Technologies). The liver was then removed, placed in a sterile petri dish, and 
minced into small (2-4 mm) pieces using a sterile scalpel blade. Collagenase solution (15 mL) 
was added, and the tissue was incubated (40 min, 37°C), with occasional pipetting to dissociate 
tissue. The suspension was then filtered through a 100 µm cell strainer (Fisher Scientific, 
Waltham, MA) and centrifuged (200 x g, 5 min). The supernatant was discarded, and the cells 
were resuspended in DMEM-low glucose (15 mL) with 15 mM HEPES, and centrifuged (200 x 
g, 5 min). This was repeated for two additional washes. After the final wash, macrophages were 
suspended in DMEM:F/12 (1:1) (Life Technologies) with 10% FBS and penicillin/streptomycin, 
were counted, and plated onto 12-well collagen-coated tissue culture plates and allowed to attach 
overnight (37ºC). The next day, cells were washed with DMEM:F/12 and immunofluorescent 
staining of F4/80 was performed to identify macrophages [32] from other cell types.  
Granuloma Isolation. Granulomas and granuloma macrophages were isolated from eight-week, 
CFZ-treated mice as follows. After euthanasia, the heart was perfused with 10 mL of pre-cooled 
Hank’s buffered salt solution (HBSS) without magnesium or calcium, with 0.5 mM EGTA and 
25 mM HEPES, pH adjusted to 7.4. The portal vein was then injected with 10 mL of 1 mg/mL 
collagenase D (Worthington Biochemical Corporation, Lakewood, NJ) in DMEM-low glucose 
(Life Technologies) with 15 mM HEPES (Life Technologies). The liver was then removed, 
placed in a sterile petri dish, and minced into small (2-4 mm) pieces using a sterile scalpel blade. 
Collagenase solution (15 mL) was added, and the tissue was incubated (40 min, 37°C), with 
occasional pipetting to dissociate tissue. Following tissue digestion, the granulomas remained 
intact and suspended within the Collagenase solution. The granulomas were then removed from 
suspension, imaged microscopically to confirm that they were granulomas (due to Cy5 
fluorescence, drug content, cellularity, and fibrous superstructure). The remaining suspension 
was then filtered through a 100 µm cell strainer (Fisher Scientific, Waltham, MA) and 
centrifuged (200 x g, 5 min). The supernatant was discarded, and the remaining granuloma 
macrophages were resuspended in DMEM-low glucose (15 mL) with 15 mM HEPES, and 
centrifuged (200 x g, 5 min). This was repeated for two additional washes. After the final wash, 
macrophages were suspended in DMEM:F/12 (1:1) (Life Technologies) with 10% FBS and 
penicillin/streptomycin, were counted, and plated onto 12-well collagen-coated tissue culture 
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plates and allowed to attach overnight (37ºC). The next day, cells were washed with 
DMEM:F/12 and immunofluorescent staining of F4/80 was performed to identify macrophages 
[32] from other cell types. 
Sample Preparation for Microscopy. Cryosectioning was carried out using a Leica 3050S 
Cryostat (Leica Biosystems Inc., Buffalo Grove, IL). Samples were sectioned to 5 µm. In 
preparation for cryosectioning, portions of the liver were removed, immediately submerged in 
OCT (Tissue-Tek catalog no. 4583; Sakura), and frozen (-80°C), or stored in 10% formalin and 
sent off for staining at the University of Michigan In-Vivo Animal Core for H&E, Picro-Sirius 
red, and Ki67 staining.  
Cell Staining. Following isolation and plating, Kupffer, granuloma macrophages and liver 
sections were stained for TFEB (Bethyl Laboratories, Montgomery, TX) LAMP1 (ThermoFisher 
Scientific, Waltham, MA ), and LC3 (Sigma-Aldrich, St. Louis, MO) at dilutions of 1:5000, 
1:500, and 1:200, respectively, following manufacturers immunofluorescence histochemistry 
protocols. Immunohistochemistry of F4/80 (Abcam, Cambridge, UK) was performed at a 1:500 
dilution. The secondary antibody was Alexa-Fluor 488 (1:500 dilution) (Abcam, Cambridge, 
UK). Immunohistochemistry of TUNEL (R&D Systems, Minneapolis, MN) was performed 
using manufacturer’s protocol for tissue cryosections.  After staining, cells or tissues were 
imaged using a Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, NY) and 
Nikon DS-U3 camera (Nikon Instruments) and Photometrics CoolSnap MYO camera system 
(Photometrics, Tucscon, AZ), under control of Nikon NIS-Elements AR Software (Nikon 
Instruments). Illumination for fluorescence imaging is generated using the X-Cite 120Q 
Widefield Fluorescence Microscope Excitation Light Source (Excelitas Technology, Waltham, 
MA).  
TUNEL Quantification. Following staining, liver cryosections were analyzed using a 
previously described fluorescence imaging set-up [33]. Using the nuclear (DAPI) signal to 
generate a mask in ImageJ [34] the mean fluorescence intensity of each nucleus was measured, 
and any nucleus that showed a mean fluorescence intensity above background fluorescence as 
determined using a negative control was classified as TUNEL (+). Granulomatous regions were 
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identified and analyzed separately because of of increased cellular granularity and nuclear 
content. 
Quantification of TFEB Activation. After staining, coverslips containing cell samples were 
mounted onto glass slides and imaged using the previously described imaging system [33]. To 
determine the ratio of nuclear to cytoplasmic TFEB staining, images masks were generated using 
the DAPI staining for the nucleus and a brightness adjusted TFEB staining to capture the entirety 
of the cytoplasm. The cytoplasmic fluorescence intensity was corrected by removing the 
fluorescence of the nucleus, and the ratio of total fluorescence signal between the nucleus and 
cytoplasm was then determined. Cells were classified as either xenobiotic sequestering or not on 
the basis of mean Cy5 fluorescence intensity using K-Means clustering, with clusters set to two 
using IBM SPSS Statistics version 24.0 (IBM Software, Armonk, New York). 
LC3 Quantification. After staining, coverslips containing cells were mounted onto glass slides 
and imaged using the previously described imaging system [33]. Cell area was measured by 
generating a region of interest (ROI) comprising the entirety of the cell. LC (+) inclusions were 
counted manually within the cell, and reported as LC3 (+) inclusions/cell area. Because the 
sample preparation resulted in dissolution of drug inclusions from within the cell, cells were 
classified as xenobiotic sequestering based on the presence of a drug cavity that the insoluble 
drug aggregates previously occupied. 
LAMP1 Quantification. After staining, coverslips containing cells were mounted onto glass 
slides and imaged using the previously described imaging system [33]. Cellular masks were 
generated using a brightness adjusted LAMP1 fluorescence image, and classified as xenobiotic 
sequestering based on the presence of the cavity previsouly occupied by the insoluble drug 
precipitates that accumulated within the cell. Mean LAMP1 fluorescence intensity per cell was 
reported. 
Ki67 Quantification. Sections stained for Ki67 were imaged using the brightfield imaging set-
up previously described [33]. For the CFZ-treated livers, granulomatous and non-granulomatous 
areas were determined based on the extent of cellular granularity, and analyzed separately. The 
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number of Ki67 nuclei was counted manually, and is reported as Ki67 (+) nuclei per tissue area 
following imaging across the tissue section at 10x magnification. 
TLR Staining Quantification. Using the imaging method described by Lin et al [35], the 
intensity of DAB staining in granulomatous and non-granulomatous areas was compared using a 
previously described brightfield microscopy set-up [33]. To quantify DAB stained images, a red 
filter (655 ± 30 nm), corresponding to the absorbance of the background tissue staining, and a 
blue filter (480 ± 30 nm), corresponding to the absorbance peak of DAB, were used. The density 
of DAB staining indicates TLR staining intensity. The DAB staining density was quantified 
using ImageJ, and is reported as % Tissue Area TLR2 (+).  
Analysis of Drug Distribution. Three livers from mice treated for 0, 2, 4, and 8 weeks were 
sectioned, and one section per liver was stained for F4/80 (Alexa 488; FITC channel). Ten (10x) 
magnification images were taken per section to capture the entirety of the liver section. The total 
F4/80 staining intensity captured by the FITC channel and the protonated, drug fluorescence 
intensity captured by the Cy5 channel was determined for each image. In sections with 
granulomas, the granuloma region was outlined based on the high-density pattern of nuclear 
granularity, and the total fluorescence intensities within the granuloma were measured in the 
various fluorescence channels. The relative percentage of signal intensity from the granulomas 
over the ten images was measured, and the percentage of total measured F4/80 and protonated 
drug fluorescence contributed from the granuloma was determined. Results are reported as the 
mean ± S.D of each of the three sections analyzed. 
Transmission Electron Microscopy. Organs were submerged in fixative and cut into small (<1 
mm) pieces. The organs were preserved in a glass vial with fixative and stored at 4°C. After 
three rinses with Sorensen's buffer (0.1 M), tissues were stained with 1% osmium tetroxide in 
Sorensen's buffer and washed three times in Sorensen's buffer. Dehydration was carried out with 
a graded ethanol-water series (50, 70, and 90% and two changes of 100%) for 15 min each. After 
washing with three changes of propylene oxide, the tissues were treated with Epon resin 
(Electron Microscopy Sciences) and polymerized at 60°C for 24 hours. The blocks were then 
sectioned to 70 nm using an ultramicrotome and mounted on a copper EM grid (Electron 
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Microscopy Sciences), which was then stained with uranyl acetate and lead citrate before 
imaging. Samples were imaged and analyzed at the National Center for Microscopy and Imaging 
Research (NCMIR) at the University of California, San Diego. 
Synthesis and Testing of CFZ Derivatives. A small library of R-iminophenazine analogs of 
CFZ was synthesized, as previously described [36]. For in vivo experiments, animal care was 
provided by the University of Michigan’s Unit for Laboratory Animal Medicine (ULAM), and 
the experimental protocol was approved by the Committee on Use and Care of Animals 
(Protocol PRO00005542). Mice (4 week old, male C57Bl6) were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and acclimatized for 1 week in a specific-pathogen-free animal 
facility.  The compound was dissolved in sesame oil (Shirakiku, Japan) to achieve a 
concentration of 3 mg/ml, which was mixed with Powdered Lab Diet 5001 (PMI International, 
Inc., St. Louis, MO) to produce a 0.03% drug to powdered feed mix, and orally administered ad 
libitum for 4 weeks. Following feeding, mice were euthanized via carbon dioxide asphyxiation 
and exsanguination. 
Macrophage Depletion Experiments. To deplete tissue macrophages, mice (n=3-4 per 
treatment group) were treated with liposomes containing either 7 mg/mL of clodronate or 
phosphate-buffered saline (PBS) (FormuMax Scientific Inc., Sunnyvale, CA). Liposomes were 
injected intraperitoneally, as previously described [37]. Mice were initially treated with 200 µL 
of liposomes followed by 100 µL injections twice per week to ensure continual macrophage 
depletion. Mice were fed CFZ (CFZ) or vehicle diet (untreated) continuously for a four week 
period. Following two weeks of feeding, liposome administration began for two weeks. The 
body temperature and weight of each mouse was measured daily, prior to injections. After 
completing four weeks of feeding and two weeks of liposome treatment, mice were euthanized 
and tissues were collected.  For histological analysis, formalin fixed tissue sections from the 
clodronate depletion experiments were stained for H&E and analyzed by a pathologist blinded to 
the experimental conditions at the University of Michigan In-Vitro Animal Core and scored for 
signs of inflammation and necrosis on a scale of 1-4. 
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Biochemical Analysis of CFZ in Tissues. Following treatment with CFZ for four weeks, mice 
were euthanized via CO2 asphyxiation, and organs removed and weighed. Tissue (20-30 mg) was 
homogenized in 500 µL of radioimmunoprecipitation assay buffer (Sigma) with added protease 
inhibitors (Halt protease and phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, 
Rockford, IL), and CFZ was extracted from tissue homogenate (350 µL) with three passes of 1 
mL of xylenes. The drug was then extracted from the xylene with three 1 mL passes of 9M 
sulfuric acid. The recovery yield was determined by spiking samples with a known concentration 
of CFZ. The concentration of CFZ or phenazine derivative present in the tissue was then 
determined using the plate reader assay (Biotek Synergy 2, Winooksi, VT) at wavelength 450 
nm, and background corrected at wavelength 750 nm, with the aid of a standard curve made with 
solutions of known concentration. 
Biochemical Analysis of Plasma Drug Concentrations. Blood was collected and centrifuged 
(7,000 × g, 5 min). The resulting serum was extracted with acetonitrile (90% extraction 
efficiency) for 10 min at 4°C with vortexing. After centrifugation (14,000 x g, 4°C, 10 min), the 
supernatant was injected into a Waters Acquity UPLC H-Class (Waters, Milford, MA) equipped 
with an Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm [inner diameter] by 100 mm; Waters, 
Milford, MA). Mobile phase A was 5 mM ammonium acetate, adjusted to pH 9.9 with 
ammonium hydroxide, and mobile phase B was acetonitrile. The flow rate was 0.35 ml/min, with 
a linear gradient from 50 to 100% phase B over 1.5 min, followed by holding at 100% for 1.5 
min, a return to 50% phase B, and then re-equilibration for 2.5 min. Standards were prepared by 
spiking untreated plasma samples with known amounts of CFZ, ranging from 0 to 15 µM. Peak 
area was determined using Empower 3 Software (Waters, Milford, MA).  
Cytokine Measurements. Following euthanasia, sections of liver or isolated granuloma were 
snap frozen and stored at -80ºC. Tissue (20-30 mg) or whole granuloma was homogenized in 500 
µL of radioimmunoprecipitation assay buffer (Sigma) with added protease inhibitors (Halt 
protease and phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, Rockford, IL). 
Protein concentration was determined using BCA assay (ThermoScientific), and samples were 
loaded using equivalent protein. The supernatants were assayed for IL-1RA by enzyme-linked 
immunosorbent assay (ELISA; Duoset; R&D Systems, Minneapolis, MN) in triplicate wells 
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according to the manufacturer's instructions. The cytokine concentrations were expressed 
nanograms per milligram of protein. 
Statistical Analysis. All data are expressed as means ± the standard deviations (SD). For 
multiple comparisons, statistical analyses were performed with one-way analysis of variance 
(ANOVA) and Tukey's post hoc comparisons. All statistical analyses were performed using IBM 
SPSS Statistics version 24.0 (IBM Software, Armonk, New York). P values less than 0.05 were 
considered statistically significant. 
8.4 Results 
8.4.1 Prolonged oral CFZ administration induces extensive liver remodeling 
First, we established the time course of granuloma formation in CFZ fed mice.  
Following short term treatment (<4 weeks), no granulomas or other signs of inflammation were 
observed in the livers (Figure 1a, 2 wk CFZ). However, as treatment progressed, drug aggregates 
began to form paralleling granuloma formation, with visible signs of local inflammation (Figure 
1a, 8 wk CFZ). The granulomas were primarily localized to areas near the portal vein, and were 
mainly comprised of immune cells, primarily macrophages (Figure 1a, Inset), surrounded by 
extensive collagen infiltration and fibrosis. Biochemical analysis of total drug concentration in 
granulomas revealed the extent of accumulation was comparable to that measured in the whole 
organ homogenates (30.3 ± 5.4 mg CFZ/ mg protein vs. 42.9 ± 23.0 mg CFZ/ mg protein, 
respectively; n=3 whole organ homogenates or isolated granulomas, p=0.36).  
Previously, CFZ was used as a probe of the mechanisms driving weak base protonation 
and precipitation inside cells [24, 26, 27]. CFZ undergoes a fluorescence shift as it forms an 
insoluble hydrochloride salt inside cells, emitting a distinct signal in the far-red, fluorescence 
wavelength [38]. In protonated form, it self-assembles into ordered aggregates (Crystal-Like 
Drug Inclusions, or “CLDIs”), which are also detectable based on their pronounced dichroism 
properties when illuminated with linearly polarized light [33]. This ability to microscopically 
monitor the distinct protonation and ordered states of the drug prompted us to ask whether CFZ 
differentially accumulated in granuloma-associated macrophages versus resting Kupffer cells, 
and whether the sequestration of the drug in granulomas had any relevance to the health status of 
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the liver. Remarkably, the preferential accumulation of the protonated form of the drug in 
granulomas was readily apparent,  evidenced by the red shifted fluorescence of the protonated 
form of the drug which can be observed through the standard Cy5 filter set of the epifluorescence 
microscope (640 nm excitation/670 nm emission) [38] (Figure 1b).  
Within these granulomas, the dramatically greater expression of markers of cellular 
proliferation and cell death provides evidence of extensive tissue remodeling (Figure 1c). 
Quantitative analysis revealed a significant increase in Ki67 (+) nuclei per tissue area within the 
granuloma when compared to the rest of the liver and the livers in untreated animals, with no 
difference observed between untreated and non-granulomatous regions (p<0.01, ANOVA, 
Tukey’s HSD; Figure SI. 18). Additionally, within the granulomas, there was a significant 
increase in the percentage of apoptotic cells per tissue area when compared to both non-
granulomatous tissue and untreated tissue, as detected by the TUNEL assay (p<0.01, ANOVA, 
Tukey’s HSD; Figure SI. 19). As expected from their role in immune surveillance, granulomas 
exhibited greater TLR9 staining as compared to both untreated livers and non-granulomatous 
regions (Figure 1e; Figure SI. 20).  
Proceeding to quantify the distribution of protonated drug in relation to granuloma-
associated macrophages and non-aggregated resting state Kupffer cells, tissue cryosections from 
three different animals fed 0, 2, 4, and 8 weeks were stained for the macrophage marker F4/80, 
and the percentage of F4/80 and Cy5 signal within non-granulomatous and granulomatous 
regions of the liver was determined from microscopic images. In both the untreated and 2 week 
CFZ fed animals, there was no indication of granuloma formation, and minimal signs of drug 
accumulation (Figure 2a,b), resulting in 100% of both the Cy5 and F4/80 signal being localized 
to non-granulomatous regions of the organ (Figure 2e). After 4 weeks of treatment, protonated 
drug (Cy5 signal) began to co-localize with F4/80 positive cells (Figure 2c). With increased drug 
loading, granulomas began to form and trap a greater fraction of the protonated drug (Figure 2c, 
yellow arrows) in relation to the fraction trapped by the Kupffer cells (Figure 2c, white arrow). 
At this stage, 10% of the total F4/80 signal within the liver was localized within the granuloma 
regions, accounting for nearly 10% of the total Cy5 signal (Figure 2e). As drug loading further 
increased between four to eight weeks of treatment, there was a significant increase in protonated 
drug (Cy5 signal) (p<0.01, ANOVA, Tukey’s HSD) and macrophages (p<0.001, ANOVA, 
Tukey’s HSD) within the granuloma. Since the far-red fluorescence is specific to the protonated, 
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hydrochloride form of CFZ [39], granuloma-associated macrophages preferentially sequestered 
the protonated form of the drug, while the unprotonated form of the drug is distributed mostly in 
non-aggregated resting state Kupffer cells and hepatocytes. 
8.4.2 Macrophages incorporated within granulomas exhibit elevated phagolysosomal 
activity 
Next, we determined how aggregation of macrophages as granulomas resulted in a 
differing macrophage phenotype from resting Kupffer cells. Due to the fact that CFZ becomes 
protonated in lysosomes, its lysosomal accumulation may result in activation of the transcription 
factor TFEB, which controls lysosomal biogenesis and is the master regulator of lysosomal 
proton pump (V-ATPase) expression [40]. Kupffer cells were isolated from the livers of 
untreated animals, and granulomas and granuloma-associated macrophages were isolated from 
the livers of 8-week CFZ treated animals, plated, and stained for TFEB, as well as LAMP1 and 
LC3, markers for lysosomes [41] and autophagic flux [42], respectively (Figure 3a). 
Significantly greater TFEB activation occurred within the Cy5-positive, granuloma-associated 
macrophage population, as compared to the Cy5-negative macrophage population, both obtained 
from the same drug treated animals (n=30 cells per group) (p<0.05, ANOVA, Tukey’s HSD) 
(Figure 3b). However, the level of TFEB activation did not significantly differ from the general 
population of Kupffer cells obtained from untreated animals.  Nevertheless, granuloma-
associated (Cy5-positive) macrophages also were significantly larger in size as compared to the 
general population of (Cy5-negative) drug-treated macrophages, and as compared to resting state 
Kupffer cells from untreated mice (p<0.05, ANOVA, Tukey’s HSD) (Figure 3c).  Similarly, 
granuloma-associated macrophages also showed increased lysosomal-associated membrane 
protein (LAMP1) (n=25-30 cells per group) (p<0.05, ANOVA, Tukey’s HSD) (Figure 3d) as 
well as an increase in LC3 (+) inclusions which is a marker of autophagy (p<0.05, ANOVA, 
Tukey’s HSD) (n=30 cells per group) (Figure 3e).  
8.4.3 Accumulation of insoluble hydrochloride salt precipitates induced granuloma 
formation 
To determine if granuloma formation was a general property of phenazine compounds, or 
specifically induced by the propensity of CFZ to precipitate out in the lysosomal 
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microenvironment, we tested Compound 568 (Figure 4a-d), a previously characterized derivative 
of CFZ that is less prone to precipitate in lysosomal pH and chloride concentrations [43]. 
Compound 568 has the same phenazine backbone as the CFZ molecule (Figure 4a), but it has an 
ethyl alcohol group instead of the isopropyl group of CFZ (Figure 4e). This compound has been 
previously studied side-by-side with CFZ, in terms of solubility [36], intracellular accumulation 
[36], hydrochloride salt formation [43], and skin pigmentation [43]. Through the small 
alterations in chemical structure, the solubility of the derivative in the presence of serum proteins 
is also greatly increased relative to CFZ [36]. Thus, following oral treatment of mice with 
Compound 568, the livers were analyzed (Figure 4b-d) and compared to those of their CFZ-
treated counterparts (Figure 4f-h).  
Remarkably, within the livers of mice treated with Compound 568, no granuloma 
formation was detected (Figure 4c). In the corresponding, CFZ-treated mice, granulomas were 
found throughout the organ, replete with CLDIs (Figure 4f, g, h). Rather than accumulating as 
insoluble aggregates, the fluorescence from Compound 568 was mostly localized within the bile 
canaliculi of the liver (Figure 4d). This indicated that the hepatocytes are able to actively 
eliminate Compound 568 from the organism by hepatobiliary clearance. Consistent with the 
reduced liver accumulation and increased hepatobiliary clearance, the measured liver  
concentrations of Compound 568 were 10-fold lower as compared to those of CFZ (0.27 ± 0.05 
mg/g tissue vs. 2 mg/g tissue [43]). Mice treated with compound 568 also had 10-fold lower 
serum concentrations (0.77 ±0.12 µM), compared those treated with CFZ [26].  
8.4.4 Drug sequestration in granulomas reduces toxic effects of CFZ 
To obtain additional insights into the organization of granulomas, livers of CFZ treated 
mice were subjected to electron microscopy (Figure 5, Supplemental Figure 4).  Upon close 
examination (Figure SI. 21, GM) the membrane-bound, CLDIs can be observed (Supplemental 
Figure 4a, CLDI). In a region proximal to the macrophage described in supplemental figure 4, a 
neutrophil (Supplemental Figure 4, N) is present. While these cells are among the so-called 
“professional phagocytes” within the body, no CLDIs are observed in this particular cell, and 
tend to be found within tissue macrophages, lending credence to the hypothesis that CLDI 
stabilization is a macrophage-specific phenomenon. The collagen fibers (Figure SI. 21, CF) that 
make up the extracellular space of the granuloma are also visible, wrapping around the cell. One 
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striking feature of the granuloma-associated macrophages was that there are numerous, dark 
deformed inclusions throughout the cytoplasm that resemble damaged or depolarized 
mitochondria (Figure SI. 21, M). Previously, CFZ has been shown to directly damage 
mitochondria via depolarization of the mitochondrial membrane, resulting in the accumulation of 
similar structures throughout the cytoplasm [27, 44].  
Nevertheless, hepatocytes surrounded the granulomas, and the differences between the 
two cell types were quite striking. In the region between a small granuloma and the surrounding 
non-granulomatous region of the liver (Figure 5), it was evident that hepatocytes (HC) possessed 
intact mitochondria with no signs of drug induced alterations (Figure 5a). The border region 
between the granuloma and surrounding hepatocytes highlighted the differences between the two 
cell types (Figure 5b), with granuloma-associated macrophages containing numerous damaged 
mitochondria (Figure 5b, M). The region in between the granuloma and hepatocyte was also 
comprised of numerous membrane-bound extracellular vesicles (Figure 5b, V), typical of 
hepatocyte-monocyte and hepatocyte-hepatocyte communication within the liver. 
Proceeding to probe the role of granulomas in relation to drug accumulation and 
associated toxicity, we chemically depleted the liver macrophages of mice following two weeks 
of treatment with CFZ, and continuously depleted the macrophages for an additional two weeks 
of CFZ treatment. The clodronate liposome-injected, CFZ-treated mice weighed an average of 
nearly 5 grams less than the other treatment groups (p<0.001, ANOVA, Tukey’s HSD) (Figure 
6a) and had a significantly lower body temperature (Figure 6b) (p<0.05, ANOVA, Tukey’s 
HSD) (Table 1) during the last week of liposome treatment. On the final day of the experiment, 
the clodronate liposome-injected, CFZ-treated mice also weighed significantly less (Figure 6c) 
and had a significantly reduced body temperature (Figure 6d) (p<0.001, ANOVA, Tukey’s HSD) 
compared to all other treatment groups, with no significant difference in body mass or body 
temperature among the other experimental groups (p>0.05, ANOVA, Tukey’s HSD). Taken 
together, this points to a deleterious and synergistic combination of macrophage reduction and 
drug therapy, resulting in systemic toxicity [45]. Upon gross examination, (Figure 6e) the livers 
of the PBS liposome-injected, untreated mice showed little external signs of inflammation, and 
appeared normal. Similarly, the livers of PBS liposome-injected, CFZ-treated mice displayed the 
characteristic deep red pigmentation typical of CFZ accumulation [26] with no outward signs of 
tissue damage. In the livers of clodronate liposome-injected, untreated mice there were some 
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minor sites of necrosis and inflammation noted on the liver due to clodronate treatment, but 
overall, did not appear significantly affected. In contrast to this, the livers from the clodronate 
liposome-injected, CFZ-treated did not exhibit signs of extensive protonated CFZ accumulation, 
and showed signs of pronounced inflammation and tissue necrosis (Figure 6e). There were minor 
increases in inflammation within the PBS liposome-CFZ treatment group detected upon H&E 
staining, localized to the site of granulomas, while the clodronate liposome-CFZ treatment 
groups showed signs of tissue necrosis and increased inflammation, primarily localized to areas 
surrounding the central vein (Figure 6f), which is typically surrounded by perivascular 
granulomas.  
Macrophage depletion by clodronate in the liver was quantified using F4/80 staining, 
revealing a mean (±S.D.) 42 (±15)% reduction in macrophages in livers of CFZ-treated mice, as 
compared to the PBS liposome-injected, CFZ-treated mice (p<0.05, ANOVA, Tukey’s HSD) 
(Figure SI. 24). This reduction in macrophages was accompanied by a mean (±S.D.) reduction of 
32 (± 6) % in the amount of protonated drug (Cy5 signal) compared to that of the PBS liposome 
injected animals of the CFZ-treated group (p<0.05, ANOVA, Tukey’s HSD; Figure SI. 25). Due 
to the reduction in macrophages, less CFZ is able to become trapped within macrophages and 
granulomas in its relatively more tolerated protonated form, resulting in increased exposure to 
the cytotoxic soluble form of CFZ, harming the liver and leading to systemic drug-induced 
toxicity.  
In addition to the 30% reduction in granuloma size relative to the PBS liposome-injected 
counterparts (p<0.05, Student’s unpaired two-tailed t-test) the cellular turnover within clodronate 
liposome-injected granulomas was also significantly reduced. The frequency of apoptotic cells in 
the granulomas of the liposomal clodronate treated animals was also reduced (p<0.05, ANOVA, 
Tukey’s HSD; Figure 6g; Figure SI. 22). However, some of the cells surrounding the granulomas 
displayed increased frequency of apoptotic cells, which may correspond to regions of acute 
necrosis observed in the H&E staining (Figure 6f). Indicating that the reduced size and drug 
sequestering capacity associated with clodronate treatment also led to a less differentiated 
granuloma phenotype, the reduction in apoptosis in the clodronate-treated granulomas was 
paralleled by a reduction in the number of cells undergoing DNA synthesis (detected through 
Ki67 staining) as compared to control, PBS liposome-injected animals. The PBS-liposome 
injected mice that were also CFZ-treated  showed significantly higher Ki67 (+) nuclei/tissue area 
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compared to all other non-granulomatous regions (p<0.001, ANOVA, Tukey’s HSD; Figure 6h, 
Figure SI. 23). While the granulomas of the clodronate liposome-injected, CFZ-treated mice also 
showed elevated Ki67 nuclei/tissue area compared to all other non-granulomatous regions, there 
was reduced Ki67 staining when compared to the granulomas of the PBS liposome injected, 
CFZ-treated mice. These results are consistent with a greater rate of cellular turnover over in 
drug sequestering, “functional” granulomas, as compared to the smaller granulomas of the 
clodronate-treated livers.  
Lastly, we determined how clodronate liposomes influenced the levels of the anti-
inflammatory cytokine IL-1RA [24], which was found to be upregulated following a prolonged 
(8 week) treatment with CFZ. Consistent with the previously reported study, the livers of the 
PBS liposome-injected, CFZ-treated mice showed significantly elevated levels of IL-1RA 
(Figure 7b; p<0.05, ANOVA, Tukey’s HSD). However, in the clodronate liposome-injected, 
CFZ-treated group, IL-1RA levels were similar to that of the untreated control groups (p>0.05, 
ANOVA, Tukey’s HSD). To further determine if the granuloma macrophages themselves were 
responsible for the increased IL-1RA production in CFZ-treated mice, granulomas were isolated 
from 8 week-CFZ fed livers and compared with whole-tissue homogenates of 8-week CFZ fed 
livers. The levels of IL-1RA production between the granulomas and whole-organ homogenates 
were both significantly higher as compared to the livers of control, untreated mice (p<0.05, 
ANOVA, Tukey’s HSD) (Figure 7c), although within treated mice, the levels of IL-1RA present 
in whole-organ tissue homogenates were not significantly different from that present in the 
granulomas (p=0.963, ANOVA, Tukey’s HSD).  
8.5 Discussion 
Many adverse drug reactions (ADRs) are associated with hepatotoxicity [46], which is 
generally thought to be related to the degradation or metabolic activation of drug molecules into 
reactive intermediates. For example, acetaminophen overdose depletes glucuronide, leading to a 
secondary metabolism pathway which produces a hepatotoxic acetaminophen metabolite that 
causes liver damage [47]. Because the liver is the primary site of drug metabolism within the 
body, a multitude of drugs exert idiosyncratic, hepatotoxic side effects. We therefore postulated 
that drug-induced liver granulomas may be a toxicity mechanism, downstream of immune cell-
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mediated inflammatory reactions that have the potential to interfere with liver structure and 
function.  
Normally, liver granulomas are triggered by bacteria or other pathogens and they are 
typically thought of as sites of active infection [9]. This made us wonder about how drugs may 
trigger granuloma formation, and the relationship between drug-induced granulomas and 
hepatotoxicity. Using CFZ as a model drug, we discovered that granulomas specifically 
sequester large amounts of CFZ in a protonated, insoluble form that is membrane impermeant 
and is therefore more readily compartmentalized and isolated from the rest of the liver as 
compared to the unprotonated free base form of the drug [28].  Additional studies with a closely 
related phenazine derivative of CFZ that is less prone to precipitating out in the lysosomal pH 
and chloride microenvironment supports the active role of granulomas in weak base ion trapping 
and sequestration of insoluble hydrochloride salt form of drugs. Furthermore, chemical depletion 
of macrophages confirmed the ability of granuloma-associated macrophages to protonate CFZ 
and sequester it from hepatocytes, serving as a toxicity-reducing mechanism within the liver and 
systemically.  
Interestingly, there are many other drugs on the market, such as methyldopa [48] and 
phenylbutazone [49], that are known to induce the formation of hepatic granulomas.  Based on 
our observations with CFZ, we hypothesize that granulomas act as integrated, dynamic “super-
structures” or “organoids” comprised of specialized macrophages which effectively respond to 
xenobiotics that form insoluble complexes within the liver. Granuloma-associated macrophages 
were distinctively different from the non-aggregated, resting state Kupffer cells of the liver, 
based on their expression of various phenotypic markers associated with an expanded 
endolysosomal compartment, as well as their high rates of apoptosis and expression of Ki67, and 
activation of lysosomal biogenesis pathways.  Xenobiotic sequestering granuloma-associated 
macrophages are embedded in a collagenous matrix, effectively isolating the drug from the 
neighboring hepatocytes. Conversely, non-aggregated, resting state Kupffer cells are primarily 
surrounded by hepatocytes or endothelial cells, and are localized to the sinusoidal regions of the 
organ.  
Of noteworthy significance, granuloma formation appeared as a highly specific response 
of macrophages to the formation of insoluble precipitates by the protonated form of CFZ in the 
presence of high chloride concentrations like that which occur in lysosomes.  By slightly altering 
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the chemical structure of CFZ, the formation of granulomas was inhibited, leading to increased 
biliary excretion (Figure 4d), and therefore enhancing clearance and reducing net accumulation 
within the liver, as well as reducing overall exposure.   
Macrophage depletion experiments provided additional evidence for the active role of 
granuloma-associated macrophages in CFZ sequestration and hepatoprotection. Treatment with 
liposomal clodronate on its own induced some signs of liver damage upon gross examination, 
and more apparent necrosis and inflammation was observed within the liposome-treated and 
drug-fed mouse group, resulting in necrosis in entire sections of liver lobes, originating at the 
periphery of the liver. Additionally, liposomal clodronate treatment, combined with drug therapy 
led to a reduction in body weight and temperature that was not observed in the clodronate-
untreated group, eliminating the possibility that this necrosis was a clodronate-specific 
phenomenon, and may be a drug-induced toxicity phenomenon. Treatment of mice with 
liposomal clodronate reduced CFZ-induced granuloma size as well as the sequestration of the 
protonated, insoluble (membrane-impermeant) form of the drug. The larger granulomas within 
the PBS-CFZ treated livers also showed higher cellular turnover than the clodronate-CFZ livers 
(Supplemental Figure 6).  This increased turnover and apoptosis within the functional granuloma 
further delineates the differences between the granuloma-associated macrophages and non-
aggregated resting state Kupffer cells within the liver, which is reflected in the changes in the 
cellular and molecular architecture of the granulomas, clearly observed in the TEMs (Figure 5, 
Supplemental Figure 4). Lastly, treatment with liposomal clodronate completely inhibited IL-
1RA production to levels of untreated animals, suggesting granulomas are actively producing 
large amounts of IL-1RA, which is a key anti-inflammatory mediator. 
As a transcriptional regulatory mechanism mediating the observed phenotypic changes, 
TFEB activation emerged as a likely candidate (Figure 3b). TFEB activation can explain the 
expanded endolysosomal compartment of granuloma-associated macrophages, as compared to 
both drug-exposed and untreated resting state Kupffer cells. It can also explain the increased 
LAMP1 and LC-3 staining (Figure 3e). The activation of TFEB can promote lysosomal and 
membrane biogenesis, as well as increases expression of the lysosomal acidification mechanism, 
namely vacuolar-type proton ATP-ase [50, 51]. Of noteworthy significance, elevated TFEB 
activation within the xenobiotic sequestering granuloma-associated macrophages, but not within 
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the drug-treated non-aggregated Kupffer cells also implicates TFEB as a hepatoprotective, 
xenobiotic response pathway.  
Of noteworthy significance, TFEB activation and its role in cell survival has been mostly 
studied as it relates to cancer cells, where it is negatively associated with the survival of the 
organism [52, 53]. TFEB’s role in cancer cell survival may be related to the increase in 
lysosomal and autophagic activity within the cell. Many chemotherapeutics are weakly basic, 
amphiphilic lysosomotropic compounds such as doxorubicin, which has reduced efficacy in 
human cancer cells following TFEB activation and increased autophagy [54]. In a study 
performed using different hydrophobic, weakly basic anti-cancer agents, these drugs became 
trapped within lysosomes, and thus, induced TFEB activation. This led to increased lysosomal 
exocytosis as a cytoprotective mechanism to remove the drug from the cell, which may be a 
mechanism of chemoresistance to cancer drugs [55]. Similarly, the extent to which granuloma 
formation protects the liver from drug induced toxicity, our results point to a natural, protective 
role of TFEB activation in the protection of the organ and ultimately to the survival of the host.   
8.6 Conclusions 
To summarize, accompanying the massive bioaccumulation of weakly basic drug, the 
liver undergoes extensive remodeling through the development of large granulomas comprised 
of macrophages with distinctly different properties from neighboring non-aggregated 
macrophages.  Granulomas were structurally and functionally distinct structures from the 
surrounding tissue, and effectively function as an organ within an organ – an “organoid”- helping 
to limit the exposure of soluble drug to hepatocytes, reducing hepatic damage. Granuloma-
associated macrophages restricted the cytotoxic activity of the drug by sequestering the drug as 
membrane-impermeant insoluble aggregates, while shielding hepatocytes from the free base 
form of the drug by forming multiple layers of membranes and collagenous matrices around 
themselves. As a potential master regulator of xenobiotic sequestering macrophages of drug 
induced granulomas, TFEB activation can explain the expanded lysosomal compartment, 
membrane turnover and acidification mechanisms that are involved in stabilizing the insoluble, 
intracellular aggregates formed by the protonated, hydrochloride salt form of the drug. 
Confirming the protective role of hepatic granulomas, inhibition of granuloma formation reduced 
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hepatic IL-1RA production, and led to acute necrosis within the liver and systemic indications of 
drug-toxicity. 
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8.8 Figures 
 
 
Figure 8-1 CFZ treatment remodels the liver through granuloma formation  
 
A) Increased CFZ treatment results in formation of large granulomas throughout the organ comprised of immune 
cells. B) CLDIs accumulate extensively within the granuloma, and retain their intrinsic Cy5 fluorescence. C) 
Granulomatous areas of the liver exhibit higher Ki67 activation when compared to both non-granulomatous areas 
and untreated livers. D) Granulomatous areas of CFZ treated livers show elevated apoptotic nuclei detected via 
TUNEL assay when compared to both non-granulomatous areas and untreated livers. E) CLDI accumulation in 
granulomas results in elevated TLR2 expression within the granuloma, but not the surrounding tissue. Scale bar is 
50 um 
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Figure 8-2 Increased drug loading results in macrophages becoming concentrated within granulomas, and increased 
drug accumulation mainly within the granuloma.  
 
A-D) Untreated, 2, 4 and 8 week immunofluorescence images of liver cryosections stained for the macrophage 
marker F4/80 (green) and CLDI fluorescence (red). E) The total percentage of F4/80 or Cy5 fluorescence signal 
coming from the granuloma compared to the non-granulomatous tissue area was determined, revealing a significant 
increase from four to eight weeks of treatment. Yellow arrows point to granuloma macrophages loaded with CLDIs, 
while white arrows point to Kupffer cells with CLDIs. (n=3 animals per time point, 10 images per liver 
cryosections) (*=p<0.01, ANOVA, Tukey’s HSD, #=p<0.001, ANOVA, Tukey’s HSD). 
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Figure 8-3 Granuloma macrophages are phenotypically different from both untreated and drug treated macrophages  
 
A) Images showing untreated Kupffer cells, drug-treated macrophages and granuloma macrophages isolated from 8 
week CFZ-treated liver stained for TFEB, LAMP1 and LC3. B) Granuloma macrophages show significantly 
elevated TFEB translocation to nucleus compared to untreated and drug-treated macrophages. C) Granuloma 
macrophages are significantly larger than their untreated and drug-treated macrophage counterparts. D) Granuloma 
macrophages show significantly elevated expression of LAMP1 within the cell, indicating increased lysosomal 
content within the cell. E) Granuloma macrophages show increased punctate LC3 staining within the cytoplasm of 
the cell compared to untreated and drug-treated macrophages, indicating increased autophagic flux within the cell, 
which may be necessary to form new membranes to trap the CLDI. Scale bar is 15 um. (n=30-35 cells per group, 
*=p<0.05, ANOVA, Tukey’s HSD). 
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Figure 8-4: The accumulation of insoluble aggregates and granuloma formation is dependent on the isopropyl group 
in the CFZ molecule 
 
A) The derivative 568 replaces the isopropyl group with an ethyl alcohol, limiting its ability to form insoluble 
aggregates within the liver and does not induce granulomas as is seen in CFZ. B) H&E staining of a liver from a 
mouse treated with 568 shows no signs of granuloma formation. Scale bar is 200 um. C) The fluorescence of 
derivative 568 can be detected in the bile canaliculi of the liver, showing that the liver may be actively removing the 
chemical and eliminating it from the body. Scale bar is 200 um. D) Zoomed in region of the bile canaliculi showing 
the fluorescence of derivative 568. Scale bar is 50 um. E) Chemical structure of CFZ. F) H&E staining of CFZ 
treated liver shows extensive granuloma formation. G) CFZ treatment leads to insoluble aggregate and 
hydrochloride salt accumulation. H) Zoomed in region of CLDIs within the liver. Scale bar is 50 um. Note: 
Brightness for derivative 568 fluorescence images have been elevated to show biliary localization of drug. 
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Figure 8-5 TEM of 8-week CFZ treated liver showing granuloma surrounded by hepatocytes  
 
A) A healthy hepatocyte located on the periphery of the granuloma shows normal mitochondria unaffected by the 
drug. B) Border region between the granuloma and healthy liver tissue. The granuloma macrophage is loaded with 
CLDIs, and as a result, shows damaged mitochondria. In between the granuloma macrophage is region of cellular 
debris, which may limit exposure of toxic drug to the tissue. The neighboring hepatocyte shows healthy 
mitochondria. (M: Mitochondria, HN: Hepatocyte nucleus, HC: Hepatocyte, D: Debris, CLDI: Crystal-Like Drug 
Inclusion) 
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Figure 8-6 Chemical depletion of macrophages leads to signs of toxicity in animals fed CFZ.  
A, B) Daily mouse body mass and temperature taken during final week of liposome injection. C, D) Box plot of 
mouse body weight and temperature taken on final day of experiment. (*=p<0.001, ANOVA, Tukey’s HSD). E) 
Macroscopic images of livers removed from mice treated with PBS or clodronate liposomes, fed either a control or 
supplemented diet. The clodronate CFZ fed livers showed signs of necrosis upon gross examination. F) H&E 
staining of liver sections from macrophage-depleted and healthy animals. The clodronate-CFZ treated livers showed 
signs of necrosis radiating outward from the hepatic portal vein, while the PBS-CFZ treated mice only showed 
minor inflammation localized to the granulomatous areas. Scale bar is 100 um. G) TUNEL staining of liver 
cryosections from clodronate experiments. Apoptosis in the PBS-CFZ treated groups was localized primarily to the 
granulomatous regions, while the necrotic, clodronate-CFZ livers showed reduced apoptosis within the granuloma 
and elevated apoptosis in small, localized regions of the liver, consistent with the previously observed necrosis. 
Scale bar is 25 um. H) Immuno-histochemical staining for cellular replication marker Ki67 within liver sections. 
Granulomatous regions of PBS-CFZ treated livers showed significantly elevated cellular replication compared to the 
granulomas of the clodronate-CFZ treated livers. Scale bar is 200 um. 
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Treatment Average Body Mass (g) (n=3-4 
mice per group) 
Average Body Temperature (ºC) 
(n=3-4 mice per group) 
PBS + Control Diet 26.3 ± 1.4 34.2 ± 0.5 
PBS + CFZ Diet 25.7 ± 0.8 34.3 ± 0.3 
Clodronate + Control Diet 27.4 ± 1.1 34.4 ± 0.6 
Clodronate + CFZ Diet 21.2 ± 1.4* 33.1 ± 0.9* 
 
Table 8-1 Chemical depletion of macrophages and drug treatment leads to indications of failing health 
 
Mice treated with clodronate and fed a CFZ-supplemented diet showed significantly reduced body weight and body 
temperature, two classic markers of drug toxicity. (*=p<0.05, ANOVA, Tukey’s HSD). 
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Figure 8-7 Formation of granulomas is necessary for the increased IL-1RA production within the liver of CFZ-
treated mice 
A) Liver cryosections of PBS or clodronate treated mice fed a control diet or CFZ-supplemented diet stained for 
F4/80 (green) and showing CLDI fluorescence. Treatment with clodronate reduces hepatic macrophages, resulting in 
reduced granuloma size and CLDI accumulation within the granuloma. B) IL-1RA production is inhibited within 
clodronate-CFZ treated mice, while it is significantly elevated in the PBS-CFZ treatment group. C) The granulomas 
which form ultimately are responsible for the production of IL-1RA, producing similar levels of IL-1RA to whole-
organ homogenates. Scale bar is 50 um. (*=p<0.05, ANOVA, Tukey’s HSD). 
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This manuscript is currently in preparation, and supplemental figures are available in Appendix 
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Chapter 9 
Conclusions 
9.1 Macrophages Actively Stabilize Crystal-Like Drug Inclusions 
 The macrophage has unique properties that allow it to both accumulate and stabilize the 
crystal-like drug inclusions (CLDIs) that result from prolonged clofazimine administration. The 
active stabilization of CLDIs by the macrophage was discovered after revealing the changes that 
the cell and organs both undergo to increased drug treatment and the subsequent increase in 
CLDI accumulation. As the length of treatment progresses, the macrophage population within 
the lung, liver, and spleen expands significantly. This larger macrophage population increases 
the amount of drug that can be sequestered and stabilized as a CLDI within these organs. As a 
result of the increased macrophage population, the amount of drug found in the liver, lung, and 
spleen increasing massively from weeks 3 to 8, when the drug shifts from being primarily found 
in its soluble form to its insoluble form[1, 2]. During this time, the macrophage also actively 
altered its internal membrane to maximize drug loading, while at the same time, minimizing the 
total required surface area of membrane necessary to stabilize the crystal. This was observed in 
alveolar macrophages, which acquired the drug in the form of small volume, spherical vesicles at 
early stages of treatment (<4 weeks) [3]. As this is not energy efficient [4], the cell forms larger, 
polyhedral crystals, occupying more cellular volume but allowing for increased intracellular drug 
loading. 
The alteration in membrane arrangement the macrophage undergoes does not come 
without a cost to the cell. Due to the stress put upon the lysosome brought about by drug trapping 
[5, 6], the macrophage activates a key nuclear transcription factor, TFEB. Upon instances of 
lysosomal or nutrient stress, TFEB translocates from the cytosol to the nucleus, where it 
increases the expression of a variety of genes, those most critical for CLDI stabilization being 
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related to lysosomal biogenesis and membrane formation [7, 8]. Activation of TFEB within 
CLDI-containing macrophages resulted in increased cell size, lysosomal content, and autophagic 
flux, all pointing to cellular adaptations brought about to stabilize the CLDI. Increasing 
autophagic flux allows for degradation of cellular material, increasing the ability to form 
lysosomal membranes which trap and stabilize CLDIs, all within a cell that has increased in size 
to trap and stabilize more drug. As more lysosomes form, increased soluble drug can potentially 
become ion-trapped [9], leading to increased drug accumulation and subsequent CLDI 
stabilization. The increased membrane production also allows these cells to increase in size, 
increasing their capacity for CLDI accumulation. 
Additionally, the specificity of the macrophage as the active stabilizer of clofazimine 
biocrystals was confirmed following the chemical depletion of these cells in the liver, spleen, and 
peritoneal cavity. Without macrophages in the liver and spleen, CLDI accumulation (detected as 
a reduced ratio between the intrinsic far-red fluorescence of the CLDI [10] and the nuclear 
signal) was significantly reduced. The inability to actively stabilize the CLDI within the 
macrophage reduced the total drug that became trapped within those organs, indicating that both 
CLDI stabilization and the accumulation of drug in general is a macrophage-specific 
phenomenon. Finally, when macrophages of the peritoneal cavity were removed and isolated 
biocrystals were introduced, there was a significant reduction in the estimated half-life of the 
CLDI within the peritoneum when compared to the group with a healthy peritoneal macrophage 
population. Macrophages are not the only cell present in the peritoneum, with B- and T-cells also 
residing within the cavity [11]. The depletion method used only affects highly phagocytic cells, 
and since these cells are not one of the so-called “professional phagocytes” of the body like the 
macrophage [12], they remain within the cavity. However, their endolysosomal system is not 
equipped to phagocytose the CLDI and stabilize it within the endolysosomal compartment, 
leading to the CLDI remaining in the relatively more basic extracellular environment, inducing 
solubilization and CLDI degradation; this points to an active and specific role that the 
macrophage plays in CLDI accumulation and stabilization.  
9.2 Multi-parameter Microscopy and Drug Analysis 
 The development and refinement of a multi-parameter microscopy imaging and 
acquisition strategy as it relates to intracellular drug accumulation has the potential to be a useful 
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tool in drug discovery and development, especially in the early stages. Here, we applied this 
technique to link changes in the protonation state (far-red fluorescence [10]), cellular 
accumulation (absorbance), and the organization of drug (linear diattenuation/dichroism) within 
the cell. As it relates to general drug development, microscopic analysis, and more specifically, 
polarized light microscopy, is a commonly used high throughput technique to study 
solubilization and precipitation of compounds in vitro [13]. However, multi-parameter imaging 
that combines two or more types of imaging modalities is becoming more and more common in 
drug development. For instance, flow cytometry to study phenotypic changes to individual cells, 
rather than to entire populations of cells within a cell culture vessel can be used to elucidate 
specific effects to a certain cell type following drug treatment [14].  
The multi-parameter imaging and acquisition strategy that was developed can be used to 
study both in vitro accumulation and precipitation of drugs in cultured cells, and to study 
changes to specific populations of live cells following in vivo drug treatment. To this end, 
studying the cellular pharmacokinetics of a therapeutic is becoming increasingly important in 
pre-clinical drug development and lead selection [15]. Since the efficacy of a drug is highly 
dependent on its ability to concentrate itself at the proper site of action [16], be it a cellular 
receptor or organelle, it is vital in the early stages of drug development to determine exactly 
where a drug molecule is concentrating once it enters a cell at a precise level. Currently, single-
cell pharmacokinetic studies are performed using fluorescence [17] and fluorescence anisotropy 
[18] microscopy to study the localization of drug molecules within subcellular compartments at 
the early stages of drug development to aid in deciding which target compounds to further 
develop. Combining linear diattenuation anisotropy and absorbance microscopy with more 
commonly applied techniques (i.e. fluorescence and fluorescence anisotropy) has the potential to 
improve the power of these analyses. For example, linear diattenuation anisotropy is highly 
specific to even the most minor changes in molecular order present in a sample [19]. Given this, 
certain drugs, particularly those that are lipophilic, will intercalate within lipid membranes 
intracellularly, resulting in an altered membrane structure and phospholipidosis [20, 21], which 
can potentially be detected as an increased intracellular linear diattenuation signal. 
One other powerful application of this analytical polarization imaging method involves 
the ability to rapidly distinguish one polymorphic form of a chemical entity from another. 
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Simply put, polymorphism occurs when a compound has multiple possible molecular 
arrangements of molecules in a solid phase [22], resulting in different crystal structures. In the 
case of clofazimine, the drug undergoes a polymorphic change during bioaccumulation, 
changing its underlying crystal structure, which is detectable as both a marked increase in far-red 
fluorescence and linear diattenuation [3, 10]. Many drugs that are currently being brought to the 
market are poorly soluble chemical entities [23], and one method used to improve solubility is 
formulating the proper crystal polymorph of the drug [24].  It is estimated that over 50% of 
therapeutic agents show some form of polymorphism [25] and ensuring that the formulation that 
is being delivered to the patient contains the proper crystal form of the drug is vital in ensuring 
that the drug product works as intended.  
The dissolution rate and solubility of a formulation can be significantly affected if the 
active pharmaceutical ingredient is not in the proper polymorphic form, or if the polymorph 
changes during formulation, manufacturing, storage, and administration; the bioavailability and 
efficacy of the drug product can be altered significantly following a change in the polymorph in 
the formulation, resulting in reduced therapeutic benefits [22, 24-26]. To this end, ensuring that 
the patient is receiving the correct form of the active pharmaceutical ingredient when taking their 
medications is vital. Currently, a variety of techniques are utilized to study the polymorphic form 
present in drug formulations, including infrared spectroscopy, nuclear magnetic resonance, and 
x-ray diffraction [22]. The “gold-standard” for analysis of polymorphs is single crystal x-ray 
diffraction, but preparation of a crystal that is appropriate for analysis can be difficult [27], 
making it challenging to study polymorph stability in real-time. Multi-parameter microscopy 
combining polarization microscopy with other imaging modalities such as fluorescence can 
potentially be utilized to analyze polymorph stability in vitro under a variety of conditions. 
Nonlinear optical stokes ellipsometric microscopy has been previously used to differentiate 
between two polymorphic forms of d-mannitol (orthorhombic and monoclinic), a common 
excipient in pharmaceutical formulations [28]. Similarly, using the multi-parameter imaging 
system developed here, the two polymorphic forms of clofazimine can be readily discriminated. 
Using quantitative multi-parameter imaging, stability of polymorphic forms of drug within a 
formulation can be studied in real-time under a variety of conditions. Additionally, insoluble 
polymorphs can be directly incubated with cells and their stability under intracellular conditions 
can be monitored in real time. 
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9.3 Macrophage Stabilization of Intracellular Drug Biocrystals and Potential for 
Therapeutic Development 
Development of poorly soluble, acidic and basic drugs into a workable drug product 
presents a number of challenges to formulation scientists, leading to novel strategies such as salt 
formation and taking advantage of the acid-base chemistry [29-31]. Instead of attempting to 
deliver the drug as a form that must solubilize to reach the site of action, why not formulate 
crystalline forms of the drug and use that as a drug product that can deliver the therapeutic to a 
specific site of action? Specific targeting of macrophages is a hot topic in drug design currently, 
in particular, for cancer therapeutics and other immunomodulatory therapies [32-35] as a strategy 
to minimize off-target effects and toxicity. In the work presented in the previous chapters, it was 
shown that macrophages actively promote the stabilization and accumulation of drug biocrystals, 
due in large part to their increased activation of TFEB, a master regulator of lysosome 
biogenesis, among other critical cellular functions related to the endolysosomal system [7]. Due 
to the macrophage’s increased expression of lysosomal acidification mechanisms, particularly 
the vacuolar-type proton ATP-ase (V-ATPase) [36], these cells are also equipped to stabilize 
biocrystals introduced to the body. Interestingly, phagocytosis of extracellular CLDIs in vitro 
resulted in increased production of the anti-inflammatory cytokine IL-1RA and reduced 
production of the pro-inflammatory TNF-α [37]. While it is not known if this occurs in vivo, 
biocrystal accumulation within the liver resulted in IL-1RA upregulation [38], so it is not 
unreasonable to believe that formulations of insoluble clofazimine biocrystals show the same 
immunomodulatory effects. 
Additionally, the discovery of the particular subset of liver macrophages, the xenobiotic 
sequestering macrophage and the adaptations that they undergo shows the potential for why 
these cells may be a future avenue for insoluble drug targeted therapies. Following loading with 
biocrystals, the macrophage adjusted its internal membrane arrangement to maximize loading 
while minimizing the volume that the drug cargo occupied. By loading the cell with an insoluble 
aggregate, rather than just through exposure to the soluble form of the drug, the cell also alters its 
endolysosomal system through activation of TFEB. This induces production of lysosomes within 
the cell [7], and subsequently, expression of lysosomal acidification mechanisms  increases [39], 
actively promoting the stability of these crystals within this subset of cells. The macrophages’ 
226 
 
ability to actively adapt its cargo carrying capacity to an external cargo loading stimulus makes 
the macrophage the prime candidate for targeting and loading with insoluble drug aggregates, 
serving as a long term cellular drug depot, slowly releasing drug directly at the site of action, be 
it in a tumor-associated macrophage within the tumor micro-environment or at a locally inflamed 
area where immunomodulation is necessary. 
It is not unreasonable to believe that other poorly soluble, weakly basic drug molecules 
can be reformulated into stable, hydrochloride salts forms which can target macrophages where 
they can stably reside and slowly release drug to the surrounding tissue environment. As it stands 
currently, more than 78% of drugs currently in use contain at least one ionizable moiety within 
the molecule [30]. For weakly basic drugs, around 20% have a pKa in the range of lysosomal pH 
(4<pKa<6.5) [30], meaning that these drug molecules should be explored for potential salt 
formation and lysosomal targeting. As a delivery strategy, formulating hydrochloride salt forms 
of drug poses several challenges. Firstly, the salt crystals need to remain in an environment 
containing the proper pH and salt content to prevent conversion from to the free base form of the 
drug and solubilization. To accomplish this, the drug would need to be delivered in a solution 
that is at or below the pHmax of the salt form of the drug. When the pH is at or below the pHmax 
(i.e. is more acidic), the solid, salt form of the drug will be most stable form of the drug, while at 
pH values above the pHmax (i.e. a more basic solution), the solid, free base form of the drug will 
be more thermodynamically stable, resulting in conversion and destabilization of the solid 
dosage form [40, 41]. The solution would also need to have the proper counter-ion concentration 
to prevent dissolution of the salt as well; mimicking the lysosomal environment (pH of 
approximately 4.5 and chloride concentration of above 80 mM[42, 43]) should allow for the 
stabilization of a wide variety of hydrochloride salt drugs. 
Once a proper solution for delivery has been designed, formulating a vehicle to deliver 
the stable crystal to the tissue or cell of interest must be developed. Currently, liposomal 
formulations are extensively used in cancer therapeutics due to the ability to modify the surface 
of the liposome with targeting ligands or antibody surface modifications [44]. By modifying the 
surface of the liposome, cancerous tissues or cells can be specifically targeted, reducing off-
target effects and limiting toxicity [45]. Aside from delivering drug in solution, liposomal 
formulations have been used to deliver insoluble drug formulations as well. For example, the 
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anti-cancer therapeutic Doxil, a liposomal formulation of doxorubicin hydrochloride, is 
comprised of liposomes loaded with a crystalline precipitate of drug [46]. Doxorubicin has a risk 
for cardiotoxicity, but formulations of Doxil show significantly reduced instances of 
cardiotoxicity due to the specific targeting of the tumor [47]. Using the remote loading approach 
that is used to formulate Doxil [48], other weakly basic drugs can potentially be explored as 
candidates for development into liposomal formulations which can specifically target sites of 
interest and limit systemic toxic events. 
By targeting the site of interest, either through formulating a liposome of size that will 
undergo phagocytosis by macrophages, or through addition of targeting moieties to the surface of 
the liposome, lower doses of drug would be needed, reducing possibilities for off-target reactions 
and toxicity. Additionally, if properly formulated, these crystalline formulations can act as a 
cellular drug depot similar to the CLDIs that are found within macrophages. Even following 
cessation of treatment, CLDIs remain within macrophages of the liver and spleen [1], where they 
act as a cell-assembled drug depot and help keep plasma concentrations of clofazimine at levels 
above the minimum inhibitory concentration for Mycobacterium tuberculosis and 
Mycobacterium leprae [49]. Sustained or continuous release depot-type formulations have been 
utilized extensively since the 1970s [50] to deliver poorly soluble drugs over the course of 
months or years. These types of formulations increase patient compliance, as they eliminate the 
need to take a pill daily or weekly, reducing missed dosages. In all, formulations of insoluble, 
weakly basic crystalline drugs should be considered for development in the future as a method 
for site-specific drug delivery and loading. 
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Appendix A 
Supporting Information in Chapter 2 
 
Figure SI. 1- Degradation of human tPA. 
Western blot of human tPA (htPA) that was added to homogenized mouse lung and shows the rapid degradation of 
the parent protein (MW ~68kDa; lane 2). This is further illustrated by the increased signal intensities of smaller 
molecular degradation products. This is apparent as early as 5 min after the addition of htPA (5µg) to lung 
homogenate (lane 1) and continues to be evident at 15 (lane 3) and 30 min (lane 4). MWM= molecular weight 
marker. 
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Figure SI. 2- Brightfield images of LRP1 stained lung through different filters.  
Bright field images with blue filter show greater intensity of staining than red filter images. A representative image 
of an LRP1 stained mouse lung (40X) section in the (A) bright field; (B) with the red filter; and (C) the blue filter.  
Scale bar is 50µm. 
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Figure SI. 3- Thresholding of tissue section. 
Threshold applied images from bright field red and blue filters. The red filtered image captures all tissue positive 
areas on the slide. The blue filtered image captures only stained area on the tissue. A representative bright field 
image (A) of stained mouse lung section (40X) with the threshold-applied red filter image (B) and the threshold-
applied blue filter image (C). Scale bar is 50µm. 
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Figure SI. 4- Mouse liver and lung sections stained for LRP1. 
Sections of LRP1 stained and unstained sections of mouse liver and lung (40X).  Representative (A) LRP1 stained 
liver; (B) unstained liver; (C) LRP1 stained lung and (D) unstained lung. Scale bar is 50µm. 
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Figure SI. 5- Ratio of LRP1 staining in liver and lung. 
As in the mouse, the ratio of LRP1 staining in macaque monkey liver and lung sections were similar. Representative 
color light micrographs of (A) liver and (B) lung sections (40X) stained for LRP1 and 3’3’-diaminozenzidene 
(DAB) that is depicted by the brown staining. (C) Quantitation of the ratio of LRP1 staining in liver and lung 
sections was not different between the two groups (p=0.969 by unpaired Student’s t-test). Data are mean (±S.E.M.) 
of 7 sections/group. Scale bar is 50µm. 
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Methods 
 
Western Blot of Human tPA in Mouse Lung Homogenate  
The lungs of a post-mortem C56Bl/6 male mouse were perfused blood-free and homogenized in 
the absence of protease inhibitors as previously described (1). Briefly, the sample was 
homogenized (Tissuemiser, Fisher Scientific, Pittsburg, PA) on ice in the presence of tissue 
extraction reagent (Pierce, Rockford, IL). Residual red blood cells were lysed by the addition of 
red blood cell lysing buffer (1 mL; Sigma, St. Louis, MO).  Homogenate was transferred to a 
microcentrifuge tube and clarified by centrifugation (13,000 x g, 4°C) for 20 min. A known 
amount of htPA (5 µg) was added to the homogenate (1 mL) and it was incubated (37°C). Over 
time, aliquots (50 µL) were removed from the primary sample and transferred to the freezer (-
80°C). Upon completion of the experiment, an equal volume (30 µL) of each sample was 
subjected to 12.5% SDS-PAGE. Following electrophoresis, proteins were transferred to PVDF 
and the membrane was probed for human tPA (1:10,000 dilution of a rabbit anti-human tPA 
antibody; Molecular Innovations). Protein was detected using a secondary fluorescent antibody 
(goat anti-rabbit IgG cy5, 1:5000 dilution) and an image of the blot was acquired using a 
Typhoon Variable Mode Imager (GE Healthcare).  
 
Image Acquisition and Analysis Workflow 
Digital images of stained and unstained lung and liver sections at 40X magnification were 
acquired on a Ti Eclipse inverted microscope (Nikon Instruments, Inc., Melville, NY, USA) 
using bright field optics under Kohler illumination. To acquire and quantify DAB stained 
images, a red filter (655 ±30 nm), which corresponds to the absorbance peak of the background 
staining, and a blue filter (480 ± 30 nm), which corresponds to the absorbance peak of DAB, 
were used (Figure S1). The density of DAB staining is indicative of LRP1 receptor density.  To 
quantify DAB staining density all images were analyzed with ImageJ.  The red filter image was 
first converted to grey scale (Figure S2).  Then, a threshold was applied to this image to select 
the pixels corresponding to the tissue region. This threshold was based on a visual inspection of 
the tissue sample, capturing pixel intensities that corresponded to the tissue itself. This was 
performed on five control lung and liver images, allowing for an average background tissue 
signal to be determined for each organ. The average threshold value, as determined from the 
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untreated tissue samples, was applied to the corresponding blue image, selecting the pixels 
corresponding to the darkly stained DAB positive regions.  The selected pixels for the red image 
was used as a measure of the total area of the tissue region, and the selected pixels for the blue 
were used as a measure of the tissue area with DAB signal.  Dividing the pixel area of DAB 
signal by the total tissue area was then used to calculate the % area stained measurement.   
For the comparative analysis of lung and liver LRP1, the area and area fraction (%area) 
measurements were acquired. The area captures the total image in square pixels while the %area 
measures the percentage of pixels that fall within the set threshold over the total area. The ratio 
of LRP1 positive staining was determined by dividing the pixel area of DAB signal by the total 
tissue area which was used to calculate the % area stained measurement. Any nonspecific 
background staining removed from the true LRP1 signal, by subtracting the background % tissue 
area with LRP1 staining measured with a negative control (unstained) set of images from the % 
tissue area with LRP1 staining from the experimental (DAB stained) set of images (Figure S3).
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Appendix B 
Supporting Information in Chapter 3 
 
1. Synthesis of 3 (N-(4-Aryl)-2-nitroaniline). 
General Procedure A: K2CO3 (1.76 g, 12.8 mmole) and KF (0.49 g, 12.8 mmole) was mixed 
well by grinding in a mortar. This mixture was added to the 20 mL microwave reaction vial. 
Then aniline 1 (15.3 mmole, 1.2 equivalents), followed by fluoronitrobenzene 2 (1.35 mL, 
12.8 mmole) were added and the reaction mixture was irradiated under a microwave at 180°C 
for a total of about 16 h and monitored by TLC at regular intervals. The solid mixture was 
extracted with DCM (4 × 20 mL), washed with 1N HCl (2 × 30 mL), water (2 × 50 mL), dried 
(Na2SO4) and the solvent was removed under reduced pressure to yield the crude product. It 
was purified using flash chromatography. 
General Procedure B: To a solution of aniline 1 (10 mmole) and powdered KOH (2.81g, 50 
mmole) in DMSO (10 mL) was added slowly fluoronitrobenzene (1.32 mL, 12.5 mmole) over 
a period of 0.5h. It was stirred at room temperature for 3h. The content was poured over ice 
and neutralized with 2N HCl. The precipitated orange solid was filtered, washed with water 
(200 mL), dried under suction and then under high vacuum overnight. 
2. Synthesis of 4 (N-Arylbenzene-1,2-diamine). 
General Procedure C: A 250-mL round bottom flask was flushed with N2 and then charged 
with the nitro compound, 3, MeCN (60 mL) and 10% Pd/C (0.11g). It was flushed again with 
N2 and sealed with rubber septum. The evacuated flask was filled with H2 and it was stirred at 
RT in a H2 atmosphere using a balloon overnight. TLC results after overnight stirring 
indicated completion of reaction. The solution was filtered with the aid of celite. The solvent 
was removed under reduced pressure to yield the compound 4. It was purified if necessary. 
3. Synthesis of 5 (3-Imino-N,5-bis(aryl)-3,5-dihydrophenazin-2-amine hydrochloride). 
General Procedure D: To a solution of the diamino compound (2.9 mmole) in glacial AcOH
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(4.5 mL) was added a solution of FeCl3.6H2O (8.7 mmole, 3 equivalent) in water (15 mL) and 
12 N HCl (0.4 mL, 4.5 equivalent). The reaction was left stirring at room temperature 
overnight after dilution with 7 mL of H2O. The reaction was further diluted with 10 mL of 
H2O. After 1h, the precipitate was filtered, washed with excess water, dried under suction and 
then inside a vacuum desiccator. 
4. Synthesis of 6 ((E)-3-(Isopropylimino)-N,5-bis(aryl)-3,5-dihydrophenazin-2-amine). 
General Procedure E: The phenazine hydrochloride (0.1g) was suspended in dioxane or 
EtOH (1 mL). To this suspension was added isopropylamine (0.2 mL) and the mixture was 
heated in a sealed tube for 5 h. The solution was filtered and the flask was washed with EtOH 
(1 mL). The filtrate was diluted with H2O until it becomes slightly turbid. The compound was 
crystallized and then recrystallized from aqueous EtOH or purified by the flash 
chromatography. 
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Figure SI 6- Synthesis scheme for phenazine compounds.  
Treatment of aniline derivatives 1 with 2-fluoronitrobenzene 2 following the published procedure [12] (Method A 
using KF/K2CO3 or B using KOH/DMSO) gave the secondary amine derivatives 3 in 22 - 63% yield. Reduction of 
the nitro group was carried out using 10% Pd/C catalyst under hydrogen atmosphere to yield the diamine 4 in 55 - 
99% yield. Then the diamine 4 was oxidised[3, 5] in aqueous ferric chloride solution to give the corresponding 
phenazine salts 5 in 70 - 96%. The dimethoxyphenazine salt 5A was demethylated using borontribromide in 
dichloromethane to give the hydroxyphenazine hydrobromide 5G in 67% yield. The phenazine salts 5 on treatment 
with variety of primary amines gave the corresponding phenazine derivatives 6 in 10 - 85% yield. 
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General procedures and characterization data of riminophenazine derivative compounds 
 
A (6-206566) 
 
 
N-(4-Methoxyphenyl)-2-nitroaniline, 3A (General Procedure A): Purified by the flash chromatography using 5-40% 
EtOAc/hexanes. Yield: 1.25g (63%); 
1
H NMR (500 MHz, CDCl3) δ 9.41 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.35 – 
7.31 (m, 1H), 7.23 – 7.19 (m, 2H), 7.03 – 7.00 (m, 1H), 6.99 – 6.95 (m, 2H), 6.75 – 6.70 (m, 1H), 3.86 (s, 3H). 
N-(4-Methoxyphenyl)benzene-1,2-diamine, 4A (General Procedure C): Purified using 5-40% EtOAc/Hexanes 
gradient Yield: 0.62g (59%); 
1
H NMR (500 MHz, CDCl3)  δ 7.06 – 7.00 (m, 2H), 6.82 – 6.78 (m, 2H), 6.76 – 6.70 
(m, 3H), 6.67 (td, J = 7.5, 1.4 Hz, 1H), 3.77 (s, 3H), 3.17 (q, J = 7.2 Hz, 2H) & 1.24 (t, J = 7.2 Hz, 3H). 
3-Imino-N,5-bis(4-methoxyphenyl)-3,5-dihydrophenazin-2-amine hydrochloride, 5A (General Procedure D): Yield: 
1.2g (90%); MS (ESI
+
), m/z: 423.2 (M+1); 
1
H NMR (500 MHz, CD3OD) δ 8.21 – 8.16 (m, 1H), 7.81 – 7.72 (m, 
3H), 7.56 (d, J = 1.1 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.25 – 7.21 (m, 2H), 7.18 – 7.14 (m, 1H), 7.03 – 7.00 (m, 1H), 
6.98 –6.95 (m, 1H), 6.86 – 6.83 (m, 1H), 6.39 (s, 1H), 3.91 (s, 3H) & 3.85 (s, 3H). 
(E)-3-(Isopropylimino)-N,5-bis(4-methoxyphenyl)-3,5-dihydrophenazin-2-amine,[1, 2] 6A (General Procedure E): 
Yield: 67 mg (66%); MS (ESI
+
), m/z: 465.2 (M+1);  
1
H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 7.6 Hz, 1H), 7.60 (t, 
J = 8.1 Hz, 1H), 7.23 (d, J = 6.7 Hz, 1H), 7.17 – 7.07 (m, 3H), 6.98 (d, J = 7.9 Hz, 1H), 6.93 – 6.81 (m, 4H), 6.62 (d, 
J = 8.2, 2.4 Hz, 1H), 6.52 (d, J = 8.3 Hz, 1H), 5.33 (s, 1H), 3.83 (d, J = 11.8 Hz, 6H), 3.44 (h, J = 6.3 Hz,1H) & 1.07 
(t, J = 6.5 Hz, 6H). 
 
B (8-206567) 
 
 
4-((2-Nitrophenyl)amino)benzonitrile, 3B (General Procedure A): Purified by the flash chromatography using 5-
40% EtOAc/hexanes. Yield: 0.84g (28%); 
1
H NMR (500 MHz, CDCl3) δ 9.43 (s, 1H), 8.23 (dd, J = 8.6, 1.5 Hz, 
1H), 7.66 (d, J = 8.2 Hz, 2H), 7.54 – 7.44 (m, 2H), 7.33 (d, J = 8.7 Hz, 2H), 7.02 – 6.95 (m, 1H). 
4-((2-Aminophenyl)amino)benzonitrile, 4B (General Procedure C): Yield: 0.38g (99%); 
1
H NMR (500 MHz, CDCl3) 
δ 7.45 (d, J = 8.5 Hz, 2H), 7.17 – 7.07 (m, 2H), 6.84 (d, J =7.8 Hz, 1H), 6.82 – 6.78 (m, 1H), 6.68 (d, J = 8.5 Hz, 
2H), 5.62 (s, 1H) & 3.79 (s, 2H). 
4-((5-(4-Cyanophenyl)-3-imino-3,5-dihydrophenazin-2-yl)amino)benzonitrile hydrochloride, 5B (General Procedure 
D): Yield: 0.33g (85%); MS (ESI
+
), m/z:: 413 (M+1); 
1
H NMR (500 MHz, (CD3)2SO) δ 10.13 (s, 1H), 9.56 – 9.37 
(m, 2H), 8.45 (d, J = 8.1 Hz, 2H), 8.30 – 8.23 (m, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 8.3 Hz, 2H), 7.82 – 7.77 
(m, 2H), 7.71 (s, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.10 – 7.05 (m, 1H), 6.18 (s, 1H). 
(E)-4-((5-(4-Cyanophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-yl)amino)benzonitrile, 6B (General Procedure 
E): Yield: 49 mg (48%); MS (ESI
+
), m/z: 455.2 (M+1);  
1
H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.1 Hz, 2H), 
7.73 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.24 – 7.14 (m, 
2H), 7.03 (s, 1H), 6.37 (d, J = 8.1 Hz, 1H), 5.18 (s, 1H), 3.41 (p, J = 6.1 Hz, 1H), 1.08 (d, J = 6.2 Hz, 6H). 
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C (12-206693) 
 
 
2-Nitro-N-phenylaniline, 3C (General Procedure A): Purified by the flash chromatography using 3% 
EtOAc/hexanes. Yield: 0.52g (23%); 
1
H NMR (400 MHz, CDCl3) δ 9.49 (s, 1H), 8.20 (dd, J = 8.6, 1.7 Hz, 1H), 
7.44 – 7.34 (m, 3H), 7.30 – 7.20 (m, 4H), 6.77 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H). 
N-Phenylbenzene-1,2-diamine, 4C (General Procedure C): Yield: 0.41g (97%); 
1
H NMR (400 MHz, CDCl3) δ 7.26 
– 7.17 (m, 2H), 7.12 (dd, J = 7.8, 1.5 Hz, 1H), 7.06 – 6.97 (m, 1H), 6.86 – 6.71 (m, 5H), 5.17 (s, 1H), 3.76 (s, 2H). 
3-Imino-N,5-diphenyl-3,5-dihydrophenazin-2-amine hydrochloride, 5C (General Procedure D): Yield: 0.32g (74%); 
1
H NMR (400 MHz, (CD3)2SO) δ 9.67 (s, 1H), 9.38 (s, 2H), 8.21 – 8.14 (m, 1H), 7.95 – 7.83 (m, 3H), 7.77 – 7.70 
(m, 4H), 7.55 – 7.46 (m, 4H), 7.34 (s, 1H), 7.29 – 7.24 (m, 1H), 7.02 – 6.95 (m, 1H), 6.21 (s, 1H). 
(E)-3-(Isopropylimino)-N,5-diphenyl-3,5-dihydrophenazin-2-amine,[1] 6C (General Procedure E): Yield: 65 mg 
(85%); 
1
H NMR (400 MHz, CDCl3) δ 7.76 – 7.59 (m, 4H), 7.49 – 7.25 (m, 7H), 7.17 – 7.04 (m, 3H), 6.89 (s, 1H), 
6.45 (d, J = 8.1 Hz, 1H), 5.25 (s, 1H), 3.39 (d, J = 6.2 Hz, 1H), 1.04 (d, J = 6.2 Hz, 6H). 
 
D (4-206694) 
 
 
2-Nitro-N-(4-(trifluoromethyl)phenyl)aniline, 3D (General Procedure A): Purified by the flash chromatography 
using 15-65% EtOAc/hexanes. Yield: 0.15g (7%); 
1
H NMR (400 MHz, CDCl3) δ 9.47 (s, 1H), 8.23 (d, J = 8.5 Hz, 
1H), 7.65 (d, J = 8.3 Hz, 2H), 7.48 – 7.43 (m, 1H), 7.40 – 7.34 (m, 3H), 6.93 – 6.87 (m, 1H).  
N-(4-(Trifluoromethyl)phenyl)benzene-1,2-diamine, 4D (General Procedure C): Yield: 0.13g (99%); 
1
H NMR (400 
MHz, CDCl3) δ 7.41 (d, J = 8.6 Hz, 2H), 7.14 – 7.03 (m, 2H), 6.85 – 6.72 (m, 2H), 6.70 (d, J = 8.6 Hz, 2H), 5.41 (s, 
1H), 3.76 (s, 2H). 
3-Imino-N,5-bis(4-(trifluoromethyl)phenyl)-3,5-dihydrophenazin-2-amine hydrochloride, 5D (General Procedure 
D): Yield: 0.12g (94%); 
1
H NMR (400 MHz, (CD3)2SO) δ 9.75 (s, 1H), 9.40 – 9.22 (m, 2H), 8.34 (d, J = 8.1 Hz, 
2H), 8.27 – 8.23 (m, 1H), 8.22 – 8.17 (m, 1H), 8.01 (d, J = 8.1 Hz, 2H), 7.96 – 7.90 (m, 1H), 7.85 – 7.77 (m, 4H), 
7.73 – 7.68 (m, 1H), 7.66 – 7.62 (m, 3H), 7.47 (t, J = 8.1 Hz, 1H), 7.28 (s, 1H), 7.05 (dd, J = 7.0, 3.0 Hz, 1H), 6.18 
(s, 1H). 
(E)-3-(Isopropylimino)-N,5-bis(4-(trifluoromethyl)phenyl)-3,5-dihydrophenazin-2-amine, 6D (General Procedure 
E): Yield: 52 mg (52%); MS (ESI
+
), m/z: 541.1 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 8.02 (d, J = 8.2 Hz, 2H), 
7.72 (dd, J = 7.8, 1.3 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.23 – 
7.12 (m, 2H), 7.00 (s, 1H), 6.39 (d, J = 7.9 Hz, 1H), 5.22 (s, 1H), 3.42 (hept, J = 6.3 Hz, 1H), 1.08 (d, J = 6.2 Hz, 
6H), 9.07 – 8.48 (m, 1H). 
 
E (11-206695) 
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N-(4-Fluorophenyl)-2-nitroaniline, 3E (General Procedure B): Yield: 0.52g (22%); 
1
H NMR (400 MHz, CDCl3) δ 
9.40 (s, 1H), 8.21 (dd, J = 8.6, 1.6 Hz, 1H), 7.40 – 7.33 (m, 1H), 7.25 (dd, J = 9.8, 3.8 Hz, 2H), 7.12 (t, J = 8.5 Hz, 
2H), 7.05 (dd, J = 8.6, 1.3 Hz, 1H), 6.81 – 6.74 (m, 1H). 
N-(4-Fluorophenyl)benzene-1,2-diamine, 4E (General Procedure C): Purified using 12-15% EtOAc/Hexanes 
gradient. Yield: 0.36g (79%); 
1
H NMR (400 MHz, CDCl3) δ 7.05 (dd, J = 7.8, 1.5 Hz, 1H), 7.02 – 6.97 (m, 1H), 
6.95 – 6.87 (m, 2H), 6.83 – 6.64 (m, 4H), 5.06 (s, 1H), 3.74 (s, 2H). 
3-Imino-N,5-bis(4-fluorophenyl)-3,5-dihydrophenazin-2-amine hydrochloride, 5E (General Procedure D): Yield: 
0.36g (96%); 
1
H NMR (500 MHz, (CD3)2SO) δ 9.56 (s, 1H), 9.41 – 9.17 (m, 2H), 8.18 (d, J = 7.3 Hz, 1H), 7.84 – 
7.71 (m, 6H), 7.52 – 7.47 (m, 2H), 7.41 – 7.34 (m, 2H), 7.25 – 7.17 (m, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.24 – 6.19 
(m, 1H). 
(E)-N,5-bis(4-Fluorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine,[2] 6E (General Procedure E): Yield: 
90 mg (59%); MS (ESI
+
), m/z: 441.1 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.45 – 
7.38 (m, 2H), 7.36 – 7.29 (m, 4H), 7.20 – 7.02 (m, 5H), 6.71 (s, 1H), 6.45 (d, J = 8.0 Hz, 1H), 5.26 (s, 1H), 3.45 
(hept, J = 6.4 Hz, 1H), 1.08 (d, J = 6.3 Hz, 6H). 
 
F (9-206696) 
 
 
4-((2-Nitrophenyl)amino)benzoic acid, 3F (General Procedure B): Yield: 1.55g (60%) (It’s a mixture of about 1:3 
ester/carboxylic acid and used in subsequent transformation as such without further purification); 
1
H NMR (500 
MHz, (CD3)2SO) δ 12.64 (s, 1H), 9.31 (s, 1H), 8.16 – 8.04 (m, 1H), 7.93 – 7.84 (m, 2H), 7.63 – 7.44 (m, 2H), 7.38 – 
7.26 (m, 2H), 7.13 – 7.00 (m, 1H). 
4-((2-Aminophenyl)amino)benzoic acid, 4F (General Procedure C): Crystallized from aqueous Methanol. Yield: 
0.24g (55%); 
1
H NMR (500 MHz, (CD3)2SO) δ 12.17 (s, 1H), 7.86 (d, J = 28.3 Hz, 1H), 7.69 (d, J = 8.7 Hz, 2H), 
7.01 (d, J = 7.8 Hz, 1H), 6.96 – 6.89 (m, 1H), 6.79 – 6.74 (m, 1H), 6.65 (d, J = 8.7 Hz, 2H), 4.95 – 4.69 (m, 2H), 
6.61 – 6.53 (m, 1H). 
4-((5-(4-Carboxyphenyl)-3-imino-3,5-dihydrophenazin-2-yl)amino)benzoic acid hydrochloride, 5F (General 
Procedure D): Yield: 0.17g (70%); 
1
H NMR (400 MHz, (CD3)2SO) δ 13.05 (s, 2H), 9.76 (s, 1H), 9.33 (s, 2H), 8.45 – 
8.40 (m, 2H), 8.28 – 8.23 (m, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.87 (d, J = 8.4 Hz, 2H), 7.82 – 7.74 (m, 2H), 7.68 – 
7.64 (m, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.11 – 7.03 (m, 1H), 6.23 – 6.19 (m, 1H). 
(E)-4-((5-(4-Carboxyphenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-yl)amino)benzoic acid, 6F (General 
Procedure E): Yield: 90 mg (59%); MS(ESI
+
), m/z: 494.1 (M+1);  
1
H NMR (400 MHz, CD3OD)  δ 8.38 (d, J = 8.0 
Hz, 2H), 8.27 – 8.19 (m, 1H), 8.07 (d, J = 8.2 Hz, 2H), 7.81 – 7.72 (m, 2H), 7.69 (s, 1H), 7.59 (d, J = 7.9 Hz, 2H), 
7.40 (d, J = 8.2 Hz, 2H), 7.26 – 7.16 (m, 1H), 6.34 (s, 1H), 1.28 (d, J = 6.6 Hz, 6H). 
 
G (5-206608) 
 
 
Method for chemical synthesis of 4-((5-(4-Hydroxyphenyl)-3-imino-3,5-dihydrophenazin-2-yl)amino)phenol 
hydrobromide, 5G: To the solution of the phenazine 5A (56 mg) in DCM (3 mL) was added BBr3 in DCM (1 mL) 
and the solution was stirred at RT for 4 days. Water (4 mL) was added to quench the reaction, the precipitate was 
filtered, washed with water (15 mL) and dried under vacuum desiccator for 2 days. Yield: 39 mg (67%); MS (ESI
+
), 
m/z: 395.1 (M+1); 1H NMR (400 MHz, (CD3)2SO) δ 10.38 (s, 1H), 9.74 (s, 1H), 9.27 (s, 1H), 8.70 (s, 1H), 8.20 (s, 
1H), 7.81 – 7.64 (m, 3H), 7.42 (s, 1H), 7.34 – 7.19 (m, 2H), 7.16 – 7.05 (m, 3H), 6.85 (s, 2H), 6.73 – 6.60 (m, 1H), 
6.31 (s, 1H). 
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 (E)-4-((5-(4-Hydroxyphenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-yl)amino)phenol, 6G (General Procedure 
E): Purified using 40-100% EtOAc/Hexanes gradient. Yield: 19 mg (65%); MS (ESI
+
), m/z: 437.2 (M+1); 
1
H NMR 
(400 MHz, (CD3)2SO) δ 10.03 (s, 1H), 9.50 (s, 1H), 7.60 (d, J = 7.5 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.21 – 7.00 (m, 
5H), 6.84 (d, J = 7.9 Hz, 1H), 6.82 – 6.80 (m, 1H), 6.78 – 6.74 (m, 2H), 6.72 – 6.69 (m, 1H), 6.49 (t, J = 8.3 Hz, 
2H), 5.26 (s, 1H), 3.33 (q, J = 6.8 Hz, 1H), 1.03 – 0.98 (m, 6H). 
 
H (1-206570) 
 
 
(E)-N,5-bis(4-chlorophenyl)-3-((2-methoxyethyl)imino)-3,5-dihydrophenazin-2-amine,[1] 6H (General Procedure 
E): Purified using 10-50% EtOAc/Hexanes gradient. Yield: 18 mg (17%); MS (ESI
+
), m/z: 490.1 & 492.1 (M+1); 
1
H 
NMR (400 MHz, CDCl3)  δ 7.74 – 7.67 (m, 3H), 7.38 – 7.26 (m, 7H), 7.24 – 7.09 (m, 3H), 6.84 (s, 1H), 6.50 – 6.44 
(m, 1H), 5.28 (s, 1H), 3.72 (t, J = 6.2 Hz, 2H), 3.40 (s, 3H), 3.31 (t, J = 6.2 Hz, 2H). 
 
I (7-206568) 
 
(E)-2-((10-(4-Chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)ethanol ,[3] 6I (General 
Procedure E): Yield: 41 mg (40%); MS (ESI
+
), m/z: 475.1 & 477.1 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 7.74 – 
7.65 (m, 3H), 7.33 – 7.28 (m, 2H), 7.27 – 7.21 (m, 5H), 7.21 – 7.07 (m, 3H), 6.83 (s, 1H), 6.47 (d, J = 7.7 Hz, 1H), 
5.25 (s, 1H), 3.88 (t, J = 5.3 Hz, 2H), 3.23 (t, J = 5.3 Hz, 2H). 
 
J (13-206689) 
 
(E)-N,5-Bis(4-chlorophenyl)-3-(methylimino)-3,5-dihydrophenazin-2-amine,[3] 6J (General Procedure E): Purified 
using 15 - 60% EtOAc/Hexanes gradient. Yield: 28 mg (29%); MS (ESI
+
), m/z: 446.1 & 448.1 (M+1); 
1
H NMR 
(400 MHz, CDCl3) δ 7.69 (d, J = 8.6 Hz, 3H), 7.35 – 7.24 (m, 7H), 7.20 – 7.11 (m, 2H), 6.83 (s, 1H), 6.46 (d, J = 
8.1 Hz, 1H), 5.27 (s, 1H), 3.06 (s, 3H). 
 
K (3-206690) 
 
(E)-3-(Butylimino)-N,5-bis(4-chlorophenyl)-3,5-dihydrophenazin-2-amine,[3] 6K (General Procedure E): Purified 
using 35 - 45% EtOAc/Hexanes gradient. Yield: 38 mg (37%); MS (ESI
+
), m/z: 487.1 & 489.1 (M+1); 
1
H NMR 
(400 MHz, CDCl3) δ 7.72 – 7.64 (m, 3H), 7.32 – 7.25 (m, 6H), 7.19 – 7.08 (m, 3H), 6.81 (s, 1H), 6.44 (d, J = 8.0 
Hz, 1H), 5.24 (s, 1H), 3.14 (t, J = 6.9 Hz, 2H), 1.61 – 1.55 (m, 2H), 1.38 – 1.31 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H). 
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L (15-208923) 
 
(E)-3-((10-(4-Chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)-propanamide, 6L 
(General Procedure E): Yield: 18 mg (24%); MS(ESI
+
), m/z: 502.0 & 504.0 (M+1);  
1
H NMR (400 MHz, CDCl3)  δ 
7.77 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.34 – 7.25 (m, 8H), 7.23 – 7.18 (m, 2H), 6.91 (s, 1H), 6.54 (d, J 
= 8.3 Hz, 1H), 5.32 (s, 2H), 3.38 (t, J = 6.2 Hz, 2H), 2.65 (t, J = 6.2 Hz, 2H). 
 
M (16-208922) 
 
(E)-N,5-Bis(4-chlorophenyl)-3-((2-(5-methoxy-1H-indol-3-yl)ethyl)imino)-3,5-dihydrophenazin-2-amine, 6M 
(General Procedure E): Yield: 26 mg (20%); MS(ESI
+
), m/z: 604.0 & 606.0 (M+1);  
1
H NMR (400 MHz, CDCl3)  δ 
7.84 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 7.25 – 7.21 (m, 3H), 7.20 – 
7.09 (m, 5H), 7.06 – 7.04 (m, 1H), 6.90 – 6.83 (m, 3H), 6.41 (d, J = 8.1 Hz, 1H), 5.19 (s, 1H), 3.82 (s, 3H), 3.49 (t, J 
= 7.0 Hz, 2H), 3.07 (t, J = 7.0 Hz, 2H). 
 
N (17-208921) 
 
(E)-N,5-Bis(4-chlorophenyl)-3-((2-morpholinoethyl)imino)-3,5-dihydrophenazin-2-amine,[4] 6N (General 
Procedure E): Yield: 38 mg (33%); MS(ESI
+
), m/z: 544.0 & 546.0 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 7.72 – 
7.66 (m, 2H), 7.36 – 7.24 (m, 7H), 7.23 – 7.06 (m, 3H), 6.84 (s, 1H), 6.45 (d, J = 8.2 Hz, 1H), 5.24 (s, 1H), 3.74 – 
3.65 (m, 4H), 3.33 (t, J = 7.3 Hz, 2H), 2.68 (t, J = 7.3 Hz, 2H), 2.50 – 2.40 (m, 4H). 
 
O (19-209042) 
 
(E)-4-(2-((10-(4-Chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)-ethyl)benzene-1,2-diol, 
6O (General Procedure E): Yield: 13 mg (17%); MS(ESI
+
), m/z: 567.0 & 569.0 (M+1); 
1
H NMR (400 MHz, 
CD3OD)  δ 8.22 – 8.17 (m, 1H), 7.98 – 7.92 (m, 2H), 7.78 – 7.73 (m, 2H), 7.59 – 7.55 (m, 2H), 7.51 (s, 1H), 7.48 – 
7.45 (m, 2H), 7.36 – 7.32 (m, 2H), 7.17 – 7.13 (m, 1H), 6.67 (d, J = 7.9 Hz, 1H), 6.55 – 6.52 (m, 1H), 6.28 – 6.22 
(m, 1H), 5.89 (s, 1H), 3.47 (d, J = 7.3 Hz, 2H), 2.72 (t, J = 7.3 Hz, 2H). 
 
 
 
248 
 
P (10-206691) 
 
(E)-N,5-Bis(4-chlorophenyl)-3-(phenethylimino)-3,5-dihydrophenazin-2-amine,[2, 5] 6P (General Procedure E): 
Yield: 53 mg (46%); MS (ESI
+
), m/z: 535.0 & 537.0 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 7.75 – 7.65 (m, 3H), 
7.37 – 7.26 (m, 8H), 7.23 – 7.16 (m, 3H), 7.15 – 7.09 (m, 3H), 6.86 (s, 1H), 6.46 (d, J = 8.3 Hz, 1H), 5.28 (s, 1H), 
3.44 (t, J = 7.7 Hz, 2H), 2.88 (t, J = 7.7 Hz, 2H). 
 
Q (14-206571) 
 
(E)-4-(2-((10-(4-chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)-ethyl)phenol, 6Q 
(General Procedure E): Purified using 12 - 60% EtOAc/Hexanes gradient. Yield: 12 mg (10%); MS (ESI
+
), m/z: 
551.1 & 553.1 (M+1); 
1
H NMR (400 MHz, (CD3)2SO) δ 7.92 (dd, J = 8.7, 2.2 Hz, 2H), 7.70 (s, 1H), 7.60 – 7.53 (m, 
2H), 7.53 – 7.45 (m, 2H), 7.44 – 7.39 (m, 2H), 7.30 (s, 2H), 6.87 – 6.77 (m, 3H), 6.72 – 6.67 (m, 2H), 6.55 (s, 1H), 
5.28 (s, 1H), 3.32 (t, J = 7.9 Hz, 2H), 2.59 (t, J = 7.8 Hz, 2H). 
 
R (21L-211916) 
 
(S,E)-N,5-Bis(4-chlorophenyl)-3-((1-phenylethyl)imino)-3,5-dihydrophenazin-2-amine,[6] 6R (General Procedure 
E): Yield: 15 mg (18%); MS(ESI
+
), m/z: 535.0 & 537.0 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ 7.77 – 7.66 (m, 2H), 
7.58 (d, J = 8.6 Hz, 1H), 7.34 – 7.27 (m, 5H), 7.23 (d, J = 7.3 Hz, 2H), 7.20 – 7.05 (m, 6H), 6.97 (d, J = 8.5 Hz, 1H), 
6.85 (s, 1H), 6.47 (d, J = 8.2 Hz, 1H), 5.22 (s, 1H), 4.34 (q, J = 6.6 Hz, 1H), 1.50 (d, J = 6.6 Hz, 3H). 
 
S (21R-211915) 
 
(R,E)-N,5-Bis(4-chlorophenyl)-3-((1-phenylethyl)imino)-3,5-dihydrophenazin-2-amine,[6] 6S (General Procedure 
E): Yield: 15 mg (18%); MS(ESI
+
), m/z: 535.0 & 537.0 (M+1);  
1
H NMR (500 MHz, CDCl3)  δ 7.74 (d, J = 7.9 Hz, 
1H), 7.71 (d, J = 7.9 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.38 – 7.29 (m, 6H), 7.26 – 7.23 (m, 2H), 7.21 – 7.17 (m, 
2H), 7.16 – 7.12 (m, 1H), 7.10 – 7.06 (m, 2H), 7.01 – 6.97 (m, 1H), 6.87 (s, 1H), 6.49 (d, J = 8.3 Hz, 1H), 5.23 (s, 
1H), 4.35 (q, J = 6.6 Hz, 1H), 1.51 (d, J = 6.5 Hz, 3H). 
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T (22L-212016) 
 
(S,E)-N,5-Bis(4-chlorophenyl)-3-((2-phenylpropyl)imino)-3,5-dihydrophenazin-2-amine, 6T (General Procedure E): 
Yield: 35 mg (60%); MS (ESI
+
), m/z: 549.1 & 551.1 (M+1); 
1
H NMR (500 MHz, CDCl3)  δ 7.76 – 7.68 (m, 3H), 
7.36 – 7.28 (m, 6H), 7.27 – 7.12 (m, 8H), 6.86 (s, 1H), 6.45 (d, J = 8.2 Hz, 1H), 5.25 (s, 1H), 3.33 (d, J = 6.4 Hz, 
2H), 3.08 (h, J = 6.8 Hz, 1H), 1.35 (d, J = 6.9 Hz, 3H). 
 
U (22R-212017) 
 
(R,E)-N,5-Bis(4-chlorophenyl)-3-((2-phenylpropyl)imino)-3,5-dihydrophenazin-2-amine, 6U (General Procedure E): 
Yield: 35 mg (60%); MS (ESI
+
), m/z: 549.1 & 551.1 (M+1); 
1
H NMR (500 MHz, CDCl3)  δ 7.75 – 7.69 (m, 3H), 
7.36 – 7.28 (m, 6H), 7.26 – 7.13 (m, 8H), 6.86 (s, 1H), 6.45 (d, J = 8.2 Hz, 1H), 5.25 (s, 1H), 3.32 (d, J = 6.8 Hz, 
2H), 3.08 (h, J = 6.8 Hz, 1H), 1.34 (d, J = 6.8 Hz, 3H). 
 
V (25L-212173) 
 
 (S,E)-2-((10-(4-Chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)-3-methylbutan-1-ol, 6V 
(General Procedure E): Purified using 15 - 50% EtOAc/Hexanes gradient. Yield: 54 mg (49%); MS (ESI
+
), m/z: 
517.13 & 519.13 (M+1); 
1
H NMR (400 MHz, CDCl3)  δ δ 7.77 – 7.65 (m, 3H), 7.42 – 7.08 (m, 10H), 6.87 (s, 1H), 
6.48 (d, J = 7.9 Hz, 1H), 5.37 (s, 1H), 3.77 – 3.64 (m, 2H), 3.24 – 3.14 (m, 1H), 1.89 – 1.72 (m, 1H), 0.88 – 0.73 (m, 
6H). 
 
W (25R-212172) 
 
(R,E)-2-((10-(4-Chlorophenyl)-3-((4-chlorophenyl)amino)phenazin-2(10H)-ylidene)amino)-3-methylbutan-1-ol, 6W 
(General Procedure E): Purified using 25 - 50% EtOAc/Hexanes gradient. Yield: 46 mg (42%); MS (ESI
+
), m/z: 
517.16 & 519.17 (M+1);  
1
H NMR (400 MHz, CDCl3)  δ 7.74 – 7.65 (m, 3H), 7.36 – 7.12 (m, 10H), 6.87 (s, 1H), 
6.48 (d, J = 8.1 Hz, 1H), 5.37 (s, 1H), 3.75 – 3.65 (m, 2H), 3.24 – 3.13 (m, 1H), 1.88 – 1.72 (m, 1H), 0.87 – 0.74 (m, 
6H). 
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Table S1- Calculated physicochemical properties, predicted cell uptake and subcellular localization properties of 
clofazimine and related phenazine analogs with chlorophenyl substitutions. 
Chemical 
ID 
R1 R2 Mol.wt
. 
pKa logP  
Predicted ease of 
cell entry 
 
 
Predicted 
intracellular 
localization 
 
CFZ Cl -CH(Me)2 473.4 pKa1 = 9.29 
pKa2 = 2.31 
7.30 Poor-Moderate 
Free base trapped in 
plasma membrane 
 
E G L M P 
A 
 
OMe -CH(Me)2 464.6 pKa1 = 9.68 
pKa2 = 2.35 
5.78 Moderate 
Free base 
membrane bound 
 
E G L M 
B 
 
CN -CH(Me)2 454.5 pKa1 = 9.35 
pKa2 = 2.30 
5.81 Moderate 
Free base 
membrane  bound  
 
E G L M  
C 
 
H -CH(Me)2 404.5 pKa1 = 10.06 
pKa2 = 2.31 
6.10 Moderate? 
Free base 
membrane bound 
 
E G L M 
D 
 
CF3 -CH(Me)2 540.5 pKa1 = 8.88 
pKa2 = 2.32 
7.85 Poor 
Free base trapped in 
plasma membrane 
 
E G L M P 
E 
 
F -CH(Me)2 440.5 pKa1 = 9.30 
pKa2 = 2.31 
6.38 Moderate 
Free base 
membrane bound 
 
E G L M 
F 
 
COOH -CH(Me)2 492.5 pKa1 = 9.77 
pKa2 = 2.29 
5.41 Poor 
A dianionic species 
is membrane 
impermeable 
 
 
Cytosol 
G 
 
OH -CH(Me)2 436.5 pKa1 = 9.49 
pKa2 = 2.35 
5.49 Moderate-good 
Free base near 
bound/permeable 
boundary 
E G L M 
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Table S2- Observed cellular staining pattern following 72 hour incubation with clofazimine and related phenazine 
analogs with chlorophenyl substitutions. Scale bar is 20 μm. 
ID Notes Transmitted microscopy images 
CFZ 
 
Orange-brown staining pattern 
associated with perinuclear 
cytoplasmic vesicles. Cells 
were homogeneously stained. 
Inferred uptake: Moderate. 
 
A 
 
Compound did not exhibit any 
intracellular staining pattern.   
Inferred  uptake: Slow. 
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B 
 
Compound formed large 
extracellular crystals. No 
intracellular staining pattern.   
Inferred  uptake: Very slow. 
 
C 
 
Very faint, brown perinuclear 
staining pattern observed 
across all cells.  
Inferred  uptake: Slow. 
 
D 
 
No intracellular staining 
pattern observed. Small 
percentage of cells with 
orange crystals.  
Inferred  uptake: Very slow.  
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E 
 
Very faint, brown perinuclear 
staining pattern observed 
across all cells.   
Inferred uptake: Slow. 
 
F 
 
Most cells did not exhibit any 
staining. A few cells with 
associated black precipitates, 
likely derived extracellularly.  
Inferred uptake: Very slow.  
 
G 
 
Dark brown perinuclear 
staining pattern associated 
with cytoplasmic vesicles.  
Inferred  uptake: Good. 
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Table S3- Calculated physicochemical properties, predicted cell uptake and subcellular localization properties of 
clofazimine and related phenazine analogs with different R-imino substitutions. 
Chemical 
ID 
R1 R2 Mol.wt
. 
pKa logP  
Predicted ease of 
cell entry 
 
 
Predicted 
intracellular 
localization 
 
H 
 
Cl 2-methoxyethyl 489.4 pKa1 = 8.70 
pKa2 = 2.31 
6.48 Moderate 
Free base 
membrane bound 
 
E G L M  
I 
 
Cl 2-hydroxyethyl 475.4 pKa1 = 8.65 
pKa2 = 2.31 
5.84 Moderate 
Free base 
membrane bound 
 
E G L M  
J 
 
Cl Methyl 445.3 pKa1 = 9.88 
pKa2 = 2.33 
6.53  
Moderate 
Free base 
membrane bound 
 
E G L M  
K 
 
Cl n-butyl 487.4 pKa1 = 9.59 
pKa2 = 2.32 
7.85 Poor-Moderate 
Free base trapped in 
plasma membrane 
 
E G L M P 
L 
 
Cl 3-amino-3-
oxopropyl 
502.4 pKa1 = 9.20 
pKa2 = 2.32 
5.44 Moderate 
Free base 
membrane bound 
 
E G L M  
M 
 
Cl 2-(5-methoxy-
1H-indol-3-
yl)ethyl 
604.5 pKa1 = 9.51 
pKa2 = 2.33 
8.49 Poor- 
Free base trapped in 
plasma membrane 
E G L M P 
N 
 
Cl 2-
morpholinoethyl 
544.7 pKa1 = 9.16 
pKa2 = 4.94 
pKa3 = 2.32 
6.33 Moderate 
Free base 
Membrane bound 
E G L M 
O 
 
Cl 2-(3,4-
dihydroxyphenyl
)ethyl 
567.5 pKa1 = 9.00 
pKa2 = 2.33 
7.94 Poor- 
Free base trapped in 
plasma membrane 
E G L M P 
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Table S4. Observed cellular staining pattern following 72 hour incubation with clofazimine and related phenazine 
analogs possessing R-imino group substitutions. Scale bar is 20 μm. 
ID Notes Live Cells Fixed Cells 
H 
 
Brown staining associated with 
vesicles/membranes. Fixed 
cells also exhibited staining, 
suggesting nonspecific 
partitioning.  Inferred  uptake: 
Moderate 
  
I 
 
Dark brown, crystal-like 
inclusions present in live cells 
but absent in fixed cells.  
Inferred uptake: 
Excellent.   
J 
 
Orange perinuclear staining  
pattern associated with 
cytoplasmic membranes. 
Staining not observed in fixed 
cells. Inferred uptake: Good.   
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K 
 
Very faint, brown perinuclear 
staining pattern. Inferred 
uptake: Slow. 
  
L 
 
Small brown inclusions present 
in live cells but absent in fixed 
cells. Inferred uptake: Good. 
  
M  
 
Orange-brown or purple 
inclusions present in live cells. 
Staining not observed in fixed 
cells. Inferred uptake: Good. 
  
N  
 
Faint orange staining pattern 
associated with perinuclear 
cytoplasmic vesicles. Cells 
were homogeneously stained. 
Staining not observed in fixed 
cells. Inferred uptake: 
Moderate.  
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O 
 
Most of cells have shown faint 
orange colored vesicles. Some 
cells contained orange-brown 
perinuclear staining  patterns. 
Staining not observed in fixed 
cells. Inferred uptake: Good.  
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Table S5- Calculated physicochemical properties, predicted cell uptake and subcellular localization properties of 
clofazimine and related phenazine analogs with additional R-imino substitutions. 
Chemical 
ID 
R1 R2 Mol.wt
. 
pKa logP  
Predicted ease 
of cell entry 
 
 
Predicted 
intracellular 
localization 
 
P 
 
Cl 2-phenylethyl 535.5 pKa1 = 9.51 
pKa2 = 2.32 
8.54 Poor 
Free base 
trapped in 
plasma 
membrane 
 
G L P 
Q 
 
Cl 2-(4-
hydroxyphenyl)
ethyl 
551.5 pKa1 = 9.32 
pKa2 = 2.33 
8.24 Poor 
Free base 
trapped in 
plasma 
membrane 
 
G L P 
R 
 
Cl (S)-1-
phenylethyl 
535.5 pKa1 = 8.35 
pKa2 = 2.30 
8.67 Poor- 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
S 
 
Cl (R)-1-
phenylethyl 
535.5 pKa1 = 8.35 
pKa2 = 2.30 
8.67 Poor- 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
T 
 
Cl (S)-2-
phenylpropyl 
549.5 pKa1 = 9.46 
pKa2 = 2.32 
8.91 Poor- 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
U 
 
Cl (R)-2-
phenylpropyl 
549.5 pKa1 = 9.46 
pKa2 = 2.32 
8.91 Poor- 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
V 
 
Cl (S)-1-hydroxy-
3-methylbut-2-
yl 
517.5 pKa1 = 8.28 
pKa2 = 2.30 
7.14 Poor-
Moderate 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
W 
 
Cl (R)-1-hydroxy-
3-methylbut-2-
yl 
517.5 pKa1 = 8.28 
pKa2 = 2.30 
7.14 Poor-
Moderate 
Free base 
trapped in 
plasma 
membrane 
E G L M P 
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Table S6- Observed cellular staining pattern following 72 hour incubation with clofazimine and related phenazine 
analogs possessing R-imino group substitutions. Scale bar is 20 μm. 
ID Notes Live Cells Fixed Cells 
P 
 
Large fibrous/crystal-like 
brown inclusions present in 
live cells but absent in fixed 
cells. Inferred uptake: 
Excellent.   
Q 
 
Purple-black dense 
cytoplasmic inclusions in 
live cells but absent in fixed 
cells. Inferred uptake: 
Excellent. 
  
R 
 
Orange-brown staining 
pattern associated with 
perinuclear cytoplasmic 
vesicles in live cells. No 
staining found in Fixed cells. 
Inferred uptake: Good. 
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S 
 
Orange-brown staining 
pattern associated with 
perinuclear cytoplasmic 
vesicles in live cells. Fixed 
cells do not show any 
staining. Inferred uptake: 
Good. 
  
T  
 
Faint orange perinuclear 
vesicles are present in live 
cells. Staining not observed 
in fixed cells. Inferred 
uptake: Moderate. 
  
U 
 
Fibrous/crystal-like brown 
inclusions  with orange 
perinuclear vesicles  are 
present in live cells but 
absent in fixed cells. Inferred 
uptake: Good.   
V  
 
Brown crystal-like 
inclusions appeared in live 
cells. Staining not observed 
in fixed cells. Inferred 
uptake: Good. 
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W 
 
Brown crystal-like 
inclusions are shown in live 
cells but absent in fixed 
cells. Inferred uptake: Good. 
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Appendix C 
Supporting Information for Chapter 4 
Supplemental Materials and Methods 
Mouse bronchoalveolar lavage (BAL) harvest. PBS/LPS-instilled and CFZ-treated or control 
mice were euthanized by exsanguination while deeply anesthetized with an intraperitoneal 
injection of ketamine/xylazine (100 mg/kg, 10 mg/kg). The trachea was surgically exposed and 
cannulated with an 18G needle and the lungs were lavaged by instilling 1 ml DPBS (Life 
Technologies, Carlsbad, CA) containing 0.5 mM EDTA (Sigma, St. Louis, MO). The retrieved 
BAL was then centrifuged (10 min at 400 x g, 4°C), and the supernatant was frozen (-80 °C), 
while the cell pellets were resuspended in 1 ml RPMI 1640 media (Life Technologies). To count 
total cells, the cells were stained with Trypan blue and counted using a hemocytometer.  
Immunohistochemistry and imaging. After euthanasia with ketamine/xylazine and 
exsanguination, the liver, spleen and kidneys were removed en bloc and the lungs were inflated 
with 0.8 ml (50% OCT, 15% sucrose in PBS) and frozen in Tissue-Plus OCT compound (Fisher 
HealthCare, Houston, TX). Tissue blocks were sectioned at a thickness 6 μm, using Leica 3050S 
cryostat. For immunohistochemistry, sections were fixed in 4% paraformaldehyde for 10 min, 
blocked for 2 h and incubated with primary antibody at 1 ug/ml overnight (4°C) followed by 
HRP-conjugated secondary antibody for 1 h, DAB substrate incubation (intelliPATH FLX DAB 
chromogen kit, Biocare Medical, Concord, CA) and hematoxylin counterstain. For fluorescence 
immunostaining, FITC-conjugated secondary antibody (Sigma) was incubated for 1 h, and 
Hoechst 33342 (Life Technologies) was used for nuclear detection. Non-fluorescence staining 
was performed by the Pathology Core for Animal Research (PCAR) in the Unit for Laboratory 
Animal Medicine (ULAM) at the University of Michigan. Sections were mounted on glass slides 
with ProlongGold (Life Technologies). Brightfield and fluorescence (DAPI, FITC and Cy5) 
images were acquired using the Nikon Eclipse Ti (Japan) inverted microscope equipped with a 
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Nikon Digital Sight DS-Fi2 camera (Japan) for brightfield and Photometrics Coolsnap Myo 
camera (Tucson, AZ) for fluorescence.  
SDS-PAGE and Western Blot. Harvested organs were washed in ice-cold DPBS and 
homogenized by sonication in radioimmunoprecipitation assay (RIPA) buffer (Sigma).  Halt 
protease and phosphatase inhibitor cocktail and 0.5 M EDTA (Thermo Pierce) were added to the 
RIPA buffer (1:100 dilutions) before use.  The protein concentration in homogenates was 
determined with a BCA assay (Thermo Pierce) and equal amounts of total protein were 
suspended in 4x sample buffer (Bio-Rad, Hercules, CA) and heated (4 min at 94°C).  Proteins 
were separated by SDS-PAGE in 4-15% or 4-20% bis-acrylamide gels (Bio-Rad) and 
electroblotted onto PVDF membranes (Millipore, Billerica, MA) using the Criterion system 
(Bio-Rad). After blocking for 1 h in Tris-buffered saline/Tween (TBST, pH 7.6; 20 mM Tris-
HCl, 150 mM NaCl, and 0.05% Tween20) containing 5% nonfat milk (Meijer), the blots were 
probed with primary antibodies diluted in 5% BSA or 5% nonfat milk overnight at 4°C. The 
membranes were washed with TBST and incubated with a 1:2000 dilution of HRP-conjugated 
anti-rabbit secondary antibodies (Millipore) for 1 h at room temperature. Protein bands were 
visualized on X-ray film (Thermo) using chemiluminescence (Supersignal reagents; Pierce). 
Equation for Mouse Terminal Endpoint Assessment. 
𝐷𝐿𝑃𝑆−𝑃𝐵𝑆̅̅ ̅̅ ̅̅ = √(𝑜𝐿𝑃𝑆 − ?̅?𝑃𝐵𝑆)2 + (𝑤𝐿𝑃𝑆 − ?̅?𝑃𝐵𝑆)2 + (𝑡𝐿𝑃𝑆 − 𝑡?̅?𝐵𝑆)2 
𝐷𝐿𝑃𝑆−𝑃𝐵𝑆̅̅ ̅̅ ̅̅ : total distance between LPS-instilled mouse and mean of PBS-instilled mice 
?̅?𝑃𝐵𝑆: mean oxygen saturation change of PBS-instilled mice  
𝑜𝐿𝑃𝑆: oxygen saturation change of LPS-instilled mouse 
?̅?𝑃𝐵𝑆: mean weight change of PBS-instilled mice 
𝑤𝐿𝑃𝑆: weight change of LPS-instilled mouse  
𝑡?̅?𝐵𝑆: mean temperature change of PBS-instilled mice 
𝑡𝐿𝑃𝑆: temperature change of LPS-instilled mouse 
 All changes represent percent changes from day 0 baseline 
measurement 
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Figure SI. 7- CFZ accumulation in lung macrophages. 
Clofazimine (CFZ) bioaccumulation and crystal formation in the lung occurs after 2 weeks in CD68 (+) 
macrophages. Representative brightfield and fluorescence (FITC for CD68 and Cy5 for CFZ) images of lung 
sections from control mice and mice treated with CFZ for 2 and 8 weeks. In the lung, CFZ can be seen accumulating 
inside macrophages after 2 week CFZ treatment with no crystallization. At 8 weeks, CFZ crystals can be seen 
located inside macrophages. Scale bar 10 μm. 
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Figure SI. 8- IL-1β cleavage in spleen, lung, and kidney. 
Clofazimine (CFZ) bioaccumulation does not affect IL-1β cleavage in the spleen, lung or kidney. Western blots of 
spleen, lung and kidney homogenates showing that IL-1β cleavage was not altered after 8 weeks of CFZ treatment.   
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Figure SI. 9- CFZ accumulation within IL-1RA knockout mice. 
(A) 6 week CFZ-treated IL-1RA knockout (KO) mice show reduced body weight compared to control diet treated 
littermates and wildtype (WT) mice. (B) IL-1RA KO mice display reduced liver weight compared to WT, but spleen 
are comparable. (C) Representative brightfield and fluorescence (Cy5 for crystalline CFZ) images of liver sections 
from WT and IL-1RA KO mice treated with CFZ for 6 weeks. Scale bar = 100 μm. (D) Cy5 fluorescence intensity 
values of liver sections from WT and IL-1RA KO and CFZ-treated mice. Data are the mean ± S.D. of 4 images. 
Scale bar = 100 μm. 
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Figure SI. 10- Vital signs of mice following LPS or PBS injection. 
Daily monitoring of changes in arterial oxygen saturation (A), body weight (B), temperature (C), heart rate (D), 
respiratory rate (E), and pulse distention (F) in 8 week CFZ-treated and control mice after PBS (white circle) or LPS 
(grey circle)-induced acute lung injury. Control mice lung function progressively deteriorated at a higher rate than 
CFZ-treated mice as CFZ-treated mice displayed higher arterial oxygen levels at day 5 and day 6 (A). Control mice 
injected with LPS lost weight more rapidly compared to CFZ-treated mice (B). CFZ-treated mice were more 
resistant to hypothermia (C), drop in heart rate (D) and respiratory rate (E) after the second LPS injection compared 
to control-mice (day 4). Data is the compilation of two separate experiments and presented as mean ± S.D. (PBS 
n=4, LPS n=12). Black dots represent mice that reached terminal endpoint and were euthanized. One-way ANOVA 
was used to compare changes in parameters between control vs CFZ-treated mice with PBS or LPS injections per 
timepoint and p ≤ 0.05 was considered statistically significant. *p ≤ 0.05, **p ≤ 0.01. 
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Table S7- Vital signs of control and clofazimine-treated mice (8 week treatment). P values were calculated using 
Student’s t-test (two-way, unpaired) 
 
 
 
Vital signs 
Control diet treated 
(n=16) 
CFZ treated 
 (n=16) 
P value 
Weight (g ± S.D.) 26.13 ± 1.49 24.39 ± 1.92 0.008 
Body Temperature (°C ± S.D.) 35.30 ± 0.54 35.52 ± 0.76 0.35 
Arterial O2 Saturation (% ± S.D.) 97.52 ± 0.76 99.01 ± 0.24 0.00000064 
Respiratory rate (brpm ± S.D.) 172.85 ± 18.25 154.29 ± 19.43 0.009 
Heart rate (bpm ± S.D.) 632.91 ± 89.55 573.94 ± 85.28 0.066 
Pulse distention (µm ± S.D) 512.22 ± 60.35 425.57 ± 52.32 0.00015 
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Appendix D 
Supporting Information for Chapter 5 
Supplemental Materials and Methods 
Mouse Model for Generating Biocrystals. Macrophages containing biocrystals were generated 
as published before [23,25,37]. Mice (4 week old, male C57Bl/6) were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and acclimatized for 1 week in a specific-pathogen-free 
animal facility. Animal care was provided by the University of Michigan’s Unit for Laboratory 
Animal Medicine (ULAM). The experimental protocol was approved by the Committee on Use 
and Care of Animals and all procedures were carried out in accordance with the approved 
protocol. Clofazimine (CFZ) (C8895; Sigma-Aldrich, St. Louis, MO) was dissolved in sesame 
oil (Roland, China, or Shirakiku, Japan) to achieve a concentration of 3 mg/ml, which was mixed 
with Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) to produce a 0.03% drug 
to powdered chow feed. 
Peritoneal Lavage to obtain Peritoneal Macrophages. Peritoneal lavage was done 8 weeks 
after the initiation of CFZ treatment. Mice were euthanized by exsanguination while deeply 
anesthetized by an intraperitoneal injection of ketamine (100 mg/kg)/xylazine (10 mg/kg) 
followed by sterilization of the outer skin with 70% of ethanol. A small incision was made along 
the midline of the abdomen followed by abdominal skin retraction up to the thoracic boundary 
and the animal extremities to expose the intact peritoneal wall. A smaller incision was then made 
on the peritoneal wall to expose the cavity. The entire peritoneal cavity was washed with ice-cold 
sterile Phosphate Buffered Saline (PBS) + 5% of Fetal Bovine Serum (FBS) (5–10 ml) and 
collected as peritoneal exudate. The exudate was then centrifuged (100 x g for 5 min, 4 °C) and 
resuspended in 1.5 ml of PBS + 5% of FBS. Cells were counted using a hemocytometer for 
viable cells using Trypan Blue and for biocrystal-containing cells. For preparation of microscopy 
slides, a 20 μl drop of cell suspension was placed on a glass slide and allowed to dry overnight in 
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the dark. The following day, a single drop of Prolong® Gold (Life Technologies, Carlsbad, CA) 
was added to the dry slide and a cover slip was applied prior to imaging. 
Alveolar Lavage to obtain Alveolar Macrophages. Mice were euthanized as described above 
and the trachea was surgically exposed and cannulated with an 18G luer stub and the lungs were 
lavaged to obtain alveolar exudate by instilling PBS containing 0.5 mM of EDTA in 1 ml 
aliquots for a total of 6 ml. The alveolar exudate fluid was centrifuged (400 x g, 10 min, 4 °C) 
and resuspended in RPMI 1640 media. Viable (using Trypan Blue staining method) and 
biocrystal containing cells were counted using a hemocytometer followed by preparation of 
microscope slides as mentioned above. 
Isolation of Biocrystals. At 8 weeks post-drug feeding, mice were euthanized as described 
above and spleens were harvested and cut open to prepare tissue homogenate in phosphate-
buffered saline (PBS). The tissue homogenate was sonicated for 30 min and centrifuged (100 x g 
for 1 min) to remove large cell debris. A solution of 10% sucrose in PBS was added to the 
acquired supernatant and the mixture was centrifuged (100 x g). The resulting supernatant was 
centrifuged (3200 x g for 20 min) to pellet drug inclusions which were then resuspended in 2 ml 
of 10% sucrose in water (w/v). CLDIs were further purified using a three-layer discontinuous 
gradient (50, 30, and 10% sucrose (w/v) in PBS) centrifugation method (3200 x g for 30 min, no 
brakes)[37]. 
Brightfield and Polarization Microscopy. The combination brightfield and diattenuation LC-
Pol- Scope microscope set-up is a custom built microscopic imaging system similar to the 
birefringence LC-PolScope designed by Oldenbourg et al[34], but without the polarization 
analyzer. Our LC-PolScope is built on the Nikon Eclipse Ti inverted microscope (Nikon 
Instruments, Melville, New York), with the computer-controlled universal compensator (Hinds 
Instrumentation, Hillsboro, Oregon) placed between the interference filter (623±22 nm, Semrock 
Optics, Rochester, New York) and condenser lens. Illuminating light is narrowed to 623 nm by 
the interference filter, and the light is linearly polarized by passing it through a universal 
compensator, allowing for the diattenuation of the sample to be measured. The LC in the 
universal compensator is controlled by Image J “Micro-manager” software (Vale Laboratory, 
UCSF) and is automatically rotated to produce polarized light at 0°, 45°, 90° and 135° angles, 
respective to the horizontal, during image acquisition. The image maps of diattenuation, mean 
transmittance, and angle of high transmittance are generated by image analysis algorithms 
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followed by calibration and have been published before[32,34]. Brightfield and fluorescence 
images were captured using the Nikon DS-U3 camera (Nikon Instruments) and Photometrics 
CoolSnap MYO camera system (Photometrics, Tucson, Arizona), respectively, under the control 
of Nikon NIS-Elements AR software (Nikon Instruments). Microscopy slides of samples were 
prepared as mentioned before. 
Measuring Curvature of Crystals. The diattenuation images obtained using Polarization 
microscopy were used to quantify for curvature of biocrystals using a ThreePointROI plugin for 
ImageJ, as used elsewhere[44]. Briefly, three points were marked along the maximum Feret’s 
length of the high diattenuation signal of the crystal which was used by the plugin to draw a 
circle through the three points and accordingly provide a radius of the circle (r). Curvature for 
this circle is then defined as κ = 1/r. Co-linear points that define an impossible circle resulted in a 
circle with r = “-1” or “2147483647” pixels and were marked as κ=0. A line was then drawn 
through the three points used to generate the circle to generate a chord of length (x) for that 
circle. Using the length of the chord and the radius, the angle formed by the biocrystal arc 
through that circle was then computed using the formula – θ = 2sin-1(x/2r). The arc length of the 
biocrystal was then computed as L = θ × r where θ is in radians. Linear curvature density was 
computed as κ/L. 
Synthesis of CFZ-HCl Crystals. To grow the biomimetic crystals (CFZ-HCl) in bulk, HCl was 
added to a 2mM CFZ in methanol solution until the HCl concentration was 0.1M. After the 
solution sat for 5 minutes, water is added to the solution to double the solution volume. Within 
minutes, thin dark red crystals are observed. To grow diffraction quality crystals of CFZ-HCl, 
2mM CFZ was dissolved in benzene and 0.1M HCl was added to the solution. The solution was 
allowed to slowly evaporate and red, rectangular plate-like crystals were observed. 
Qualitative Bending/Flexibility Analysis. Crystals that were about 2 mm long and ~20 μm 
thick were isolated from the crystallization solution and manipulated to demonstrate the crystal’s 
elasticity. Crystals were placed on a microscope slide in a small amount of water to prevent the 
crystal from moving off the slide. A pair of tweezers and a crystallization probe were used to 
manipulate the crystals. Video of this procedure was taken with a Leica M205 C stereo 
microscope. See Movies 1 and 2. For analysis of bent crystals via polarization or Raman 
microscopy, bent crystals were snap-frozen over dry ice and imaged either on a glass microscopy 
slide (Polarization) or a silicon wafer (Raman). 
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Powder X-Ray Diffraction (p-XRD). Powder XRD of isolated biocrystals was carried out as 
published before[25] with Bruker D8 Advance: Cu Kα radiation (λ = 1.5406 Å), tube voltage = 
40kV, and tube current = 40 mA. Data were collected at 2θ = 4° to 40° at a continuous scan rate 
of 2.5°/min. For CFZ-HCl crystals - data was collected on a Rigaku Miniflex 600 in the Bragg- 
Brentano geometry. The data was collected from 5° – 40°, 2θ with 0.02° steps and a 1.00 s 
detection time. Data was background subtracted using Origin® (Origin Labs, Northampton, MA) 
Single Crystal X-Ray Diffraction. Single crystal X-ray data was collected on a Bruker D8 
Venture equipped with a four-circle kappa diffractometer and Photon 100 detector with Cu 
source that supplied the multi-mirror monochromated incident beam. A combination of Phi and 
Omega scans were used to collect the necessary data. A single crystal was picked and mounted 
on a 0.3mm loop using paratone oil then cooled to 100 K in a nitrogen supplied Oxford 700 
Cryostream. Data was integrated using SAINT and absorption corrected using SAINT/SADABS 
v2014/4. The final structure was solved using SHELX-2014-6. 
Raman Microscopy. Confocal Raman microscopy was performed using a WITec alpha300 R 
equipped with a near-IR 785 nm to minimize clofazimine’s fluorescence signal. Samples were 
positioned on the stage for spectral data acquisition and were observed using the reflectance 
illumination mode of the microscope. Once positioned, the 4 μm diameter 785 nm laser 
illumination spot was directed to the sample, and the Raman spectrum was acquired. Raw data 
were background subtracted from the signal obtained from pure silicon wafers and further 
baseline-corrected using Origin® (Origin Labs, Northampton, MA). 
Differential Scanning Calorimetry (DSC). Samples were analyzed using a TA Instruments 
2910 MDSC system equipped with a refrigerated cooling unit. All experiments were performed 
by heating the pre-weighed samples at a rate of 10 °C/min under a dry nitrogen atmosphere. 
Temperature and enthalpy of the instrument were calibrated using high purity indium standard. 
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Figure SI. 11- Curvature of drug biocrystals. 
Curvature (κ) of biocrystals measured from two different macrophage populations (peritoneal and alveolar) and 
isolated biocrystals from the spleen plotted as a function of their arc length (L). 
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Figure SI. 12- Face indexed image of CFZ-HCl crystal that was used for single crystals X-ray diffraction. 
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Figure SI. 13- Asymmetric unit of CFZ-HCl. 
Asymmetric unit of CFZ-HCl including the position of the water molecule and the disorder in the propyl group 
showed as a transparent overlay. The water has ~13% occupancy and the presence of water is likely due to the 
solvent used in the crystallization solution or HCl.  
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Figure SI. 14- Cl1 interaction with C5-H5 viewed along the b-axis to form a chain of CFZ-HCl molecules and along 
the c-axis to show the position of the Cl1 interaction within the zig-zag. 
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Figure SI. 15- Crystallographic projection of the major faces of the CFZ-HCl crystal.  
The rows of corrugated structure along the (001) face are colored blue and orange to help visualize the crystal 
packing. The projections show a stacking of 2 x 2 x 2 (a x b x c) unit cells. 
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Figure SI. 16- Raman spectra of CFZ-HCl crystal pre- and post-bending. 
(A) Raman Reflectance Brightfield images of (top) short CFZ-HCl crystals and (bottom) at the bent point of a long 
CFZ-HCl elastic crystal. Blue arrows indicate moving away from the confocal plane used to obtain the point spectra 
of CFZ-HCl; (B) Raman Spectra of CFZ-HCl reference crystals (top) with crystals that were subjected to 
mechanical bending (before and after) (second and third from top) and crystals that had an inherent curvature 
(bottom). 
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Figure SI. 17- Melting point of CFZ-HCl determined via DSC. 
Differential Scanning Calorimetry of CFZ-HCl. Melting Point indicated with curved arrow – 275.80 °C. 
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Table S8- Crystallographic data for CFZ-HCl. 
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Table S9- Molecular interactions within the CFZ-HCl crystal structure. 
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Appendix E 
Supporting Information for Chapter 8 
Figure SI. 18- Comparison of cellular proliferation within untreated, CFZ-treated, and granulomatous regions of 
CFZ-treated livers. 
Increased Cell Proliferation within granulomatous regions of CFZ treated livers. (n=30 images per group) 
(*=p<0.05, ANOVA, Tukey’s HSD). 
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Figure SI. 19- TUNEL assay in untreated, 2 week, 4 week, and 8 week CFZ treated-livers. 
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Figure SI. 20- Hepatic TLR2 expression measurement. (n=10 untreated and non-granulomatous regions at 10x, n=10 
granulomas) (*=p<0.05, ANOVA, Tukey’s HSD) 
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Figure SI. 21- TEM image of granuloma within liver of 8-week CFZ treated mouse.  
Granuloma-associated macrophages containing CLDIs show damaged mitochondria and formation of collagen 
fibers surrounding the cell. A neighboring neutrophil, while exposed to drug, does not contain CLDIs, indicating 
that CLDI stabilization and sequestration may be macrophage specific. 
(M: Mitochondria, GM: Granuloma-associated macrophage, CLDI: Crystal-like Drug Inclusion, CF: Collagen 
Fibers, N: Neutrophil) 
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Figure SI. 22- Hepatic apoptosis in clodronate and PBS-treated mice. 
Hepatic granulomas of PBS-CFZ treated mice show significantly higher rates of apoptosis compared to the 
clodronate-CFZ treated granulomas. (*=p<0.001, ANOVA, Tukey’s HSD). 
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Figure SI. 23- Cellular proliferation in clodronate- and PBS-treated mice. 
Clodronate treatment reduces cellular proliferation within CFZ-induced granulomas. The number of Ki67 (+) nuclei 
within granulomas is significantly reduced in clodronate-CFZ treated mice. (n=30 images per treatment group, n=30 
granulomas, *=p<0.001, ANOVA, Tukey’s HSD). 
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Figure SI. 24- Hepatic macrophage quantification in clodronate- and PBS-treated mice. 
F4/80: DAPI ratio analysis reveals significant reduction in liver macrophages following clodronate depletion. (n=10 
images per liver, n=3 organs per group) (*=p<0.05, ANOVA, Tukey’s HSD). 
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Figure SI. 25- Quantification of protonated CFZ within livers of clodronate- and PBS-treated mice. 
Cy5: DAPI ratio analysis reveals significant reduction in liver CLDI accumulation following clodronate depletion. 
(n=10 images per liver, n=3 organs per group) (*=p<0.05, ANOVA, Tukey’s HSD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
